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Abstract 
Protein aggregation is a biochemical hallmark of fatal neurodegenerative disease. Protein disaggregation 
represents an innovative and appealing therapeutic strategy for the treatment of these protein-misfolding 
disorders in that it simultaneously reverses: (a) loss-of-function phenotypes associated with 
sequestration of functional soluble protein into misfolded oligomers and insoluble aggregates; and (b) 
any toxic gain-of-function phenotypes associated with the misfolded conformers themselves. In 
Saccharomyces cerevisiae, the AAA+ protein disaggregase Hsp104 increases fitness under stress by 
reversing stress-induced protein aggregation. Hsp104 is conserved among all nonmetazoan eukaryotes 
and eubacteria, but is curiously absent in metazoa. Hsp104 activity against protein aggregates 
associated with neurodegenerative disease is limited. We have engineered Hsp104 variants to antagonize 
proteotoxic misfolding linked to human neurodegenerative diseases. These engineered Hsp104 variants 
potently eradicate misfolded structures but can exhibit off-target toxicity, which may limit their 
therapeutic utility. Here, we assess the possibility that natural Hsp104 homologs might exist with 
enhanced, selective activity against neurodegenerative disease substrates. First, we report two structures 
of Hsp104 from the thermophilic fungus Calcarisporiella thermophila (CtHsp104): a 2.70 Å crystal 
structure and a 4.0 Å cryoelectron microscopy structure. Both structures reveal left-handed, helical 
assemblies with all domains clearly resolved. We thus provide the highest resolution and most complete 
view of Hsp104 hexamers to date. We also establish that CtHsp104 antagonizes several toxic protein-
misfolding events in vivo where S. cerevisiae Hsp104 is ineffective, including rescue of TDP-43, 
polyglutamine, and alpha-synuclein (aSyn) toxicity. Next, we hypothesized that therapeutic Hsp104s may 
be pervasive across extant Hsp104 sequence space. To assess this possibility, we screened a cross-
kingdom collection of Hsp104 homologs in several yeast proteotoxicity models. We uncovered 
therapeutic genetic variation among several Hsp104 homologs that specifically antagonize TDP-43 or 
aSyn condensate formation and toxicity in yeast, human cells, and C. elegans. Surprisingly, this variation 
manifested as increased passive chaperone activity, distinct from disaggregase activity, which neutralizes 
proteotoxicity of specific substrates. Thus, by exploring natural Hsp104 sequence space, we elucidated 
enhanced, substrate-specific agents to counter proteotoxicity underlying neurodegenerative diseases. Our 
findings suggest that rational tuning of Hsp104 passive chaperone activity may enable development of 
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ABSTRACT                                                                                                  
THERAPEUTIC GENETIC VARIATION REVEALED IN DIVERSE HSP104 HOMOLOGS
Zachary McDowell March 
          James Shorter 
Protein aggregation is a biochemical hallmark of fatal neurodegenerative disease. Protein 
disaggregation represents an innovative and appealing therapeutic strategy for the treatment of 
these protein-misfolding disorders in that it simultaneously reverses: (a) loss-of-function 
phenotypes associated with sequestration of functional soluble protein into misfolded oligomers 
and insoluble aggregates; and (b) any toxic gain-of-function phenotypes associated with the 
misfolded conformers themselves. In Saccharomyces cerevisiae, the AAA+ protein disaggregase 
Hsp104 increases fitness under stress by reversing stress-induced protein aggregation. Hsp104 is 
conserved among all nonmetazoan eukaryotes and eubacteria, but is curiously absent in metazoa. 
Hsp104 activity against protein aggregates associated with neurodegenerative disease is limited. 
We have engineered Hsp104 variants to antagonize proteotoxic misfolding linked to human 
neurodegenerative diseases. These engineered Hsp104 variants potently eradicate misfolded 
structures but can exhibit off-target toxicity, which may limit their therapeutic utility. Here, we 
assess the possibility that natural Hsp104 homologs might exist with enhanced, selective activity 
against neurodegenerative disease substrates. First, we report two structures of Hsp104 from the 
thermophilic fungus Calcarisporiella thermophila (CtHsp104): a 2.70 Å crystal structure and a 4.0 Å 
cryoelectron microscopy structure. Both structures reveal left-handed, helical assemblies with all 
domains clearly resolved. We thus provide the highest resolution and most complete view of 
Hsp104 hexamers to date. We also establish that CtHsp104 antagonizes several toxic protein-
misfolding events in vivo where S. cerevisiae Hsp104 is ineffective, including rescue of 
v 
vi 
TDP-43, polyglutamine, and alpha-synuclein (aSyn) toxicity. Next, we hypothesized that 
therapeutic Hsp104s may be pervasive across extant Hsp104 sequence space. To 
assess this possibility, we screened a cross-kingdom collection of Hsp104 homologs in 
several yeast proteotoxicity models. We uncovered therapeutic genetic variation among 
several Hsp104 homologs that specifically antagonize TDP-43 or aSyn condensate 
formation and toxicity in yeast, human cells, and C. elegans. Surprisingly, this variation 
manifested as increased passive chaperone activity, distinct from disaggregase activity, 
which neutralizes proteotoxicity of specific substrates. Thus, by exploring natural Hsp104 
sequence space, we elucidated enhanced, substrate-specific agents to counter 
proteotoxicity underlying neurodegenerative diseases. Our findings suggest that rational 
tuning of Hsp104 passive chaperone activity may enable development of substrate-
selective disaggregases. 
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1 
CHAPTER 1 INTRODUCTION 
1.1 Protein folding and the proteostasis network 
Proteins are folded linear polymers of amino acids and comprise the primary 
units of biological function within cells. Biological function is enciphered by both 
the sequence of amino acids and the three-dimensional conformation of the 
polypeptide chain. The observation by Anfinsen and colleagues ~60 years ago 
that denatured ribonuclease spontaneously refolds into a biologically-active 
conformation under native buffer conditions demonstrates the connection 
between sequence and conformation [1]. However, while protein folding is 
thermodynamically spontaneous, it is not necessarily kinetically favorable. 
Maturation of ribonuclease, which requires the formation of a unique combination 
of four disulfide bridges out of 105 possible combinations, proceeds over the 
course of hours in vitro [1]. By contrast, early cell-free translation systems 
suggested that protein synthesis occurs in a matter of minutes [2]. How, then, are 
these dramatically differing rates balanced in living systems? Interestingly, 
adding microsomes from rat liver to ribonuclease refolding reactions dramatically 
accelerated the rate of maturation [3], a finding that offered the first suggestion 
that living systems may harbor cellular factors to assist protein folding. 
The obstacles to protein folding in vitro are amplified in living cells due to 
several factors. These include high macromolecular concentrations (~300-400 
mg/mL), fluctuating microenvironmental conditions, and constraints imposed by 
the cotranslational nature of folding in vivo [4]. Folding is typically associated with 
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only a marginal increase in thermodynamic stability [5-8], rendering protein 
folding subject to disruption by environmental stress [9]. Additionally, many 
proteins are translated in the cytoplasm but are then transported to various 
organelles, such as the endoplasmic reticulum (ER) or mitochondria. Such 
proteins are imported in an unfolded state [10-13], necessitating mechanisms to 
both maintain unfolded polypeptides in the cytoplasm and to efficiently fold 
transported protein. These challenges underscore the need for accessory factors 
to help the proteome achieve and maintain proper conformations. 
To meet these demands, cells have evolved elaborate systems, collectively 
termed the proteostasis machinery, which ensure the fidelity of protein folding in 
vivo. These include various molecular chaperones to help proteins achieve and 
maintain their native conformations and several protein-degradation machineries 
to remove terminally misfolded protein [14, 15]. 
Many of the members of the proteostasis machinery are termed heat-shock 
proteins (Hsps), based on the discovery that their expression is dramatically 
upregulated in response to heat and other environmental stressors [16] and are 
highly conserved across all domains of life [9, 16]. Although Hsps are 
synthesized in abundant quantities under conditions of environmental stress 
(and, indeed, constitute the predominant gene expression products in such 
circumstances), they also have important roles in normal cell physiology. For 
instance, cytoplasmic forms of Hsp70 recognize extended polypeptides, folding 
intermediates, and nearly-native proteins [17]. Thus, Hsp70 is instrumental in 
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assisting folding, preventing misfolding, and stabilizing native conformations [17]. 
ER-localized Hsp70 (BiP) mediates translocation [18-20] and folding [21] of 
proteins in the ER. Hsp90 facilitates the maturation of a wide range of signal 
transducers, kinases, and transcription factors and thus impacts a broad array of 
biology, including acting as a capacitor of evolution [22]. Accordingly, it has long 
been known that yeast strains bearing deletion of Hsp70 and Hsp90 are inviable 
[23, 24], underscoring the pivotal role of Hsps in normal and stress physiology. 
 
1.2 Protein misfolding and aggregation is a marker of neurodegenerative 
disease 
The efficacy of the proteostasis network declines with age, and misfolded 
and aggregated proteins form and persist [14, 15]. The consequences of 
improper protein folding are most clearly illustrated by neurodegenerative 
disease, where deposition of fibrillar plaques has been documented as 
pathological hallmarks of neurodegenerative diseases for over a century [25, 26]. 
Neurons may be especially vulnerable to declining proteostasis because they are 
postmitotic, and therefore cannot dilute cytoplasmic aggregates through cell 
division. Interestingly, the proteins comprising these plaques and where they 
accumulate in the brain varies in each disease. Thus, in Alzheimer’s disease, 
amyloid-beta accumulates in extracellular deposits and the microtubule-associated 
protein tau accumulates in intracellular neurofibrillary tangles in cortical regions of the 
brain [27, 28]. aSyn accumulates in Lewy bodies within dopaminergic neurons of the 
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substantia nigra in Parkinson’s disease [29] (Figure 1-2C). In Huntington’s disease, 
expanded (>36) polyglutamine tracts within exon 1 of the huntingtin protein leads to its 
abnormal proteolytic processing and accumulation of mutant huntingtin (mHtt) fragments 
in intranuclear inclusions within neurons [30, 31]. TDP-43 mislocalizes from the 
nucleus to cytoplasmic inclusions in degenerating neurons in amyotrophic lateral 
sclerosis (ALS) and frontotemporal dementia (FTD) [32-34]. Indeed, cytoplasmic 
TDP-43 aggregates are the most common pathological feature of ALS, featuring 
in ~97% of sporadic ALS cases and ~45% of sporadic FTD cases [56,62]. 
Cytoplasmic aggregates of the protein FUS are also more rarely associated with 
ALS and FTD [35]. Several sporadic and familial diseases, including kuru, 
Creutzfeldt-Jakob disease (CJD), and Gerstmann-Straussler Schenker disease, 
are caused by misfolding and aggregation of the mammalian prion protein, PrP 
[36]. Thus, despite having diverse clinical manifestations, protein misfolding is a 
unifying feature of neurodegenerative disease [25].  
Mounting evidence, originating from the study of prion diseases like CJD, 
now suggests that misfolded and aggregated proteins are not simply pathological 
hallmarks of neurodegenerative disease but are drivers of disease pathogenesis. 
Prions are infectious proteins that can adopt many functionally distinct 
conformations, at least one of which is self-replicating [36]. Thus, the mammalian 
prion protein (PrP) exists in two isoforms: the normal cellular form, PrPC, which is 
rich in a helical content, and the disease-causing form PrPSc, which is rich in b 
sheets. Conformational conversion of PrPC to PrPSc is sufficient to cause 
5 
 
disease. Moreover, PrPSc has a biophysical propensity to form self-templating 
amyloid structures capable of catalyzing conversion of PrPC to PrPSc [37-40]. 
Synthetic prions constructed de novo from recombinant PrP are capable of 
infecting wild-type mice with a Creutzfeldt-Jakob-like neurodegenerative disease 
[41-45], providing strong evidence that misfolded protein is a causative agent in 
neurodegenerative disease pathogenesis. Similarly, intracerebral inoculation of 
wild-type mice with exogenously prepared aSyn fibrils induces a Parkinson’s 
disease-like phenotype in the mouse [46], suggesting that this may be a general 
phenomenon.  
Conversely, experimental evidence suggests that attenuating expression 
of specific proteins in the context of neurodegenerative disease can halt or even 
reverse disease pathogenesis. For instance, in mouse models of Huntington’s 
disease, attenuation of huntingtin expression in symptomatic mice, either via 
doxycycline-mediated huntingtin repression [47] or antisense oligomer treatment 
[48], reverses huntingtin inclusions and behavioral phenotypes. Thus, intervening 
in protein aggregation may be a relevant therapeutic strategy for 
neurodegenerative disease [49]. Taken together, these results point to the 
central role of proteostasis in neurodegenerative-disease pathogenesis. More 
specifically, they suggest that decreasing protein aggregation may halt or even 




1.3 Pathobiology of protein misfolding can be modeled in yeast 
 Although there is strong evidence linking protein misfolding and 
neurodegenerative disease, the precise molecular underpinnings of many 
neurodegenerative diseases remain unclear [50]. Many neurodegenerative 
diseases are sporadic in nature and do not manifest until late in life, suggesting 
that cellular signatures of disease are subtle and multifactorial [50]. Overcoming 
these obstacles requires simplifying the problem. One strategy is to express 
neurodegenerative disease-linked proteins in simplified eukaryotic systems, such 
as the single-celled yeast Saccharomyces cerevisiae, and observe their effects 
on yeast physiology [50]. Yeast have several advantages as an experimental 
system including ease of culture, fast doubling times, ease of genetic 
manipulation facilitating unbiased genetic interaction studies, and high 
conservation of proteostasis machinery [50]. Yeast expressing proteins 
implicated in neurodegenerative disease, including aSyn, TDP-43, and FUS 
recapitulate phenotypes associated with neurodegenerative disease including 
toxicity associated with protein expression and accumulation of aberrant 
cytoplasmic foci reminiscent of their localization within degenerating neurons [51-
53] (Figure 1-1). These phenotypes are robust, facilitating unbiased genetic 
screens for modifiers of these phenotypes [50-52, 54-56]. Such approaches have 
uncovered mechanisms of toxicity that are conserved from yeast to humans [50, 
56, 57]. For instance, in the case of aSyn, a yeast model has uncovered aSyn-
mediated defects in vesicle trafficking [54] and protein nitrosylation [56] stress as 
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conserved symptoms in Parkinson’s disease. In ALS, discoveries in a yeast 
model uncovered a genetic interaction between the pathological ALS marker 
TDP-43 and ataxin-2 [57], which have been validated in mouse models of ALS 
[58] and form the basis of clinical trials. Additionally, yeast has successfully 
predicted several other ALS disease genes [59]. Clearly, yeast has been 
demonstrated to be a relevant model system to understand basic biology related 
to how protein-misfolding stress disrupts cellular physiology, and also has 
relevant features that enable a high-throughput discovery platform for 
neurodegenerative disease. 
 
Figure 1–1 Using yeast proteotoxicity models to understand cell biology of 
neurodegenerative disease. 
(A) Schematic of yeast expression constructs. Expression of proteins linked to 
neurodegenerative disease, such as aSyn (left) connected to Parkinson’s disease and 
TDP-43 (right) connected to ALS, is controlled by a galactose-inducible promoter. Note 
that constructs can be fluorescently tagged or not. 
(B) Yeast transformed with plasmids encoding galactose-inducible aSyn-GFP (left) or 
TDP43-GFP (right) were serially diluted fivefold and spotted onto glucose (aSyn and 
TDP-43 expression off) or galactose (aSyn and TDP-43 expression on), revealing toxic 
growth defects associated with aSyn and TDP-43 expression. 
(C) Fluorescence microscopy of yeast expressing aSyn-GFP (left) or TDP43-GFP (right) 





1.4 Hsp104: A AAA+ protein disaggregase 
The largest Hsp synthesized by the yeast S. cerevisiae is Hsp104. 
Hsp104 is conserved among eubacteria, nonmetazoan eukaryotes, and some 
archaea, but is absent from metazoans [60]. In yeast, Hsp104 is found in both 
the nucleus and cytoplasm [61, 62]. Hsp104 is expressed at very low levels 
under physiological growth conditions [63], and is dispensable for growth under 
these conditions [63]. However, Hsp104 is essential for induced thermotolerance, 
in which yeast are first pretreated at 37 °C (whereas physiological growth occurs 
near 30 °C) before being exposed to extreme temperature of 50 °C [63]. Under 
extreme stresses, wild-type yeast display ~1000-fold survival benefit compared 
with Dhsp104 yeast [63] (Figure 1-2A). 
1.4.1 Hsp104 function in vivo 
How does Hsp104 protect cells from extreme thermal stress? Examination 
of yeast ultrastructure by electron microscopy before, during, and after heat 
shock offers some clues. Upon heat shock both wild-type and Dhsp104 yeast 
accumulate large electron-dense protein aggregates, which are rapidly resolved 
in the wild-type strain but persist in Dhsp104 cells [62] (Figure 1-2B). This 
observation supports a role for Hsp104 in clearing protein aggregates. Using 
synthetic yeast strains expressing a luciferase reporter for folded protein, 
Lindquist and colleagues discovered that Hsp104 mediates disaggregation and 
reactivation of previously-aggregated luciferase [62]. In vitro reconstitution of 
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luciferase disaggregation reactions revealed that Hsp104 cooperates with Hsp70 
and Hsp40 to achieve disaggregation and reactivation of previously aggregated 
luciferase [64]. In a recent proteomics study, it was reported that aggregation 
upon heat shock followed by reactivation during recovery is the predominant 
response to heat shock for many endogenous yeast proteins [65]. 
In addition to its role in thermotolerance, Hsp104 regulates the formation, 
elimination, and propagation of yeast prions [66]. Similar to mammalian prions, 
yeast prions are infectious and embodied by self-replicating amyloidogenic 
conformers of their protein determinants. However, unlike mammalian prions, 
which cause neurodegenerative disease [38], prions in yeast are often benign 
and can even confer selective advantages [67-72]. The canonical yeast prion 
[PSI+] is comprised of self-replicating conformers of the protein Sup35 [73-75]. 
Sup35 is a translation-termination factor in yeast; the yeast prion state [PSI+] is 
associated with a nonsense suppression phenotype [74]. Perplexingly, either 
overexpression or deletion of Hsp104 eliminates [PSI+] [76]. In vitro reconstitution 
of Sup35 conformational conversion in the presence or absence of Hsp104 has 
been instrumental in explaining these findings [77, 78]. At low concentrations, 
Hsp104 stimulates Sup35 fiber formation [77, 78]. In this way, Hsp104 severs 
yeast prions to ensure their dissemination to daughter cells upon division [79]. At 
higher concentrations, Hsp104 prevents Sup35 conversion to amyloid [77, 78]. 
Thus, in addition to its canonical role as a protein disaggregase, Hsp104 can also 
act as a chaperone for some substrates, inhibiting their misfolding and 
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aggregation. Interestingly, Hsp104 even exhibits some passive chaperone 
activity against Sup35 (e.g. inhibiting Sup35 conformational conversion without 
consuming ATP) [77], although inhibition of Sup35 assembly is most efficient 
under conditions where ATP can be consumed [77]. When high concentrations of 
Hsp104 are added to pre-formed Sup35 fibers, Hsp104 disassemble Sup35 
fibers to monomers and noninfectious aggregates [77, 78]. Thus, Hsp104 was 
the first enzyme discovered to disassemble amyloid fibers [77, 78]. 
Hsp104 also plays a role in maintaining the material state of various 
membraneless organelles involved in RNA homeostasis. Thus, yeast rely on 
Hsp104 to maintain the fluidity of P bodies, which are constitutively active sites 
involved in mRNA processing and degradation [80]. Hsp104 is also required to 
disassemble stress granules that form in response to heat stress in yeast [81, 
82], which are inactive storage sites for proteins and RNA that form rapidly upon 
onset of stress [83]. Clearly, Hsp104 is important for modulating the material 
states of diverse membraneless organelles  
1.4.2 Hsp104 structure and mechanism 
Hsp104 is a member of the Hsp100 family of proteins [84]. These are 
collectively AAA+ (ATPases Associated with diverse cellular Activities) protein 
translocases [85-87]. Hsp104 couples energy derived from ATP hydrolysis to 
extraction of monomeric protein from a variety aggregated structures, including 
amorphous aggregates, amyloids, and preamyloid oligomers [62, 64, 77, 78, 88]. 
It can perform these activities on its own [77, 78, 88, 89] or in collaboration with 
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cofactors Hsp70, Hsp40, and Hsp110 [64, 90] (Figure 1-2C). Indeed, Hsp104 
was the first protein factor discovered to have these unique activities [62, 64, 77, 
78, 90]. Typically, proteins processed by Hsp104 are restored to active soluble 
states and are not degraded [62, 65, 91, 92]. However, Hsp104 can also promote 
the proteasomal degradation of some select clients [93, 94]. 
 Hsp104 assembles into asymmetric ring-shaped hexamers that undergo 
conformational changes upon ATP binding and hydrolysis, which drive substrate 
translocation across the central channel to power protein disaggregation [85-88, 
95-97]. Subunit doping experiments have revealed how Hsp104 coordinates 
protomers within the hexamer to disaggregate diverse clients [88]. Interestingly, 
Hsp104 employs operational plasticity to disassemble aggregated substrates 
with a wide range of stabilities [88]. Thus, for some substrates with weak 
stabilities, such as amorphous luciferase aggregates, only a single Hsp104 
protomer needs to bind substrate and hydrolyze ATP to facilitate disaggregation 
[88]. For more stable substrates, such as Sup35 amyloid fibers, Hsp104 switches 
to a cooperative mechanism whereby additional subunits participate in both 
substrate binding and ATP hydrolysis to effect disassembly of these substrates 
[88]. Thus, Hsp104 can readily remodel both amorphous aggregates and stable 
amyloid fibers. This feature is unique to Hsp104, as the bacterial homolog ClpB 
only operates in a cooperative fashion and cannot resolve amyloid fibers [88]. 
Each protomer of Hsp104 is comprised of an N-terminal domain (NTD), 
two nucleotide binding domains (NBDs), a coiled-coil middle domain (MD), and a 
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short C-terminal extension. The NTD mediates initial substrate binding [87, 98, 
99], is important for cooperative substrate handling necessary for amyloid 
disaggregation, and also is a site of Hsp70 interaction [87, 98, 99]. The two 
NBDs are AAA+ domains but are from distinct clades of the AAA+ superfamily, 
suggesting that Hsp104 arose from a gene fusion[100]. Each NBD contains 
conserved Walker A and Walker B motifs that mediate ATP binding and 
hydrolysis, respectively; catalytic arginine fingers and sensor-1 and -2 motifs [87]. 
Additionally, each NBD has a tyrosine-bearing pore loop that are required for 
ATP-dependent substrate translocation [88, 101]. The MD is a regulatory domain 
inserted within NBD1 that wraps around the exterior of the hexamer [85, 95, 96] 
and regulates disaggregase activity [102]. Additionally, the MD contains an 
Hsp70 binding site, and Hsp70 binding is proposed to activate Hsp104 for 
disaggregation [87]. The C-terminal extension mediates interactions with 
downstream chaperones such as Sti1 [86, 87] and is important for 
hexamerization in some homologs [103] but not others [95]. 
 In recent years, high-resolution structures of Hsp104 obtained with 
cryoelectron microscopy (cryo-EM) have offered a new perspective on both 
Hsp104 structure as well as its mechanism of disaggregation [85, 86, 96]. In the 
presence of ATP or ADP, Hsp104 exists in an open, left-handed spiral 
conformation featuring a noncanonical AAA+ interface between NBD2 of 
protomer 1 and NBD1 of protomer 6 [95, 96]. Cryo-EM structures of Hsp104 in 
the presence of the model substrate b-casein and the slowly hydrolysable ATP 
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analog ATPgS reveal Hsp104:substrate interactions and distinct conformations 
that may reflect Hsp104 translocation mechanism [85]. In contrast to the open, 
left-handed helix observed in the ATP state, in the presence of ATPgS and 
casein, Hsp104 occupies two right-handed helical, substrate-engaged states 
termed closed and extended [85]. Conformational switching between the open, 
left-handed helical conformation, closed, and extended states in different 
nucleotide and substrate states is proposed to underlie a ratchet-like mechanism 
of polypeptide translocation (Figure 1-2D) [85, 86]. Hydrogen exchange mass 
spectrometry (HX-MS) studies corroborate that Hsp104 switches between open 
and closed states during ATP hydrolysis [97]. In the cryo-EM structures, Hsp104 
contacts casein almost entirely via pore loop tyrosines, which are arranged in a 
two-turn spiral establishing directional substrate translocation and establishing 





Figure 1–2 Hsp104 is a protein disaggregase that is required for thermotolerance 
in yeast. 
(A) Hsp104 is required for thermotolerance. When exposed to extreme thermal 
stress (i.e. treatment at 50 °C), wild-type yeast display ~1000-fold survival 
advantage over Dhsp104 yeast (Sanchez and Lindquist, 1990). 
(B) Evidence that Hsp104 is a protein disaggregase. Electron-dense protein 
granules condense upon heat shock at 44 °C and are rapidly resolved in wild-
type cells, but persist in Dhsp104 cells (Parsell et al., 1994). 
(C) Schematic of Hsp104 action. Hsp104, in collaboration with cochaperones 
Hsp70 and Hsp40, employs ATPase-driven polypeptide translocation to extract 
monomeric polypeptides from aggregated structures. The end product of this 
reaction is typically solubilized, functional protein. 
(D) Conformational states of Hsp104 determined by cryo-EM. Hsp104 is 
observed to occupy an open, left-handed spiral (left) in the presence of the 
nonhydrolyzable ATP analog, AMPPNP, and either closed (middle) or extended 
(right) right-handed helices in the presence of casein and the slowly hydrolysable 
ATP analog ATPgS. Switching between these states is proposed to underlie a 




1.5 Hsp104 remodels protein aggregates associated with 
neurodegenerative disease 
Could Hsp104 be added back as a disruptive technology to enhance the 
proteostasis network in mammalian lineages [60, 104, 105]? Hsp104 is well 
tolerated in mammalian cells, enhances their thermotolerance, disaggregates 
heat-denatured luciferase aggregates, and reduces the aggregation and toxicity 
of various disease-linked proteins. These findings suggest a gain-of-function in 
the proteostasis network of these cells [104, 106, 107]. Hsp104 also collaborates 
effectively with human chaperones Hsp70, Hsp40, Hsp110, and small Hsps [108-
111]. In vitro, Hsp104 can dissolve fibrils composed of tau, amylin, 
polyglutamine, amyloid beta, prion protein, and aSyn that are associated with 
human diseases [88, 109, 112]. Hsp104 has also been applied in several animal 
disease models. Hsp104 expression reduces polyglutamine toxicity in 
Caenorhabditis elegans, fly, and rodent models [113-116]. Hsp104 reduces 
dopaminergic neuron degeneration in a rat model of Parkinson’s disease [109]. 
Indeed, Hsp104 is the only protein factor known to eliminate aSyn oligomers and 
fibrils and exhibit protective effects in the rat substantia nigra [109]. Furthermore, 
the substantia nigra of rats expressing Hsp104 and aSyn have a decreased load 
of phosphorylated aSyn inclusions, suggesting a link between the protein-
disaggregase activity of Hsp104 and the protection of dopaminergic neurons 
[109]. Thus, Hsp104 can indeed buffer proteotoxicity in diverse animal systems 
and is a therapeutic candidate for several neurodegenerative disorders. 
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However, Hsp104 activity against neurodegenerative disease proteins can be 
limited, and typically high concentrations of Hsp104 are required for modest 
disaggregation [88]. 
 
1.6 Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding 
events 
Can Hsp104 be re-engineered to more potently suppress toxicity of 
neurodegenerative disease-linked substrates? Large libraries of Hsp104 variants 
have been generated, introduced into yeast models of TDP-43, FUS, and aSyn 
toxicity, and screened for suppressors of proteotoxicity [108, 117-120]. In this 
way, dozens of Hsp104 variants, differing from the wild-type protein by single 
missense mutations in NBD1 (e.g. Hsp104Q347L), the middle domain (e.g. 
Hsp104A503V), and NBD2 (Hsp104N566I), that potently antagonize toxicity of a 
range of neurodegenerative disease-linked proteins, including TDP-43, FUS, 
aSyn, have been isolated [108, 118, 120, 121]. Potentiated Hsp104 variants 
have a substantially increased ATPase, disaggregase, and unfoldase activities 
relative to wild-type Hsp104, and efficiently eradicate preformed fibrils composed 
of TDP-43, FUS, and aSyn [108, 121]. Thus, potentiated Hsp104 variants have 
substantial ability to disaggregate disordered luciferase aggregates even in the 
absence of Hsp70 and Hsp40, whereas wild-type Hsp104 has no activity in this 
context [108]. Consistent with these ensemble observations, HX-MS studies 
reveal that some potentiated variants accelerate ADP release, thereby increasing 
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ATPase activity [122]. Subunit doping experiments demonstrate that potentiated 
variants are more resilient to subunits that are defective in ATP hydrolysis [108]. 
Collectively, these results suggest that potentiated Hsp104 variants are more 
robust ATP-dependent protein disaggregases. 
Potentiated Hsp104 variants also protect against proteotoxic damage in 
vivo in metazoan systems. Thus, they protect dopaminergic neurons in C. 
elegans from aSyn-mediated degeneration [108]; and disassemble FUS 
inclusions in mammalian cells [123]. However, the increased disaggregase 
activity observed for potentiated variants is a double-edged sword: although the 
increased activity facilitates the counteraction of proteotoxic misfolding, 
potentiated variants are also promiscuous unfoldases [121], which can lead to 
toxicity [108]. In vitro protein unfolding experiments have been informative in this 
respect. Potentiated Hsp104 variants unfold GFP bearing both a short unfolded 
hexahistidine tag as well as a longer RepA1-70 tag whereas wild-type Hsp104 
does not unfold either substrate in the presence of ATP and only unfolds RepA`1-
70-GFP in the presence of a mixture of ATP and ATPgS [121], suggesting that 
toxicity arises through promiscuous unfolding of transiently unfolded polypeptides 
within nearly-native proteins or complexes. Thus, strategies to mitigate off-target 




1.7 Research aims 
 Several obstacles impede our ability to develop therapeutic Hsp104 
variants. We do not understand how Hsp104 selects clients for unfolding and 
disaggregation, which limits our ability to tailor Hsp104 activity for specific 
substrates. This issue is problematic because artificial potentiated Hsp104 
variants can have damaging, off-target effects due to promiscuous unfoldase and 
disaggregase activity, which might restrict therapeutic applications. Second, 
Hsp104 sequence space remains largely unexplored. Thus, it is unclear, for 
example, whether natural Hsp104 homologs exist with divergent enhanced and 
selective activity against neurodegenerative disease substrates. In this thesis, I 
investigate how Hsp104 sequence space can inform our understanding of how to 
engineer Hsp104 for therapeutic purposes. In Chapter 2, I present a structural 
and functional characterization of an Hsp104 homolog from the thermophilic 
fungus Calcarisporiella thermophila (CtHsp104) and demonstrate that while 
structural organization of Hsp104 is conserved, it has divergent therapeutic 
activity to counteract aSyn, polyglutamine, and TDP-43 toxicity in yeast. In 
Chapter 3, I explore how pervasive therapeutic Hsp104 variants are among 
natural Hsp104 homologs by characterizing a collection of 15 additional Hsp104 
homologs from diverse eukaryotes and 2 prokaryotic species. I discovered that 
natural therapeutic Hsp104 variants are widespread. In contrast to CtHsp104, 
other therapeutic Hsp104 homologs are typically substrate-specific. Therapeutic 
Hsp104 homologs antagonize TDP-43 and aSyn condensate formation in yeast, 
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human cells, and C. elegans. Mechanistic studies and mutational analysis 
suggest that therapeutic activities are due to genetic variation that impacts 
passive chaperone activity of Hsp104 homologs for select substrates. Thus, our 
results highlight passive chaperone activity as a mode of toxic substrate 
neutralization by Hsp104 and suggest that manipulating passive chaperone 
activity of Hsp104 is a novel route to generating substrate-specific designer 




CHAPTER 2 STRUCTURE OF CALCARISPORIELLA 
THERMOPHILA HSP104 DISAGGREGASE THAT ANTAGONIZES 
DIVERSE PROTEOTOXIC MISFOLDING EVENTS 
 
This chapter has been previously published: Michalska K.*, K. Zhang*, Z.M. 
March*, C. Hatzos-Skintges, G. Pintilie, L. Bigelow, L.M. Castellano, L.J. Miles, 
M.E. Jackrel, E. Chuang, R. Jedrzejczak, J. Shorter^, W. Chiu^, and A. 
Joachimiak^. (2019). Structure of Calcarisporiella thermophila Hsp104 
disaggregase that antagonizes diverse proteotoxic misfolding events. Structure. 




 During severe stress conditions, the capacity of the cell to protect its 
proteins can become overwhelmed by excessive misfolding and aggregation. 
However, once normal conditions are restored, the aggregation process is 
reversed by specialized disaggregases that reactivate proteins trapped in 
aggregates. These include the hexameric AAA+ protein Hsp104 [87]. In yeast, 
Hsp104 provides several selective advantages, including: (1) conferring 
thermotolerance by refolding proteins trapped in heat-induced aggregates [87], 
(2) remodeling amyloid fibrils, which empowers yeast to harness protein-based 
epigenetic elements (prions) for adaptive purposes [87], (3) promoting 
degradation of select substrates [124, 125], (4) regulating material properties of 
membraneless organelles [83], and (5) promoting yeast longevity and fitness by 
ensuring partitioning of damaged proteins and aggregates to the mother cell 
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during cell division [87]. Protein disaggregases such as Hsp104 are unique 
among protein-remodeling factors as they can unfold misfolded and aggregated 
proteins. This disaggregase activity offers an intriguing therapeutic strategy to 
restore proteostasis in humans where it has gone awry, as with 
neurodegeneration [117]. 
  Hsp104 forms hexamers that harbor a central channel through which 
substrate is translocated [87]. Each protomer is composed of five domains: an N-
terminal domain (NTD) that has roles in substrate recognition and translocation, 
two nucleotide-binding AAA+ domains (NBDs 1 and 2, further divided into large-
L, and small-S subdomains) that bind and hydrolyze ATP and translocate 
substrate, a coiled-coiled middle domain (MD) insertion in NBD1 that enables 
interdomain communication and collaboration with the Hsp70 chaperone system, 
and a short C-terminal tail (CTT) that has been reported to be necessary for 
hexamer formation (Figure 2-1A) [87]. 
 Several structures of bacterial ClpBs and eukaryotic Hsp104 variants have 
been reported with varying resolution and complex architecture (Table 2-1). Low-
resolution (11–21 Å) cryo-electron microscopy (cryo-EM) single-particle 
reconstructions of ClpB from Thermus thermophilus (TtClpB) in the apo state or 
complexed with ADP [126] or with AMP-PNP [127] show flat hexameric rings with 
a substantial internal cavity. Similar arrangements were reported for low-
resolution cryo-EM structures of an Escherichia coli ClpB (EcClpB) derivative 
BAP (ClpB variant engineered to interact with ClpP where S722-N748 of ClpB 
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are replaced with V609-I635 of ClpA) complexed with ClpP [128], and for 
Saccharomyces cerevisiae Hsp104 (ScHsp104) variant Hsp104N728A complexed 
with ADP, ATP, or ATPγS [129, 130]. Only in one case was an attempt made to 
obtain reconstruction with no symmetry imposed [129], all other models were 
generated with C6 symmetry. Recently, much higher-resolution (4-5 Å) cryo-EM 
structures have been reported for ScHsp104 [85, 96] and BAP [131], which 
revealed dramatic nucleotide- and substrate-dependent changes in complex 
architecture. For instance, ScHsp104 adopts an open left-handed helical 
hexamer in the presence of AMP-PNP [85, 96] whereas ScHsp104 adopts a 
closed, right-handed helical hexamer when complexed with ATPgS and casein 
[85, 96]. Additionally, several crystal structures of TtClpB (Lee et al., 2003), 
EcClpB [128], and Hsp104 from Chaetomium thermophilum (ChtHsp104) [132] 
show that protomers are arranged in left-handed helical filaments that are 
reminiscent of the discrete helical hexamers observed via cryo-EM. The various 
hexameric models advanced for Hsp104 may represent different stages of the 
folding pathway or different functional states of the Hsp104 conformational 
ensemble. However, the quality of the models varies widely. In some structures, 
only the NBDs and MDs can be modeled [128, 131]. In two EcClpB structures, 
the NTDs have been modeled (Protein Data Bank (PDB) ids: 4D2U and 4D2Q). 
Thus, to better understand how Hsp104 architecture relates to function a higher 
resolution view is needed. 
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Sequence diversity among Hsp104 orthologs has important functional 
implications. For instance, ScHsp104 possesses potent amyloid-remodeling 
activity necessary for inheritance of beneficial yeast prions whereas bacterial 
ClpB has limited ability to remodel amyloid [88]. Moreover, single missense 
mutations within ScHsp104 can profoundly enhance functionality [108, 119]. At 
the same time, the vast majority of sequence space among natural Hsp104s 
remains unexplored. For example, it is unclear whether there are natural Hsp104 
variants with divergent enhanced or selective activity against misfolded proteins 
implicated in neurodegenerative diseases, such as aSyn or TDP-43. Indeed, 
Hsp104 variants with desirable therapeutic disaggregase activity may have 
arisen through natural selection as an adaptation to unique proteomes and 
environmental conditions. 
Here, we present data that advance our understanding of these two 
frontiers of Hsp104 structure and function. We determined the structures of 
Hsp104 from the thermophilic fungus Calcarisporiella thermophila (CtHsp104) in 
the presence of ADP by X-ray crystallography (at 2.70 Å) and cryo-EM single 
particle reconstruction (at 4.0 Å). Moreover, we establish that CtHsp104 
antagonizes several toxic protein-misfolding events where ScHsp104 is 
ineffective, including rescue of TDP-43, polyglutamine (polyGlu), and αSyn 
toxicity. Thus, we provide the first evidence for a natural Hsp104 ortholog with 




Table 2–1 Structures of ClpB and Hsp104 variants available in EMD and PDB 
sorted by resolution. 
Rh and Lh correspond to right- and left-handedness of the oligomer, NS stands for 
negative staining. 








ClpBY503D E. coli ATPγS NS-EM Flat 20 Å [128] 4D2X/2559 
ClpBE432A E. coli ClpP NS-EM Flat 18 Å [128] 4D2Q/2555 
ClpB T. thermophilus apo Cryo-EM Flat 17.7 Å [127] 1241 
ClpB E. coli ClpP NS-EM Flat 17 Å [128] 4D2U/2557 
ClpB T. thermophilus ADP Cryo-EM Flat 16.7 Å [127] 1242 
Hsp104N728A S. cerevisiae ATPγS Cryo-EM Flat 13 Å [130] [130] 
1358/
1602 
Hsp104N728A S. cerevisiae ADP Cryo-EM Flat 12.8 Å [130] 1599 
ClpB T. thermophilus AMP-PNP Cryo-EM Flat 12.1 Å [127] 1243 
Hsp104N728A S. cerevisiae ATP Cryo-EM Flat 11.5 Å [130] 1600/1601 
ClpBE271A/E668A T. thermophilus ATP Cryo-EM Flat 11.2 Å [127] 1244 
Hsp104DN S. cerevisiae ATPγS Cryo-EM Flat 11 Å [130] 1359 
Hsp104 S. cerevisiae AMP-PNP Cryo-EM Lh Spiral 5.64 Å [85, 96] 5KNE 
Hsp104 S. cerevisiae ADP Cryo-EM Lh Spiral 5.6 Å [85, 96] 5VY8/8744 
ClpBDWB E. coli ATPγS/Casein Cryo-EM Rh Spiral 4.6 Å [131] 5OFO 
ClpBDWB E. coli ATPγS Cryo-EM Rh Spiral 4.5 Å [131] 5OG1 




Cryo-EM Rh Spiral 4.1 Å [85, 96] 5VYA/8746 




Cryo-EM Rh Spiral 4.0 Å [85, 96] 5VJH/8697 
Hsp104 C. thermophila ADP Cryo-EM Lh Spiral 4.0 Å This work 
6D00/
7782 
Hsp104 C. thermophilum ADP X-ray Lh Spiral 3.70 Å [132] 5D4W 
ClpB E. coli ClpP X-ray Lh Spiral 3.50 Å [128] 4CIU 
ClpB T. thermophilus ADP X-ray Lh Spiral 3.00 Å [127] 1QVR 





2.2.1 Crystal structure of CtHsp104 
We crystallized a double arginine-finger mutant (R328M/R757M) of CtHsp104 
(CtHsp1042R) in complex with ADP. The complex crystallized in the P65 space group with 
a single protein chain in the asymmetric unit. We determined its structure by molecular 
replacement using individual subdomains of ClpB homologs from T. thermophilus and E. 
coli as search probes (see Methods). The structure was refined to 2.70 Å resolution 
(Figures 2-1B, C). 
Similarly, to other eukaryotic Hsp104 variants, CtHsp104 consists of five 
domains: NTD (residues 1-144) followed by a 13-residues long linker 145-157), NBD1 
(residues 158-404 and 530-547), MD (residues 405-529), NBD2 (residues 548-861) and 
CTT (residues 863-882), part of which remains disordered (Figure 2-1A). In the crystal 
structure, both NBDs bind ADP (Figures 2-1B, C). The CTT is enriched in acidic 
residues and is unique to eukaryotic Hsp104 variants but somewhat variable among 
orthologs (Figure 2-2). Conserved channel-facing loops in the NBDs are disordered, 
including the two canonical tyrosine-containing loops, B6-B7 and D7-D8, that engage 
translocating substrate and another channel-facing segment, loop B8-B9 [85]. 
Our structure reveals some notable differences compared to previous Hsp104 
crystal structures. These include the resolvability and location of the NTD. The NTD is 
located in close proximity to NBD1 in TtClpB, whereas the NTD-NBD1 linker in 
CtHsp104 is nearly fully extended, positioning the NTD ~30 Å away from NBD1 (Figure 
2-3A). In ChtHsp104 and EcClpB structures NTDs are disordered. Additionally, we 
observe helix L2 of the MD of CtHsp104 is bent while helices L3 and L4 are fused into a 
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single long helix L3, similar to the structure of ChtHsp104 (Heuck et al., 2016) (Figure 2-
1B,C; Figure 2-3A,B).  
 In the crystal lattice, molecules are packed along a 65 screw axis to form a left-
handed spiral filament with a 16.2 Å rise. This arrangement is similar to the packing 
previously observed for ChtHsp104 [132], which has ~53% sequence identity with 
CtHsp104. In ChtHsp104, the space group was determined as P21, with 3 molecules in 
the asymmetric unit and twinning [132]. However, closer inspection suggests that 
different interpretations, including one in the P65 space group, are possible. The 
observed helical motif is reminiscent of the architecture displayed in the crystal structure 
of TtClpB (~52% sequence identity with CtHsp104) [127], where the hexagonal 
symmetry is slightly violated (Figure 2-3F), and EcClpB (~49% sequence identity with 
CtHsp104) [128]. While rather loose packing of the TtClpB molecules creates a wider 
central tunnel along the filament, the tighter interprotomer associations in ChtHsp104 




Figure 2–1 Crystal structure of CtHsp104. 
(A) The domain architecture of Hsp104, showing residue numbers corresponding to 
domain boundaries. Sections colored gray are not visible in the crystal structure. (B) The 
crystal structure of monomeric CtHsp104 showing the domain arrangement. (C) 
Secondary structure of CtHsp104 to illustrate packing contacts created by the 
molecules, second monomer is shown in a surface representation. Missing segments 





Figure 2–2 Sequence alignment of Hsp104 homologs and TtClpB 




Figure 2–3 Comparison of Hsp104/ClpB crystal structures. 
(A) Superposition of CtHsp104 (magenta, this work) with ChtHsp104 (green, chain D; 
[132]) and TtClpB (yellow, chain B; [127]). (B) Superpositions of MDs, color coding as in 
A). (C) Superpositions of NTDs: CtHsp104 (magenta), TtClpB (yellow, chain B) TtClpB 
(orange, chain C). (D-F) Surface representation of CtHsp104, ChtHsp104 and TtClpB, 
respectively. Every other protomer is colored grey. Darker shades correspond to the N-
terminal domain. The ADP nucleotide is shown in red. The minimal “tunnel” seen in 
CtHsp104 is a result of incomplete model with residues 248-250 not visible in the 




2.2.2 The CTT 
The C-terminal region of Hsp104, including conserved VLPNH motif 
(V857IRNH861 in CtHsp104) and the acidic stretch of residues unique to eukaryotic 
orthologs, has been previously named C-terminal domain (CTD). In ScHsp104, 
this fragment has been linked to various functions, including cochaperone 
recruitment [133] and hexamerization [103]. Analysis of the available Hsp104 and 
ClpB structures indicates that the VLPNH motif rather than being an extension 
actually belongs to NBD2, whereas the non-globular fragment, here termed CTT, 
corresponds to downstream ~20 amino acids (Figures 2-1A; Figure 2-4). In 
CtHsp104, Val855 (Val889 in ChtHsp104) is part of the e3 β-strand while the 
following section is connected to NBD2 by interactions with helix E3 and the 
subsequent E3-e2 loop (Figure 2-4). This association is enabled by non-
conserved Arg859, which is typically substituted by a proline residue in other 
homologs, as seen in ChtHsp104 (Figure 2-4). In the latter case, no stabilizing 
hydrogen bonds can be made and the visible portion of the C-terminal region 
following the e3 strand protrudes from the domain body. A similar arrangement is 
observed in TtClpB, in which the e3 strand and its flanking region, though not 
identical in sequence, obey the general chemical characteristics (hhPxb where h-




Figure 2–4 Structure of C-terminal region of Hsp104. 
(A) C-terminus of CtHsp104 shown in 2DFo-mFc electron density map contoured at 1.2σ 
level. Hydrogen bonds are shown as red lines. Protomer n is colored grey and protomer 
p-1 is colored pink. (B) Superposition of CtHsp1042R (grey and pink) with ChtHsp104 
(green, [132]) and TtClpB (yellow, [127]). (C) Sequence alignment of C-terminus of 
CtHsp104, ChtHsp104, ScHsp104 and TtClpB (Prepared with Espript [134]). (Work of 
Dr. Karolina Michalska) 
 
2.2.3 Cryo-EM single particle reconstruction of CtHsp104 
Given the apparent non-active conformation of CtHsp104 in the crystal, 
we used cryo-EM single particle analysis to investigate the structure of wild-type 
(WT) CtHsp104 in vitrified solution (Figure 2-5A, B). The reconstructed 3D map 
(Figure 2-5C), determined from over 220,000 particles, has a resolution of 4.4 Å 
unmasked or 4.0 Å masked (Figure 2-5D). The NBDs and MD are well resolved 
at 3-5 Å (Figure 2-5C). However, the flexible NTD-NBD1 linker allows several 
possible NTD orientations, limiting NTD resolution to ~10 Å (Figure 2-5C). 




Our cryo-EM structure reveals that CtHsp104 forms an open one-turn left-
handed spiral hexamer, similar to those reported for ScHsp104 [96] (Figure 2-
5C; Figure 2-6A,B,C). Cryo-EM map for all domains is visible in each of the six 
protomers (P1-P6) (Figure 2-6A,B,C; Figure 2-8; Figure 2-9). In particular, MDs 
are resolved well for 5 protomers (P1-P5), compared with 3/6 for ScHsp104 
maps (Figure 2-9). All helices in the NBDs matched well with helical densities in 
the map (Figure 2-5; Figure 2-6; Figure 2-7; Figure 2-8; Figure 2-9; Figure 2-
10).  
As in ScHsp104, NBD1 and NBD2 from the 6 protomers form a helix, with 
NBD2 from P1 contacting NBD1 of P6 at the seam (Figure 2-6A). The MD in P1 
reaches across but does not contact the MD of P6 (Figure 2-6A). Thus, the 
CtHsp104 structure observed by cryo-EM is significantly more open than that 
observed in the crystal. Interestingly, we also found classes (representing ~10% 
particles) without density for the MD, which shows an even more open cleft (data 
not shown). 
AAA+ interfaces are similar in the crystal filament and cryo-EM hexamer, 
except for the P1-P6 interface, where we observe an atypical interaction between 
NBD2 from P1 and NBD1 of P6, as reported for ScHsp104 [85, 96]. This 
interaction generates the spiral architecture. In P1, only NBD2 is supported by 
the interaction with NBD1 of P6. Nucleotide occupancy in P1 NBD1 is the lowest 
of the 12 AAA+ domains, although it varies at each binding site across all 6 
protomers (Figure 2-7C). Interactions between seam protomers also include an 
interaction between NBD2 (residues 852-854 from the e2-e3 hairpin) of P1 and 
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loop B4-B5 (residues 225-233) of P6. In protomers P2-P6, the C-terminal helix 
E3 (residues 816-835) from protomer p interacts with helix D4 (residues 575-590) 
in protomer p-1. Likewise, in protomers P2-P6, the MD of protomer p interacts 
significantly with the MD and NBD1 of protomer p-1. By contrast, in P1 the MD is 
largely unbound. Two loops in (p-1)NBD1 are involved in its interaction with the 
MD, including loop B4-B5 (residues 225-233) (same residues that in P6 contact 
the P1 NBD2 at the seam), and loop B3-b2. 
 
 
Figure 2–5 Quality of cryo-EM data. 
(A) Cryo-EM micrograph and (B) class averages of CtHsp104 particles. (C) Resmap 
coloring of complex, showing higher resolutions for Nuclear Binding Domains (NBDs), 
and lower resolutions for N-Terminal Domains (D) Gold standard Fourier Shell 






Figure 2–6 The cryo-EM and X-ray structures of CtHsp104. 
(A) Segmented complex with each protomer (P1-P6) colored differently in cryo-EM model. 
(B) Same structure as in (A), but with each domain colored differently. (C) Each domain 
is drawn using a simplified representation (ellipsoid); helices in MD which extend from one 
protomer to another are drawn as green tubes. (D) Crystal structure is drawn using a 
simplified representation (ellipsoid), the NTD domains are in vastly different positions in 
the crystal compared to the cryo-EM complex, illustrating the high flexibility of the NTD-






Figure 2–7 CtHsp104 nucleotide binding sites in cryo-EM protomer 5 and in the X-
ray structure. 
(A) Protomer 5 of the cryo-EM structure, with NBD1 and NBD2 nucleotide binding 
pockets enlarged to show detail. (B) In the crystal structure, the P protomer is shown in 
grey, the (p-1) protomer is shown in pink. The ADP moiety is shown in ball-and-stick 
model in 2mFo-DFc electron density map contoured at 1σ level. (C) Relative occupancy 
of ADP in cryo-EM structure for NBD1 and NBD2 ADP sites in each protomer 1 through 





Figure 2–8 Protomer orientation in the cryo-EM map. 
Hexameric complex fitted to cryo-EM map (top left), and pairs of individual protomers 
arranged so as to show interactions (top row). On the top row, the black arrow points to 
the MD domains from P6, P4 and P2 which are in different position w.r.t. the protomers 
P5, P3 and P2. These different positions may be dependent on nucleotide binding or 
other arrangements of the NBD1 and NBD2 domains based on the protomer’s position in 
the complex. The bottom row shows the protomers expanded but in the same orientation 
they have in the complex. The relative step along the spiral is also indicated. Similar 
steps are seen for P5, P4 and P3 w.r.t. P6, however bigger steps are seen for P2 and 




Figure 2–9 Comparison of protomer orientations in three Hsp104 cryo-EM maps. 
Linearly arranged protomers 1 through 6 from three cryo-EM data sets: CtHsp104 (top), 
ScHsp104-AMP-PNP [96], and ScHsp104-ATP [85]. An arrow indicates rise along 





Figure 2–10 Nucleotide binding sites in CtHsp104 protomers. 
Nucleotide highlighted (red) in binding pockets in NBD1 (dark blue) and NBD2 (light 
blue) in each protomer of Hsp104. NTD is shown in purple and CTT shown in orange. 
(Work of Dr. Kaiming Zhang) 
 
2.2.4 Nucleotide binding by CtHsp104  
In the crystal structure, protomers interact via canonical AAA+ interfaces: 
NBD1-NBD1 and NBD2-NBD2 (Figure 2-1C). In this arrangement, nucleotide-
binding sites of both NBDs are occluded by the neighboring protomer, but the 
ADP ligands are bound exclusively by one NBD chain (Figure 2-1B,C). 
Specifically, the lower-affinity site in NBD1 [135] shows nucleotide anchored by 
hydrophobic interactions with the adenine ring and hydrogen bonds between the 
diphosphoryl group on ADP and the P-loop of the NBD (Figure 2-7A,B). The 
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putative arginine fingers from the adjacent protomer, R327 and mutated R328M 
are located in the same vicinity, but do not participate in nucleotide binding, as 
seen in the crystal structure (Figure 2-7B). It is noteworthy that they may only 
bind to the g-phosphate of ATP and not necessarily interact with ADP. The side 
chain of R328M is trapped between helices B9 and B11 whereas the poorly 
defined R327, appears to stack against helix B11 (Figure 2-7B). NBD1-NBD1 
interactions involve several hydrogen bonds: helix (p-1)B11 interacts with the b3-
B6 section (with participation of D239), loop (p-1)B3-b2 and helix B5 bind to helix 
C3. R196 from (p-1)B3-b2 also bridges with loop B2-B3 (Figure 2-7B). The high-
affinity site in NBD2 [135] shows the ADP molecule forming a similar pattern of 
interactions as in NBD1, namely hydrophobic contacts between the base and 
protein and hydrogen bonds connecting the diphosphoryl group and sugar moiety 
to the NBD (Figure 2-7A,B). The side chain of the putative (p-1) arginine finger, 
R757M, is located between helices D12 and D10, more than 8 Å away from the 
closest oxygen atom of the diphosphoryl moiety (Figure 2-7B). The protomer-
protomer interactions involving NBD2 rely only on two hydrogen bonds between 
helix (p-1)D4 and helix E1 as well as a single hydrogen bond connecting (p-1)D2 
with helix E3. In contrast to NBD1, NBD2L subdomain does not interact with (p-
1)NBD2, possibly explaining the high mobility of NBD2 manifesting in poorer 
electron density and high temperature factors. 
The ATP ligand provided with the sample buffer appears to be hydrolyzed 
as the cryo-EM map is compatible with ADP binding in all NBDs, in a similar 
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arrangement as observed in the crystal structure (Figure 2-6C; Figure 2-10). 
Indeed, nucleotide-binding sites in P5, and two nearby arginine residues from P4 
are well resolved in the cryo-EM density. R327M, in particular, comes very close 
to the ADP molecule (Figure 2-11). 
 
 
Figure 2–11 Sample electron microscopy density maps. 
Top: Protomers 4 and 5 (left) and a close up on the nucleotide binding pocket (right). 
The density for the ADP molecule bound to P5 is clearly visible, as are two interacting 
arginine residues (196 and 327) from P4. Note that the latter are not as well resolved in 
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other protomers, which have lower relative ADP-occupancy. Bottom: Three fragments of 
the density showing resolved helices and beta sheets, as expected at ~4 Å resolution. 
(Work of Dr. Kaiming Zhang) 
 
2.2.5 Hexamer flexibility 
Comparison of the crystal and cryo-EM structures highlight dramatic 
conformational changes in: (1) channel width, (2) helical rise, and (3) NTD, 
NBD1, and MD orientation (compare Figure 2-3D,E,F; Figure 2-6C,D). The 
central channel ranges from the wide pore (25-30 Å), that could accommodate 
substrate in cryo-EM reconstructions, to a narrow one, as seen in the crystal 
filaments, which likely represent an inactive state. In all reported structures, the 
helical rise ranges from 0-16 Å within the left-handed spiral hexamers, 
suggesting a broad spectrum of possible protomer-protomer interfaces, perhaps 
even a continuum of states between the flat (as reported for some cryo-EM 
structurers) and spiral arrangements (Table 2-1). This high positional and 
conformational freedom may enable accommodation of diverse substrates and 
might promote local refolding of substrate secondary structure within the channel. 
Notably, the orientations of the NTD, NBD1, and MD change drastically between 
the crystal structure and cryo-EM structure (Figure 2-6C,D). In the crystal 
structure, the 13-residue linker connecting the NTD with NBD1 is in an extended 
conformation, placing the NTD ~30 Å outside of the spiral (Figure 2-6D). Thus, 
the NTD interacts with the MD on the next protomer without disrupting NBD-NBD 
contacts (Figure 2-1B; Figure 2-6D). In contrast, in the cryo-EM structure, the 
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NTD sits on “top” of the hexamer and contacts neighboring NTDs (Figure 2-6C). 
The P6 NTD contacts NBD1 on P1, limiting complex size to a hexamer (Figure 
2-6C). Overall, the hexameric assembly extracted from continuous spiral filament 
in the crystal shares several features with our cryo-EM model and prior 
reconstructions of ScHsp104 [85, 96]. 
 
2.2.6 Comparison of ScHsp104 and CtHsp104 structure 
 Two previous cryo-EM studies on ScHsp104 have revealed a spiral 
hexameric architecture, similar to the CtHsp104 structure [85, 96]. Figure 2-9 
shows each extracted protomer side by side for CtHsp104, ScHsp104-AMP-PNP 
[96], and ScHsp104-ADP [85]. The NTDs of ScHsp104 in the AMP-PNP and 
ADP states are visible in P3, P4, and P5, but not for P1, P2 and P6. In 
CtHsp104, all protomers have defined NTDs, however, they are not as well 
resolved as the rest of the map, at only ~10 Å (Figure 2-5C). MD resolution also 
varies in each state. Interestingly, in ScHsp104-AMP-PNP, the MD has a slight 
downward bend, whereas it is more horizontal in our cryo-EM map and model 
(Figure 2-9). These slight variations support the hypothesis that MD 
conformation is affected by the presence and type of nucleotide. 
 
2.2.7 CtHsp104 does not depend on the NTD or CTT for hexamerization 
To probe the determinants of CtHsp104 oligomerization in solution, we 
used size exclusion chromatography (SEC) and dynamic light scattering (DLS). 
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We tested CtHsp104 constructs lacking the NTD (CtHsp104ΔN, residues 153-
882) or the NTD and CTT (CtHsp104ΔNΔC, residues 153-864) with or without 
mutations in the Walker B motifs (E275Q:E679Q) or mutated arginine fingers 
(R328M/R757M; Table 2-2). Under low ionic strength conditions (100 mM KCl) 
all constructs migrate as hexamers in the presence of ATP. Specifically, the 
CtHsp104 hexamer is stable up to 50 µg/mL. Thus, as expected, the NTD is not 
required for hexamerization of CtHsp104. However, contrary to ScHsp104 [103], 
the CTT is also not required for CtHsp104 hexamerization. Indeed, 
CtHsp104ΔNΔC, which lacks 2/3 of the previously defined longer CTD, formed 
hexamers. Thus, CtHsp104 hexamerization is mediated entirely by NBD-NBD 
interactions. 
 
Table 2–2 Molecular weight of CtHsp104 constructs as determined by SEC and 
oligomerization state.  
(Work of Dr. Karolina Michalska) 










CtHsp104 1-888 613.6 98.7 592.2 
CtHsp104ΔN 153-888 522.0 81.8 490.9 
CtHsp104ΔN:ΔC 153-864 521.5 79.8 478.8 
CtHsp104ΔN:DWB  153-882-
E679Q/E275Q 
611.9 81.8 490.9 
CtHsp104ΔN:2R 153-882- 
R328M/R757M 




2.2.8 CtHsp104 is an ATP-driven disaggregase 
Biochemical assays were used to explore CtHsp104 functionality. First, we 
measured the ATPase activity of CtHsp104 and found that it was comparable to 
ScHsp104 (Figure 2-12A). Notably, CtHsp104 achieved optimal ATPase activity 
at 65 °C, while ScHsp104 had optimal activity at 42 °C (Figure 2-12B). Thus, 
CtHsp104 is likely adapted to function at higher temperatures, in keeping with the 
thermophilic lifestyle of C. thermophila. 
We next examined the disaggregase activity of CtHsp104 in vitro. We 
observed that CtHsp104 robustly disaggregated and reactivated luciferase 
aggregates, similar to ScHsp104 (Figure 2-12C, D). Both CtHsp104 and 
ScHsp104 were inactive alone, but were stimulated by Hsp70 and Hsp40, 
derived from yeast (Ssa1, Sis1, and Ydj1; Figure 2-12C) or human (Hsc70, Hdj1, 
and Hdj2; Figure 2-12D). 
Disaggregation of disordered aggregates by Hsp104 can be induced in the 
absence of Hsp70 and Hsp40 by the presence of a 1:1 mixture of ATP and 
ATPgS (Figure 2-12E) [88]. However, unlike ScHsp104, CtHsp104 was 
completely inactive under these conditions (Figure 2-12E). We performed the 
same disaggregation experiment at 30 °C, 37 °C, 42 °C, and 55 °C to determine 
whether CtHsp104 may have some Hsp70-independent luciferase 
disaggregation activity at elevated temperatures where CtHsp104 has enhanced 
ATPase activity. However, CtHsp104 was unable to reactivate aggregated 
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luciferase in every case (Figure 2-13A). One other possibility is that CtHsp104 
Hsp70-independent disaggregase activity is induced by a different ratio of 
ATP:ATPgS. For instance, while Hsp70-independent disaggregation by 
ScHsp104 is optimally induced by 50% ATPgS, ScHsp104A503V is optimally 
induced by 20-30% ATPgS (Torrente et al., 2016). However, we could not find an 
ATP:ATPgS mixture that stimulated CtHsp104 disaggregase activity (Figure 2-
13B). By contrast, ScHsp104 disaggregase activity was stimulated between 20-
80% ATPgS (Figure 2-13B). Thus, CtHsp104 responds differently than 
ScHsp104 and EcClpB to mixtures of ATP:ATPgS, revealing differences in how 




Figure 2–12 ATPase and disaggregase characteristics of CtHsp104. 
(A) ATPase activity of ScHsp104 and CtHsp104 assessed at 25° C. Values represent 
means ±SEM (n=2). (B) Temperature dependence of ScHsp104 and CtHsp104. Values 
represent means ±SEM (n=3). (C-D) Luciferase aggregates were incubated with 
ScHsp104 or CtHsp104 in the presence or absence of Ssa1 (0.167 µM), and 0.073 µM 
each Ydj1 and Sis1 (C) or equivalent amounts of Hsc70, Hdj1, and Hdj2 (D). Values 
represent means ±SEM (n=4). (E) Luciferase aggregates were incubated with ScHsp104 
or CtHsp104 in the presence of a 1:1 mixture of ATP and ATPγS. (F) SEVI fibrils (20 µM 
monomer) were incubated with buffer (untreated), ScHsp104 (3 µM), or CtHsp104 (3 
µM) for 0-24 hr. Fibril integrity was assessed by ThT fluorescence. Values represent 
means ±SEM (n=3-4). (Work of Dr. Laura Castellano) (G) Representative EM images of 
SEVI fibrils incubated with buffer (untreated), ScHsp104 (3 µM), or CtHsp104 (3 µM) for 
3 hr. (Work of Dr. Laura Castellano) (H) Δhsp104 yeast transformed with plasmids 
encoding ScHsp104 or CtHsp104 under the native HSP104 promoter heat-shocked at 50 
°C for the indicated time, cooled on ice, and plated onto SD-His medium. Cells were 





Figure 2–13 CtHsp104 disaggregase activity cannot be induced in the absence of 
Hsp70/40. 
(A) Luciferase disaggregation by the indicated Hsp104 in the presence of 50% ATPγS at 
the indicated temperatures. Values represent means ±SEM (n=3), and are normalized to 
ScHsp104 at 30 °C. (B) Luciferase disaggregation by the indicated Hsp104 in the 
presence of varying amounts of ATPγS at 25 °C. Values represent means ±SEM (n=3). 
 
2.2.9 CtHsp104 rapidly disassembles SEVI amyloids 
Next, we asked whether CtHsp104 can disassemble a recalcitrant, 
ordered amyloid. Thus, we chose SEVI amyloid fibrils that enhance HIV infection 
[89]. ScHsp104 remodels SEVI fibrils (Figure 2-12F,G) whereas EcClpB does 
not [89]. CtHsp104 also rapidly remodeled SEVI fibrils (Figure 2-12F,G). EM 
revealed that CtHsp104 and ScHsp104 remodeled SEV fibrils into small, 
amorphous structures (Figure 2-12F,G). Thus, amyloid-remodeling is likely a 
general property of eukaryotic Hsp104 orthologs, whereas prokaryotic Hsp104 
orthologs exhibit reduced amyloid-remodeling activity [77, 88, 89]. 
 










































2.2.10 CtHsp104 complements thermotolerance defects of Δhsp104 yeast 
Next, we defined how CtHsp104 functions in yeast. ScHsp104 is essential 
for acquired thermotolerance in yeast, where it reactivates heat-aggregated 
proteins [87]. To assess whether CtHsp104 can complement ScHsp104 function 
in thermotolerance, we transformed Δhsp104 yeast with a plasmid encoding 
CtHsp104 under the control of the native HSP104 promoter. Transformed yeast 
were pre-treated at 37 °C for 30 min to induce Hsp104 expression, then exposed 
to 50 °C heat stress for varying times. CtHsp104 expression conferred 
thermotolerance to yeast, albeit more weakly than ScHsp104. After a 20 min heat 
shock, ~40% of yeast expressing CtHsp104 survived compared with ~75% of 
yeast expressing ScHsp104 (Figure 2-12H). These observations combined with 
in vitro studies (Figure 2-12C) suggest that CtHsp104 can collaborate effectively 
with ScHsp70 and ScHsp40, dispelling the notion of a stringent species barrier 
between Hsp104 and Hsp70. 
 
2.2.11 CtHsp104 rescues diverse proteotoxicity models 
  Next, we asked whether CtHsp104 could suppress proteotoxicity in yeast 
associated with expression of several proteins: αSyn, polyGlu, and TDP-43, 
involved in human neurodegenerative disease. αSyn is a lipid-binding protein that 
normally localizes to the plasma membrane, but mislocalizes to aberrant 
cytoplasmic inclusions termed Lewy Bodies in degenerating dopaminergic 
neurons in Parkinson’s disease [117]. This phenotype can be mimicked in yeast, 
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where overexpression of αSyn is toxic [117]. Expanded polyGlu tracts in several 
proteins are sufficient to cause severe neurodegenerative diseases, including 
Huntington’s disease and the spinocerebellar ataxias [136], and in yeast 
overexpression of extended polyGlu tracts (e.g. 103Q) is toxic [137]. TDP-43 is 
an RNA-binding protein with a prion-like domain that mislocalizes from the 
nucleus and forms cytoplasmic aggregates in degenerating neurons of ALS and 
FTD patients and also forms cytotoxic inclusions in yeast [117]. Coexpression of 
ScHsp104 is insufficient to mitigate the aggregation and toxic phenotypes 
associated with overexpression of any of these proteins [108] (Figure 2-
14A,B,C). However, we have defined a suite of potentiated ScHsp104 variants 
such as ScHsp104A503S, that can potently suppress toxicity associated with 
overexpression of TDP-43, αSyn, and FUS in yeast and metazoa [117] (Figure 
2-14A,B,C). We transformed yeast overexpressing TDP-43, αSyn, or an 
expanded polyGlu tract (103Q) with CtHsp104 to determine whether CtHsp104 
could ameliorate toxicity associated with overexpression of any of these proteins. 
We observed a modest rescue of TDP-43 toxicity upon CtHsp104 
overexpression, whereas ScHsp104 was ineffective and ScHsp104A503S strongly 
suppressed TDP-43 toxicity (Figure 2-14A). To our surprise, CtHsp104 robustly 
rescued αSyn and polyGlu toxicity (Figure 2-14B,C). Indeed, CtHsp104 was 
almost as effective as ScHsp104A503S in rescuing αSyn toxicity and similar in 
efficacy to ScHsp104A503S in rescuing 103Q toxicity (Figure 2-14B,C). By 
contrast, ScHsp104 was ineffective (Figure 2-14B,C). Further, rescue of TDP-
43, αSyn, and 103Q toxicity by CtHsp104 was not due to decreased expression 
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of these disease proteins (Figure 2-14A,B,C). Thus, unlike ScHsp104, CtHsp104 
is naturally endowed with the ability to combat TDP-43, αSyn, and 103Q toxicity. 
The NTD of Hsp104 has roles in substrate recognition and inter-subunit 
collaboration within hexamers, and deletion of the Hsp104 NTD inhibits 
potentiated activity against neurodegenerative disease proteins [138]. Hence, we 
tested whether CtHsp104ΔN suppressed αSyn and polyglutamine toxicity. 
CtHsp104ΔN suppressed αSyn and polyglutamine toxicity as well as CtHsp104WT 
(Figure 2-14D). Thus, the NTD of CtHsp104 is dispensable for its ability to 
rescue αSyn and polyglutamine toxicity in yeast. 
 
2.2.12 Rescue of polyGlu toxicity is not simply due to the elimination of 
Rnq1 prions  
Expression of polyGlu proteins is only toxic in yeast that also harbor the 
prion [RNQ+] [137]. Overexpression of polyGlu in [rnq-] strains (which lack Rnq1 
prions) is non-toxic [137]. Therefore, it is possible that CtHsp104 could rescue 
polyGlu-associated toxicity either by directly antagonizing polyGlu misfolding and 
aggregation or through disruption of [RNQ+] inheritance. To assess the latter 
possibility, we monitored the conformational state or Rnq1, the protein 
determinant of [RNQ+], in yeast expressing 103Q and Hsp104 variants using 
semi-denaturing detergent agarose gel electrophoresis (SDD-AGE). In 103Q 
yeast transformed with an empty vector we observed SDS-resistant Rnq1 
polymers indicative of Rnq1 prions (Figure 2-14E). By contrast, an isogenic [rnq-] 
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strain was resistant to polyGlu toxicity and lacked SDS-resistant Rnq1 polymers 
(Figure 2-14C,E). Overexpression of ScHsp104 had little effect on SDS-resistant 
Rnq1 polymers (Figure 2-14E). SDS-resistant Rnq1 polymers were reduced in 
strains expressing ScHsp104A503S, CtHsp104, and CtHsp104ΔN but were still 
present compared to the [rnq-] control, which entirely lacked these species 
(Figure 2-14E). Thus, it is unlikely that CtHsp104 or Hsp104A503S rescue of 103Q 
toxicity is solely due to [RNQ+] disruption. 
CtHsp104 antagonizes several toxic protein-misfolding events where 
ScHsp104 is ineffective, including rescue of TDP-43, polyGlu, and αSyn toxicity. 
Remarkably, CtHsp104 achieved this rescue without exhibiting any off-target 
toxicity at 37 °C, unlike potentiated Hsp104 variants like Hsp104A503V or 
Hsp104A503S which are toxic to yeast at 37°C (Figure 2-14F). Thus, CtHsp104 
confers enhanced protection against neurodegenerative disease proteins without 
toxic side effects, a valuable feature for a potential therapeutic agent. These 
results suggest that natural Hsp104 variation is an invaluable, untapped resource 




Figure 2–14 CtHsp104 rescues diverse proteotoxicity models. 
(A-C) Δhsp104 yeast transformed with plasmids encoding galactose-inducible TDP-43 
(A) or αSyn-YFP (B) and the indicated galactose-inducible FLAG-tagged Hsp104 were 
serially diluted fivefold and spotted onto glucose (expression off) or galactose 
(expression on). (C) Wild-type yeast transformed with plasmids encoding galactose-
inducible 103Q-CFP and the indicated galactose-inducible FLAG-tagged Hsp104 were 
serially diluted fivefold and spotted onto glucose (expression off) or galactose 
(expression on). (D) Δhsp104 yeast expressing αSyn-YFP or 103Q-CFP and 
CtHsp104WT or CtHsp104ΔN were serially diluted fivefold and spotted onto glucose 
(expression off) or galactose (expression on). (E) (top) Lysates from yeast expressing 
103Q-CFP and the indicated Hsp104 were subjected to Semi-Denaturing Detergent 
Agarose Gel Electrophoresis (SDD-AGE) and probed for endogenous Rnq1 prions using 
a polyclonal anti-Rnq1 antibody. (bottom) The same lysates were subjected to SDS-
PAGE and Western blotting for total Rnq1 and PGK to confirm equal loading of samples. 
(F) CtHsp104 does not exhibit reduced growth at 37°C. Hsp104 variants were expressed 
in the 416GAL vector in Δhsp104 yeast in the absence of any disease protein. The 
strains were serially diluted five-fold and spotted in duplicate onto galactose (inducing) 





Figure 2–15 The effect of ADP on MD conformation. 
(A) The NBD1 ADP binding site is directly adjacent to helices C1 (residues 339-357) and 
C3 (residues 384-402) (bright blue for emphasis, with several resolved side chains), 
which is in turn with the MD domain (green). Hence, binding of ADP and subsequent 
hydrolysis potentially directly affects the conformation of the MD domain. (B) The same 
ADP-affected region shown for two protomers, P4 (with the highest ADP occupancy for 
NBD1), and P1 (the lowest ADP occupancy). The presence of ADP favors a 
conformation where the two helices C1/C3 (bright blue) are pulled towards the ADP, in 
turn pulling the MD domain inward as well. Crystal structure is most similar to protomer 











The AAA+ protein disaggregase Hsp104 is conserved in all nonmetazoan 
eukaryotes and eubacteria, although attention has historically been focused on 
Hsp104 from S. cerevisiae and the bacterial ortholog ClpB. Here, we present the 
highest resolution crystal structure combined with cryo-EM single particle 
reconstruction of the spiral hexamer in vitrified solution of a eukaryotic Hsp104 
ortholog from the thermophilic fungus C. thermophila. The main body of 
CtHsp104 hexamers is composed of the two AAA+ NBDs that are encircled by 
the six MDs forming a ring-like unit in the crystal and interrupted ring in solution. 
The “top” site, decorated by NTDs that are highly flexible, can adopt very 
different orientations (Figure 2-1; Figure 2-3; Figure 2-5), and a “bottom” site 
renders for the first time the location of the CTT. Comparisons of our crystal and 
cryo-EM structures highlight dramatic conformational changes in (1) channel 
width, (2) helical rise, and (3) NTD, NBD1, and MD orientations (Figure 2-
3D,E,F; Figure 2-6C,D).  
The structures presented here add to a range of structural data 
demonstrating that Hsp104 forms a highly dynamic assembly. The channel width 
ranges from the wide pore observed (diameter ~25-30 Å) in cryo-EM 
reconstructions that appears to be ready to accept substrate to very narrow one 
(diameter ~8-10 Å), as seen in the crystal filaments, which may represent an 
inactive state. The helical rise ranges from 0-16 Å for all structures, suggesting 
that Hsp104 may exist in many stable or transient states that evolved to 
accommodate many protein sequences [88]. Notably, the relative orientations of 
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the NTD, NBD1, and MD change dramatically between our crystal structure and 
cryo-EM structure. In the crystal, the NTD is located away from the hexamer, 
allowing the MD to intercalate between NBD1 and the NTD. By contrast, in the 
cryo-EM structure the NTDs are located over the central channel of the hexamer 
and MDs wrap around adjacent NBD1s, consistent with previous reports [96]. We 
suggest that these conformational rearrangements are involved in the formation 
and function of Hsp104 hexamers and suggest a possible “breathing motion” in 
the hexamer, complementing the large conformational changes upon ATP 
hydrolysis documented by others [85, 87, 96, 138]. Overall, our findings support 
the conformational flexibility of Hsp104, and we suggest that such flexibility may 
be a generic feature of AAA+ proteins, facilitating torque generation to 
translocate substrate [139, 140]. 
The cryo-EM structure shows that ADP occupancy differs across all 6 
protomers (Figure 2-7C). ATP binding and hydrolysis drives conformational 
changes, which presumably enable translocation of the protein through the 
central channel of the hexameric assembly. The cryo-EM structure provides 
some indication about conformational differences between ADP-bound and ADP-
free states as illustrated in Figure 2-15. Two helices (C1 and C3) of NBD1, which 
are adjacent to the nucleotide-binding site, are directly connected to the MD. In 
our map, several bulky side chains in this area are moderately resolved, e.g. 
D384 close to the ADP binding site, Y353, D391, H356, H357 in the middle of the 
two helices, and R399, R469 and Y458 close to where they contact the MD. 
While at ~4 Å resolution we cannot be fully certain of side-chain placements and 
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potential salt bridges, the α-helices themselves are well-resolved in all protomers, 
hence we are certain of their position (within ~1 Å positional error). Moreover, the 
crystal structure solved at 2.70 Å resolution provides more details of this network 
of interactions that connects MD, C1, C3 and the nucleotide-binding site. 
Severing these interactions will likely affect ATP binding and hydrolysis [118, 
141].  
To compare the conformations of the C1 and C3 helices for ADP-bound 
and ADP-less states, we aligned the protomers P1 (lowest ADP occupancy) and 
P4 (highest ADP occupancy) by aligning all residues in the NBD1 except for the 
C1 and C3 helices. The superposition is shown in Figure 2-15B. The two helices 
in protomer P1, the ADP-less-like state, are highlighted in bright red, and can be 
seen to be extending outwards from the ADP site, whereas the helices in 
protomer P4, the ADP-bound state, highlighted in bright blue, can be seen to be 
drawn in towards the ADP molecule (possibly because of the D384 residue). The 
difference in positions can be expressed roughly as a shift of ~10 Å and rotation 
of ~20°. The connection of these helices to the MD in turn appears to result in the 
MD of P1 being in a more ‘open’ position (more outward from the center of the 
complex) compared to the MD domain in protomer P4. 
The “bottom” of the hexamer is much more open and featureless with 
CTTs extending from NBD2 towards the outer edges of the assembly, about 25 Å 
from the central channel exit. Our structures indicate that CTT is not a structural 
domain and shows that the portion of previously identified CTD belongs to NBD2 
(Figure 2-4). Notably, CTT remains disordered in both crystal and cryo-EM 
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structures, indicating that this element does not participate in assembly 
stabilization. Indeed, deletion of 24 C-terminal residues does not impair 
hexamerization (Table 2-2). Two acidic motifs (DEDM and EDED) in the CTT are 
somewhat conserved among Hsp104 homologs (Figure 2-4), and for ScHsp104 
have been implicated in cochaperone binding and ATPase activity [103, 133]. 
Possibly in CtHsp104 it also modulates interactions with helper proteins such as 
Sti1, in analogy to similar motifs found in Hsp70 and Hsp90 [133, 142]. Indeed, 
C-terminal acidic residues of Hsp104 are critical to cure some Sup35 prion 
variants, as are cochaperones such as Sti1, which interact with this region of 
Hsp104 [143, 144]. Thus, these acidic motifs may indirectly facilitate processing 
and folding of substrates by recruiting downstream cochaperones. 
We have additionally established a range of activities for CtHsp104 in vitro 
and in vivo. CtHsp104 functionally complements ScHsp104 in acquired 
thermotolerance in yeast, and remodels SEVI amyloid fibrils in vitro. Intriguingly, 
CtHsp104 is able to robustly suppress toxicity of diverse proteins associated with 
neurodegenerative diseases, including αSyn, polyGlu, and TDP-43 similar to 
previously defined potentiated Hsp104 variants [108, 118]. However, the 
biochemical activity of CtHsp104 more closely resembles wild-type ScHsp104 
rather than potentiated Hsp104 variants (e.g. no elevated ATPase or 
disaggregase activity) [108, 119, 145]. Thus, the ability of CtHsp104 to potently 
rescue TDP-43, polyGlu, and αSyn toxicity may result from differences in 
substrate recognition between CtHsp104 and ScHsp104. These potential 
differences in substrate recognition were not due to the NTD of CtHsp104 as 
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CtHsp104∆N could rescue polyGlu and αSyn toxicity in yeast as effectively as 
CtHsp104. An interesting direction for future studies will be to determine the 
factors underlying substrate recognition by CtHsp104.  
Our results establish that a natural Hsp104 ortholog can robustly 
antagonize proteotoxic misfolding where ScHsp104 is inactive, which has 
important implications of engineering disaggregases for therapeutic modalities. 
Sequence variation among homologous proteins is recognized as a valuable 
reservoir for rapid exploration of a protein sequence space in directed evolution 
studies [146]. Recent studies have demonstrated that molecular evolution 
techniques such as ancestral protein reconstruction can improve the 
pharmacologic properties of a protein-based drug [147]. Therefore, it will be 
important to determine whether other Hsp104 homologs are capable of 
suppressing proteotoxicity where ScHsp104 cannot, which may further illuminate 
the design of therapeutic disaggregases. 
The loss of Hsp104 from metazoan lineages was abrupt [148]. The reason 
for this loss is unknown. It is also not known why Hsp104 is not naturally 
potentiated. One possible explanation is that Hsp104 may have been lost by a 
negative selection event, since potentiated Hsp104 variants can have deleterious 
side effects, e.g. promiscuous unfoldase activity that causes increased 
temperature sensitivity, and disrupted prion inheritance [117]. However, here we 
have established that the Hsp104 ortholog CtHsp104 is naturally endowed with a 
range of therapeutic protein-remodeling activities while being well-tolerated by 
host organisms such as yeast and seemingly devoid of discernible deleterious 
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effects. Thus, it will be very interesting to understand the basis of this possible 
alternative mode of enhanced activity, and to discover whether similar activity is 
seen in other Hsp104 orthologs. 
 
2.4 Materials and Methods 
 
2.4.1 Plasmids 
The gene encoding CtHsp104 was amplified from C. thermophila cDNA (a 
gift from Dr. Adrian Tsang, Concordia University) via PCR and inserted into 
pMCSG68 vector [149]. The R328M/R757M double mutant (CtHsp1042R) was 
created using modified PIPE cloning previously described [150]. The presence of 
both mutations was confirmed by sequencing at University of Chicago Cancer 
Research DNA Sequencing Facility. The expression vectors were transformed 
into Escherichia coli BL21-Gold (DE3) cells (Agilent). The N- and C-terminal 
truncations were produced from the full-length gene using the following set of 
primers: the 153-882 construct was created using forward 
(TACTTCCAATCCAATGCCGCAGAGGAGGCGTACGAGG) and reverse 
(TTATCCACTTCCAATGTTAGATTTCCATATCCTCGTCTTCAACCATG) primers 
and the 153-864 construct was created using forward 
(TACTTCCAATCCAATGCCGCAGAGGAGGCGTACGAGG) and reverse 
(TTATCCACTTCCAATGTTATTCGATCCCGTGGTTGCGGAT) primers and were 
cloned to vector pMCSG68. Vectors encoding TDP-43, αSyn, and an expanded 
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polyGlu tract (pAG303GAL-TDP43, pAG303GAL-αSyn-YFP, pAG304GAL-αSyn-
YFP, and pAG303GAL-103Q-CFP) were from Drs. A. Gitler and M. Duennwald 
[54, 55], pAG416GAL-Hsp104, pAG416GAL-Hsp104A503V, and pAG416GAL-
Hsp104A503S have been described previously [108]. pAG416G AL-CtHsp104 was 
generated by Gateway cloning. For this paper, Hsp104 vectors were modified by 
the addition of a C-terminal 1xFLAG tag to facilitate immunodetection of 
CtHsp104. Hsp104-FLAG constructs behaved as untagged protein in all assays. 
 
2.4.2 CtHsp1042R preparation for crystallization 
30 mL of LB-phosphate media containing 10 g tryptone, 5 g yeast extract, 
5 g NaCl (BioShop), 40 mM K2HPO4 (BioShop), 0.5% glucose (Sigma Aldrich), 
150 mg ampicillin (BioShop) per liter was inoculated with 100 μL of overnight 
starter E. coli culture expressing CtHsp1042R and was grown at 37 °C, 200 rpm. 
After 16 h, large scale cultures were inoculated by adding 30 mL small scale 
overnight culture to 1 L LB-phosphate media. Cultures were grown at 37 °C, 190 
rpm to OD600 1.0, and cooled to 18 °C prior to overnight induction with 0.5 mM 
isopropyl 1-thio-b-D-galactopyranoside (IPTG) at 18 °C, 180 rpm. Cells were 
harvested via centrifugation at 6,500 rpm, 4 °C for 10 minutes and resuspended 
in 30 mL lysis buffer (50 mM HEPES-NaOH pH 8.0, 500 mM NaCl, 5% (v/v) 
glycerol, 20 mM imidazole, and 10 mM β-mercaptoethanol (β-ME), plus 1 
protease inhibitor cocktail tablet (cOmplete ULTRA, Roche, Indianapolis, Indiana, 
USA)). Resuspended cells were stored at -80 °C prior to protein purification. 
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Frozen cells were thawed, supplemented with lysozyme (final 
concentration 1 mg/mL) and lysed on ice for 1 h. Lysate was sonicated on ice 
with 4 s bursts, followed by a 20 s pause, for 4 min. Cells were then centrifuged 
at 13,000 rpm for 90 min followed by filtration through 0.45 µm syringe filters. 
Clarified lysate was manually purified using the vacuum assisted purification 
system and Sepharose High Performance Nickel Beads (GE Healthcare Life 
Sciences, Piscataway, NJ, USA) on ice. Column was washed with water, and 
pre-equilibrated with lysis buffer (50 mM HEPES-NaOH pH 8.0, 500 mM NaCl, 
5% (v/v) glycerol, 20 mM imidazole, and 10 mM β-ME) and protein was eluted 
with buffer containing 250 mM imidazole pH 8.0. Fractions containing 
CtHsp1042R were pooled and digested with recombinant His7-tagged TEV 
protease, at the ratio 1 mg/25 mg of target protein. The completeness of the His6-
tag digestion was verified by SDS-PAGE and CtHsp1042R was dialyzed overnight 
against desalting buffer (50 mM HEPES-NaOH pH 8.0, 500 mM NaCl, 5% (v/v) 
glycerol, and 10 mM β-ME) at 4 °C to remove the His6-tag. The resulting protein 
carries the N-terminal SNA sequence artifact. The CtHsp1042R protein was 
concentrated to 1.5 mL on Amicon Ultra-15 centrifugal concentrators (Millipore, 
Bedford, MA, USA) and further purified using size exclusion chromatography 
(SEC) on Superdex 200 column (GE Healthcare Life Sciences, Piscataway, NJ, 
USA) pre-equilibrated with desalting buffer to remove the His7-tagged TEV 
protease and other small molecular weight contaminants. The CtHsp1042R 
fractions containing monomeric protein were then concentrated using Amicon 
Ultra-15 concentrators (Millipore, Bedford, MA, USA) and buffer-exchanged with 
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a crystallization buffer containing 20 mM HEPES-NaOH pH 8.0, 200 mM KCl, 4 
mM dithiothreitol (DTT). Glycerol was then added to a final concentration of 10% 
prior to cryo-cooling the protein in liquid nitrogen and storage at -80 °C. 
 
2.4.3 Preparation of CtHsp104 and deletion mutants for cryo-EM, SEC and 
DLS 
The 30 mL of LB-phosphate media culture of CtHsp104 and deletion 
mutants were prepared as described above. After 16 h, large scale cultures were 
prepared by adding 30 mL small scale over-night culture to 1 L LB-phosphate 
media, prepared as above. Cell cultures were grown at 37 °C, 200 rpm to OD600 
1.0, and cooled to 15 °C prior to their induction with 0.5 mM IPTG. Cultures were 
allowed to grow at 15 °C, 180 rpm overnight. Cells were harvested via 
centrifugation at 4,500 rpm, 4 °C for 20 min and resuspended in 35 mL lysis 
buffer containing 20 mM HEPES-KOH pH 7.57, 20 mM KCl (mutants) or 100 mM 
KCl (WT), 5% (v/v) glycerol, 20 mM imidazole pH 8.0, 2 mM MgCl2, 0.5 mM ATP 
pH 8.0 and 10 mM β-ME. Resuspended cells were stored at -80 °C prior to their 
purification. Frozen cells were thawed and sonicated on ice with 2 s bursts, 
followed by a 20 s pause, for 3 min. Cells were then centrifuged at 13,000 rpm 
for 90 min followed by filtration through 0.45 μm syringe filters. Clarified lysate 
was manually purified as described above. The nickel column was pre-
equilibrated with lysis buffer and eluted with elution buffer containing 250 mM 
imidazole pH 8.0. Collected fractions were digested with recombinant His-tagged 
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TEV protease, 1 mg for every 25 mg of target protein overnight. Sample was 
concentrated down to 1.5 mL using Amicon Ultra-15 100K concentrators 
(Millipore, Bedford, MA, USA) and further purified via size exclusion 
chromatography (see below). The fractions containing CtHsp104 hexamer 
(~664kDa WT) were then collected and concentrated using 100K concentrators 
and buffer-exchanged with a buffer containing 20 mM HEPES-KOH 7.57, 20 mM 
KCl (mutants) or 100 mM KCl (WT), 2 mM MgCl2, 2 mM ATP pH 8.0 and 4 mM 
DTT. 
The samples were further characterized biophysically to determine 
conditions that support oligomerization. Due to the addition of nucleotide, the 
final CtHsp104 concentration (60.9 mg/mL) was determined via the colorimetric, 
bicinchoninic acid (BCA) protein assay @562nm (Pierce, ThermoFisher 
Scientific). Dynamic light scattering (DLS) (DynaPro Plate Reader, Wyatt) was 
used to identify dilutions suitable for cryo-EM single particle imaging. The DLS 
experiments were performed at 23 °C. CtHsp104, CtHsp104ΔN, CtHsp104ΔN:ΔC, 
CtHsp104ΔN:DWB and CtHsp104ΔN:2R (Table S1) were diluted using 20 mM 
HEPES-KOH pH 7.57, 20 mM KCl (mutants) or 100 mM KCl (WT), 2 mM ATP pH 




2.4.4 Size exclusion chromatography of CtHsp104 and deletion mutants 
Size-exclusion chromatography (SEC) was performed on a Superdex-200 
10/300GL column using AKTAxpress (GE Healthcare). The column was pre-
equilibrated with buffer containing 20 mM HEPES-KOH pH 7.57, 20 mM KCl 
(mutants) or 100 mM KCl (WT), 5% glycerol, 20 mM imidazole, pH 8.0, 0.5 mM 
ATP pH 8.0, 2 mM MgCl2, and 10 mM β-ME. The column was calibrated with 
premixed protein standards, including catalase (230 kDa), ferritin (440 kDa), and 
thyroglobulin (660 kDa). A 1.5 mL protein sample was injected into the column. 
The chromatography was carried out at room temperature at a flow rate of 1.5 
mL/min. The calibration curve of Kav versus log molecular weight was prepared 
using the equation Kav=(Ve−Vo)/(Vt−Vo), where Ve is the elution volume for the 
protein, Vo is the column void volume, and Vt is the total bed volume. The 
CtHsp104, CtHsp104ΔN, CtHsp104ΔN:ΔC, CtHsp104ΔN:DWB and CtHsp104ΔN:2R 
migrate the SEC column as hexamers (Table 2-2). 
 
2.4.5 Protein crystallization 
CtHsp1042R variant was screened for crystallization using a Mosquito 
nanoliter liquid handler (TTP Labtech, Cambridge, MA) using the sitting drop 
vapor diffusion technique in 96-well CrystalQuick plates (Greiner Bio-one, 
Monroe, NC). Prior to setting up crystallization, CtHsp1042R was diluted to 15 
mg/mL and incubated with 5 mM ADP and 10 mM MgCl2 for 10 min at 40 °C. For 
each condition, 0.5 μL of protein and 0.5 μL of crystallization formulation were 
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mixed; the mixture was equilibrated against 135 μL of the crystallization solution 
in each reservoir well. The crystallization screens MCSG-1-4 ((Anatrace, 
Maumee, OH)) were used for screening at 4 °C and 16 °C. Crystals appeared 
under MCSG-2 condition containing 0.2 M calcium acetate, 0.1 M MES-NaOH 
pH 6.0, and 10% propanol at 4 °C. 
  
2.4.6 X-ray data collection, structure determination and refinement 
Prior to flash-cooling in liquid nitrogen, CtHsp1042R crystals were cryo-
protected in mother liquor supplemented with 35% glycerol. The X-ray diffraction 
data collection was carried out at the Structural Biology Center 19-ID beamline at 
the Advanced Photon Source, Argonne National Laboratory. The data were 
collected at 100K at 0.9726 Å wavelength. The diffraction images were 
processed with the HKL3000 suite [151]. Intensities were converted to structure 
factor amplitudes in the Ctruncate program [152, 153] from the CCP4 package 
[154]. 
The structure was solved by molecular replacement using Phaser [155] 
with TtClpB (PDB id: 1QVR, [127]) and E. coli (PDB id: 1KHY) as search models. 
Specifically, the 1QVR template was divided into 6 domains. First, NBD1 
(residues 153-330) and NBD2 (residues 331-396, 511-540) were identified. This 
solution was used as a starting point to search for CTT (residues 756-850) and 
subsequently to search MD (residues 397-510) and NTD (with 1KHY as a 
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model). The resulting solution was morphed into the electron density map [156] 
and rebuilt in Buccaneer [157]. An additional round of Phaser with Buccaneer-
derived structure used as a fixed partial solution enabled the localization of 
additional residues (residues 543-578, 588-636, 651-686, 700-709, 740-755). In 
the next step, morphing and autobuilding was used [158, 159]. Finally, iterative 
manual structure corrections in Coot [160] and crystallographic refinement in 
Phenix [161] was applied to improve the model. The refinement protocol included 
optimization of TLS parameters, with the protein chain divided into 5 groups. In 
the final model, 810/882 (92%) of residues were included, corresponding to the 
following fragments: Ser2-Asp75, Glu80-Gly144, Ala156-Ala247, Gly251-Ala282, 
Ala288-Leu647, Gly661-Leu721, Thr738-Ile863 (Figure 1). In ordered segments, 
the majority of amino-acid side chains are well defined in the electron density. 
The missing segments are disordered in the crystal lattice. The structure factors 
and atomic coordinates have been deposited to the PDB under accession code 








Table 2–3 Crystallographic data processing and refinement statistics. 
Processing 
Wavelength (Å) 0.9793 
Resolution range (Å)a 30.00 - 2.70 (2.75 - 2.70) 
Space group P65 
Unit cell parameters (Å) a=139.17 c= 97.06 
Unique reflections 29,450 (1,467) 
Multiplicity 7.3 (7.1) 
Completeness (%) 100 (100) 
<I >/< σI> 23.61 (2.25) 
Wilson B factor (Å2) 49.8 




Resolution (Å) 30.00 - 2.70 
Reflections work/test set 29,413/1,496 
Rwork/ Rfreed 0.198/0.249 
Average B factor (Å2) (No of atoms)   
 Macromolecules 74.4 (6,394) 
 Ligands 82.3 (54) 
Rmsd bond lengths (Å) 0.008 
Rmsd bond angles (°) 1.17 
Ramachandran favorede (%) 97.0 
Ramachandran outliers (%) 0 
Clashscoree 7.91 
a Values in parentheses correspond to the highest resolution shell. 
b Rmerge = ΣhΣj|Ihj–<Ih>|/ΣhΣjIhj, where Ihj is the intensity of observation j of reflection h. 
c As defined by [162] 
dR = Σh|Fo|–|Fc|/Σh|Fo| for all reflections, where Fo and Fc are observed and calculated 
structure factors, respectively. Rfree is calculated analogously for the test reflections, 
randomly selected and excluded from the refinement. 





2.4.7 Cryo-electron microscopy data acquisition 
The samples were initially screened at the Advanced Electron Microscopy 
facility at the University of Chicago, National Center for Protein Science 
Shanghai and data collection was performed at the National Center for 
Macromolecular Imaging at SLAC-Stanford. Two microliter samples of CtHsp104 
hexamer (0.5 mg/mL) in a buffer 100 mM KCl, 2 mM MgCl2, 2 mM ATP pH 8.0 
and 4 mM DTT were applied onto glow-discharged 200-mesh R2/1 Quantifoil 
grids. The grids were blotted for 3 s and rapidly cryo-cooled in liquid ethane using 
a Vitrobot Mark IV [34]. The samples were screened using Talos Arctica cryo-
electron microscope [34] operated at 200 kV and then imaged in a Titan Krios 
cryo-electron microscope [34] with GIF energy filter (Gatan) at a magnification of 
130,000× (corresponding to a calibrated sampling of 1.06 Å per pixel). 
Micrographs were recorded with a Gatan K2 Summit direct electron detector, 
where each image is composed of 30 individual frames with an exposure time of 
6 s and a dose rate of 5.3 electrons per second per Å2. A total of 3,186 movie 
stacks were collected with a defocus range of 0.8-2.8 μm. 
 
2.4.8 Single particle image processing and 3D reconstruction 
All micrographs were motion-corrected using MotionCor2 [164] and CTF-
corrected using Gctf [165]. Initial particles data set was picked manually using 
EMAN2 [166], which yielded ~3,000 particles from 50 micrographs. 25 2D-class 
averages, determined by RELION [167], were used to generate an initial model 
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in EMAN2. Then, the initial model was used for template-automated particle 
picking in EMAN2, yielding a ~377,000-particle data set from the selected 2,716 
micrographs. Then, particle coordinates were imported to RELION, where the 
2D/3D classification and 3D refinement were performed. After removing poor 2D 
class averages by 2D classification for 3 times, a total data set of ~260,000 
particles was used for 3D refinement, generating the 4.1 Å map. Further 3D 
classification with C1 symmetry using the 4.1 Å map with 60 Å low-pass filter as 
an initial model was used to remove a bad class with 13.5% of the particle set. 
Next, final 3D refinement was performed using 224,915 particles, 4.4 Å map 
without mask and 4.0 Å map with mask were achieved. 
 
2.4.9 Segmentation and fitting 
The reconstructed 3D density map was segmented using Segger [168] and 
UCSF Chimera [169] generating a rough initial estimate of the 6 protomers 
expected in the assembly. Six copies of the crystallographic monomer structure 
were then rigidly fitted to the map by alignment to each of the 6 segmented 
regions. Secondary structure elements matched well between the fitted models 
and the map, especially in the NBDs. The NTD in the crystal model were well 
outside the cryo-EM density, since it has a drastically different position in the 
crystallographic structure. The NTD in the cryo-EM density is at a lower 
resolution, and secondary structures are not clearly visible as in the NBDs. Local 
exhaustive search (using the Fit to Segments tool in Segger) was thus used to 
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determine the position and orientation of each of the 6 protomers in the density; 
moderate Z-scores (2-3) indicated reasonable confidence in the final placements. 
These placements also agreed with previous cryo-EM maps [96]. The 6 
independently fitted protomers were then joined into one model (chains P1 - P6), 
also taking the ADP ligands from the crystal model (chains A-F). 
Each of the 6 rigidly fitted protomers however, appeared to have a slightly 
different conformation in the cryo-EM density. Hence we then applied the 
Molecular Dynamics Flexible Fitting, or MDFF (Trabuco et al., 2008). We applied 
the method in 10 independent runs, to be able to calculate the uncertainty in the 
resulting model. Each run consisted of 104 minimization steps followed by 105 
molecular dynamics steps, after which the model stopped deforming significantly. 
The resulting 10 structures were then input into ProMod (Pintilie et al., 2016) to 
produce a probabilistic model, which measures the uncertainty at each atom 
position given the 10 possible results. The atomic coordinates and the cryo-EM 
map have been deposited to the PDB/EMD under accession code 6D00 and 
7782, respectively. 
 
2.4.10 Proteins for biochemical assays 
Untagged Hsp104 from S. cerevisiae was expressed and purified as described 
previously [102, 108, 145]. CtHsp104 was purified from BL21(DE3)RIL cells 
grown in 2xYT broth supplemented with 25 µg/mL chloramphenicol and 100 
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µg/mL ampicillin. Protein expression was induced at an OD600 of 0.4-0.6 with 1 
mM IPTG for 16 h at 15 °C. Cells were harvested by centrifugation (4,000 g, 4 
°C, 20 min), resuspended in lysis buffer (40 mM HEPES-KOH pH 7.4, 500 mM 
KCl, 20 mM MgCl2, 2.5% glycerol, 20 mM imidazole, 2 mM β-ME) supplemented 
with 5 μM pepstatin A and complete protease inhibitor tablets [54]. All purification 
steps were carried out at 4 °C. Cells were lysed by incubation with 20 mg/mL hen 
egg lysozyme and sonication. Lysate was clarified by centrifugation at 16,000 
rpm for 20 min and loaded onto Ni-NTA resin. The resin was washed with 10 
volumes of wash buffer (40 mM HEPES-KOH pH 7.4, 500 mM KCl, 20 mM 
MgCl2, 2.5% glycerol, 20 mM imidazole, 2 mM β-ME). Protein was eluted in wash 
buffer supplemented with 350 mM imidazole. TEV protease was added to eluted 
protein, and the sample was dialyzed against wash buffer containing no 
imidazole for 4 h at room temperature followed by ~16 h at 4 °C. After dialysis 
and cleavage, the protein was loaded onto a second Ni-NTA column to remove 
the His6 tag and uncleaved protein. Eluted CtHsp104 was pooled, concentrated, 
and exchanged into high salt storage buffer (40 mM HEPES-KOH pH 7.4, 500 
mM KCl, 20 mM MgCl2, 10% glycerol, and 1 mM DTT). A portion was used 
immediately for biochemical assays, and the remainder was flash cooled in liquid 
nitrogen and stored at -80 °C until further use. 
Ssa1, Hsc70, Sis1, Ydj1, Hdj1, and Hdj2 (in pE-SUMO (Life Sensors)) 
were expressed as N-terminally His6-SUMO-tagged proteins in BL21(DE3)RIL 
cells. Transformed cells were grown at 37°C in LB media supplemented with 25 
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µg/mL chloramphenicol and 100 µg/mL ampicillin to an OD600 ~0.5. Cultures 
were cooled to 15 °C, and expression was induced with 1 mM IPTG for 16 h. 
Cells were harvested, resuspended in lysis buffer (50 mM HEPES pH 7.5, 750 
mM KCl, 5 mM MgCl2, 10% glycerol, 20 mM imidazole, 2 mM β-ME, 5 µM 
pepstatin A, and complete protease inhibitor (Roche)), and lysed by sonication. 
Lysates were clarified by centrifugation (16,000×g, 20 min, 4 °C), and incubated 
with Ni-NTA resin for 90 min at 4 °C. Resin was washed with 10 column volumes 
of wash buffer (50 mM HEPES pH 7.5, 750 mM KCl, 10 mM MgCl2, 10% 
glycerol, 20 mM imidazole, 1 mM ATP, 2 mM β-ME) and eluted with 2 column 
volumes of elution buffer (wash buffer+300 mM imidazole). To cleave the His6-
SUMO tag, Ulp1 was added at a 1:100 molar ratio, and imidazole was removed 
by dialysis against wash buffer. After dialysis, protein was loaded onto a 5 mL 
HisTrap column (GE Healthcare) and eluted with a linear imidazole gradient (20-
350 mM) over 40 column volumes. Fractions containing cleaved protein were 
pooled, concentrated, and purified further by Resource Q (Ssa1, Hsc70, Ydj1, 
and Hdj2) or Resource S (Sis1 and Hdj1) ion exchange chromatography. 
 
2.4.11 ATPase assay 
CtHsp104 (0.042 mM hexamer) was incubated with ATP (1 mM) for 5 min at the 
indicated temperatures in luciferase-refolding buffer (LRB): 25 mM HEPES-KOH 
pH 7.4, 150 mM potassium acetate, 10 mM magnesium acetate, 10 mM DTT. 
ATPase activity was assessed by the release of inorganic phosphate, which was 
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determined using a malachite green phosphate detection kit (Innova). 
Background hydrolysis was determined at time zero and subtracted. 
 
2.4.12 Luciferase reactivation assay 
Luciferase reactivation was performed as described [88]. To assemble 
aggregates, firefly luciferase (Sigma; 100 μM) in LRB (25 mM HEPES-KOH pH 
7.4, 150 mM potassium acetate, 10 mM magnesium acetate, 10 mM DTT) plus 8 
M urea was incubated at 30 °C for 30 min. The sample was then rapidly diluted 
100-fold into LRB. Aliquots were snap-cryo-cooled and stored at -80°C until use. 
Aggregated luciferase (100 nM) was incubated with CtHsp104 (0.167 μM 
hexamer) with ATP (5.1 mM) and an ATP regeneration system (1 mM creatine 
phosphate, 0.25 μM creatine kinase (Roche)) in the presence or absence of 
Hsp70 (either Ssa1 or Hsc70, 0.167 μM), and Hsp40 (either 0.073 µM each Hdj1 
and Hdj2 or 0.073 µM each Sis1 and Ydj1) for 90 min at 25°C. After 90 min, 
luciferase activity was assessed with a luciferase assay system (Promega). 
Recovered luminescence was monitored using a Tecan Safire plate reader. In 
some reactions, Hsp70 and Hsp40 were not present, and CtHsp104 
concentration was increased to 1 μM hexamer, and ATP was replaced by a 1:1 




2.4.13 Semen-derived Enhancer of Virus Infection (SEVI) remodeling 
SEVI remodeling was performed as previously described [89]. SEVI fibrils (20 μM 
monomer) were incubated with ScHsp104 or CtHsp104 (3 μM hexamer) in LRB 
buffer in the presence of ATP (5 mM) and an ATP regeneration system (0.1 mM 
ATP, 0.02 mg/mL creatine kinase, 10 mM creatine phosphate). Samples were 
incubated at 37°C for the duration of the experiments. At various time points, 
aliquots were removed, added to a 96-well plate containing a solution of 25 μM 
ThT in LRB buffer. ThT fluorescence characteristics were measured on a Tecan 
Safire2 microplate reader with excitation and emission filters set to 440 nm and 
482 nm, respectively. To assess fibril morphology by negative stain EM, reaction 
aliquots were spotted on Formvar carbon-coated grids (EM Sciences) and 
stained with 2% uranyl acetate. Samples were visualized using a JEOL-1010 
electron microscope. 
 
2.4.14 Yeast strains and media 
All yeast strains were WT W303a (MATa, can1-100, his3-11, 15, leu2-3, 112, 
trp1-1, ura3-1, ade2-1) or the isogenic strain W303aΔhsp104. Yeast were grown 
in rich media (YPD) or in synthetic media lacking the appropriate amino acids. 




2.4.15 Yeast transformation and spotting assays 
Yeast were transformed according to standard protocols using polyethylene 
glycol and lithium acetate [170]. For spotting assays, yeast were grown to 
saturation overnight in synthetic raffinose dropout media at 30°C. Cultures were 
serially diluted 5-fold and spotted in duplicate onto synthetic dropout media 




Thermotolerance assays were performed essentially as described [171], with 
some modifications. W303aΔhsp104 yeast were transformed with plasmids 
bearing either Hsp104 from S. cerevisiae or C. thermophila under the native 
HSP104 promoter (e.g. pRS313HSE-ScHsp104-FLAG or pRS313HSE-
CtHsp104-FLAG), or an empty vector control. Transformants were selected, 
grown to saturation in yeast minimal media SD-His, and then diluted to 
OD600=0.2 in SD-His. Yeast were allowed to double at 30°C (~4 h), after which 
cultures were normalized. Cells were then heat shocked at 50°C for 0-60 min and 
cooled for 2 min on ice. Cultures were diluted 1000-fold, plated on SD-His, and 




2.4.18 Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) 
SDD-AGE was performed as described [172]. To prepare lysates, yeast strains 
were grown to saturation in raffinose dropout media (SRaff-His-Ura) at 30 °C, 
then transferred to 10 mL galactose media (SGal-His-Ura) and grown for an 
additional 16h to induce polyGlu and Hsp104 expression. Following overnight 
induction, cells were normalized, washed with sterile water, and resuspended in 
spheroplasting solution (1.2 M D-sorbitol, 0.5 mM MgCl2, 20 mM Tris pH 7.5, 50 
mM b-mercaptoethanol, and 0.5 mg/mL Zymolyase 100T) and incubated for 1 
hour at 30 °C with intermittent shaking. Spheroplasts were pelleted by 
centrifugation (500xg for 5 min) and resuspended in lysis buffer (100 mM Tris pH 
7.5, 500 mM NaCl, 10 mM b-mercaptoethanol, Protease inhibitor cocktail (Sigma 
P8215), 10 mM EDTA, 2 mM PMSF, and 0.10% Triton-X 100). This suspension 
was vortexed at high speed for 2 minutes to lyse spheroplasts. Lysates were 
combined with 4X sample buffer (2X TAE, 20% glycerol, 8% SDS, 10% b-
mercaptoethanol, and 0.0025% bromophenol blue) and incubated for 5 minutes 
at room temperature. Samples were loaded onto a 1.5% agarose gel in TAE 
buffer containing 0.1% SDS. The gel was run at 3 V/cm gel length for 5 h. 
Proteins were transferred to a nitrocellulose membrane by capillary transfer 
overnight. The nitrocellulose membrane was blocked and probed for Rnq1 
conformers with an anti-Rnq1 polyclonal antibody. 
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CHAPTER 3 THERAPEUTIC GENETIC VARIATION REVEALED IN 
DIVERSE HSP104 HOMOLOGS 
 
This chapter has been posted to a preprint server and is under revision at eLife: 
March, Z.M., K. Sweeney, H. Kim, X. Yan, L.M. Castellano, M.E. Jackrel, E. 
Chuang, E. Gomes, K. Michalska, R. Jedrzejczak, A. Joachimiak, K.A. Caldwell, 
G.A. Caldwell, O. Shalem, and J. Shorter. (2020). Therapeutic genetic variation 
revealed in diverse Hsp104 homologs. BioRciv. Doi:10.1101/2020.03.25.008748. 
 
3.1 Introduction 
Alternative protein folding underpins fatal neurodegenerative diseases 
[173]. Diseases such as Parkinson’s disease (PD) and amyotrophic lateral 
sclerosis (ALS) have distinct clinical manifestations but are united by the 
prominent pathological accumulation of misfolded protein conformers [25]. The 
proteins implicated in each disease can adopt a range of misfolded 
conformations [174]. Thus, in PD, αSyn accumulates in toxic soluble oligomers 
and amyloid fibers that are the major component of cytoplasmic Lewy bodies in 
degenerating dopaminergic neurons [175-179]. Likewise, in ALS, the normally 
nuclear RNA-binding proteins, TDP-43 and FUS, accumulate in toxic oligomeric 
structures and cytoplasmic inclusions [32, 33, 53, 180, 181]. 
Protein disaggregation represents an innovative and appealing therapeutic 
strategy for the treatment of protein-misfolding disorders in that it simultaneously 
reverses: (a) loss-of-function phenotypes associated with sequestration of 
functional soluble protein into misfolded oligomers and insoluble aggregates; and 
(b) any toxic gain-of-function phenotypes associated with the misfolded 
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conformers themselves [49, 105, 182]. The AAA+ (ATPases Associated with 
diverse Activities) protein Hsp104 from Saccharomyces cerevisiae (ScHsp104) 
rapidly disassembles a diverse range of misfolded protein conformers, including 
amorphous aggregates, preamyloid oligomers, and amyloid fibers [64, 77, 78, 
86-88, 109]. Hsp104 assembles into asymmetric ring-shaped hexamers that 
undergo conformational changes upon ATP binding and hydrolysis, which drive 
substrate translocation across the central channel to power protein 
disaggregation [85-88, 95-97]. Each protomer is comprised of an N-terminal 
domain (NTD), nucleotide-binding domain 1 (NBD1), a middle domain (MD), 
NBD2, and a short C-terminal domain [86, 87]. Hsp104 can disassemble 
preamyloid oligomer and amyloid conformers of several proteins associated with 
neurodegenerative disease, including αSyn, polyglutamine, amyloid-beta, and 
tau [88, 109]. Moreover, these protein-remodeling events result in 
neuroprotection. For example, Hsp104 suppresses protein misfolding-induced 
neurodegeneration in rat and D. melanogaster models of polyglutamine-
expansion disorders [113, 114], and a rat model Parkinson’s disease [109]. 
Hsp104 is the only factor known to eliminate αSyn fibers and oligomers in vitro, 
and prevent αSyn-mediated dopaminergic neurodegeneration in rats [109]. 
However, these activities have limits and typically high concentrations of Hsp104 
are required for modest protein remodeling [88, 108, 109]. 
Previously, we circumvented limitations on Hsp104 disaggregase activity 
by developing a suite of potentiated Hsp104 variants, differing from wild-type 
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Hsp104 by one or more missense mutations in the autoregulatory middle domain 
[117]. These potentiated Hsp104 variants antagonize proteotoxic misfolding of 
several disease-linked proteins, including TDP-43, FUS, TAF15, FUS-CHOP, 
EWS-FLI and αSyn [99, 108, 118, 119, 121, 183]. However, in some 
circumstances, these Hsp104 variants can also exhibit off-target toxicity [108, 
118, 121]. Thus, uncovering other therapeutic Hsp104 variants with diminished 
propensity for off-target effects is a key objective [120]. 
Hsp104 is conserved among all non-metazoan eukaryotes [148], yet 
natural Hsp104 sequence space remains largely unexplored. This lack of 
exploration raises the possibility that natural Hsp104 sequences may exist with 
divergent enhanced and selective activity against neurodegenerative disease 
substrates. Indeed, we reported that an Hsp104 homolog from the thermophilic 
fungus Calcarisporiella thermophila antagonizes toxicity of TDP-43, αSyn, and 
polyglutamine in yeast without apparent toxic off-target effects [95]. These 
findings support our hypothesis that natural Hsp104 homologs may have 
therapeutically beneficial properties. 
Here, we survey a cross-kingdom collection of Hsp104 homologs from 
diverse lineages for their ability to suppress proteotoxicity from several proteins 
implicated in human neurodegenerative disease. We discovered several 
homologs that are capable of selectively suppressing TDP-43 or αSyn toxicity. 
Mechanistic studies and mutational analysis suggest that these activities are due 
to genetic variation that impacts passive chaperone activity of Hsp104 homologs 
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for select substrates. Thus, we establish that manipulating passive chaperone 
activity of Hsp104 represents a novel route to enhanced, substrate-specific 
agents to counter protein misfolding that causes neurodegenerative disease. 
3.2 Results 
3.2.1 Diverse Hsp104 homologs selectively suppress TDP-43 toxicity and 
aggregation in yeast 
In yeast, galactose-inducible expression of several proteins associated 
with neurodegenerative diseases, including aSyn [51], TDP-43 [52], and FUS 
[53] is toxic. However, coexpression of potentiated Hsp104 variants or the natural 
homolog Calcarisporiella thermophila Hsp104 (CtHsp104), but not ScHsp104, 
reduces this toxicity [95, 108, 118, 120]. For a deeper exploration of natural 
Hsp104 sequence space, we screened a collection of 15 additional Hsp104 
homologs from diverse eukaryotes spanning ~2 billion years of evolution and 
encompassing fungi (Thielavia terrestris, Thermomyces lanuginosus, 
Dictyostelium discoideum, Chaetomium thermophilum, Lachancea 
thermotolerans, Myceliophthora thermophila, Scytalidium thermophilum, and 
Thermoascus aurantiacus), plants (Arabidopsis thaliana and Populus 
euphratica), protozoa (Monosiga brevicollis, Salpingoeca rosetta, and 
Plasmodium falciparum), and chromista (Chlamydomonas reinhardtii and 
Galdieria sulphuraria) (Figure 3-1A, Figure 3-2). All Hsp104 homologs, except 
the homolog from Plasmodium falciparum (Pf), were non-toxic to yeast at 30 ºC 
or 37 ºC (Figure 3-3). PfHsp104 was even more toxic than the potentiated 
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Hsp104 variant, Hsp104A503V, at 37°C (Figure 3-3). This toxicity might reflect the 
very different role played by PfHsp104 in its host where it is not simply a soluble 
protein disaggregase [184-186]. Rather, PfHsp104 is a key component of a 
membrane-embedded translocon, which transports malarial proteins across a 
parasite-encasing vacuolar membrane into erythrocytes [184-186]. 
We screened the Hsp104 homologs for suppression of TDP-43, FUS, and 
aSyn proteotoxicity (Figures 3-1B,C, 3-4A,B, and 3-5). The toxic Hsp104 
homolog, PfHsp104, was unable to reduce TDP-43, FUS, and aSyn 
proteotoxicity (Figure 3-5C). By contrast, in addition to CtHsp104, which 
suppresses TDP-43 and aSyn (Figures 3-1B and 3-4A), five of these new 
homologs (from protozoa: Monosiga brevicollis (Mb) and Salpingoeca rosetta 
(Sr), from chromista: Chlamydomonas reinhardtii (Cr) and Galdieria sulphuraria 
(Gs), and the plant Populus euphratica (Pe)), suppress TDP-43 toxicity (Figure 
3-1C; see Figure 3-6 for an alignment comparing TDP-43-rescuing homologs to 
ScHsp104). Interestingly, the Hsp104 homologs that suppress TDP-43 toxicity do 
not suppress aSyn toxicity, nor do they suppress toxicity of FUS (Figure 3-5A). 
Thus, we describe the first natural or engineered Hsp104 variants that diminish 
TDP-43 toxicity in a substrate-specific manner. 
Hsp104 homologs were consistently expressed, and had minimal effect on 
TDP-43 levels (Figure 3-1D), indicating that suppression of toxicity was not due 
to reduced TDP-43 expression. Moreover, levels of the small heat-shock protein, 
Hsp26, were similar in all strains and lower than in control strains that had been 
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pretreated at 37 ºC to mount a heat shock response (HSR) [187]. Thus, 
expression of heterologous Hsp104 homologs does not indirectly suppress TDP-
43 toxicity by inducing a yeast HSR (Figure 3-1D). 
Next, we examined how these Hsp104 homologs affect TDP-43 
localization in our yeast model. In human cells, TDP-43 normally shuttles 
between the nucleus and cytoplasm, but in ALS TDP-43 becomes mislocalized to 
cytoplasmic inclusions [34]. Expression of GFP-tagged TDP-43 (TDP43-GFP) in 
yeast recapitulates this phenotype (Figure 3-1E,F) [32, 52]. Consistent with 
previous observations, expression of ScHsp104 does not affect TDP43-GFP 
cytoplasmic localization (Figure 3-1F) but slightly exacerbates formation of 
TDP43-GFP foci (Figure 3-1G). By contrast, the potentiated variant, 
Hsp104A503S, restores nuclear TDP-43 localization in ~40% of cells [108, 121] 
(Figure 3-1F) and suppresses TDP-43 foci formation (Figure 3-1F,G). Cells 
expressing Hsp104 homologs that suppress TDP-43 toxicity (e.g. Ct, Gs, Mb, Cr, 
Pe, and Sr), show at most a modest increase in nuclear TDP43-GFP compared 
to control strains lacking Hsp104 (Δhsp104) or expressing ScHsp104 (Figure 3-
1F). However, formation of cytoplasmic TDP43-GFP foci is suppressed by all 
homologs (Figure 3-1G). Thus, TDP-43 toxicity can be mitigated in yeast by 
limiting TDP-43 focus formation without restoring nuclear localization. Indeed, 
PeHsp104 and SrHsp104 reduced TDP-43 toxicity as effectively as Hsp104A503S, 




Figure 3–1 Diverse Hsp104 homologs suppress TDP-43 toxicity in yeast. 
(A) Phylogenetic tree constructed using EMBL-EBI Simple Phylogeny tool from a 
multiple sequence alignment of the indicated Hsp104 homologs generated in Clustal 
Omega (see also Supplemental Information for alignments) showing evolutionary 
relationships between Hsp104 homologs studied in this paper. C. thermophila is in 
green, TDP-43-specific homologs are colored in shades of blue, aSyn-specific homologs 
are colored in red, and non-rescuing homologs are colored in shades of gray. 
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(B) Dhsp104 yeast transformed with plasmids encoding galactose-inducible TDP-43 and 
the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from Saccharomyces 
cerevisiae, the potentiated variant A503S, or the Hsp104 homolog from Calcarisporiella 
thermophila (Ct)) were serially diluted 5-fold and spotted onto glucose (expression off) or 
galactose (expression on). 
(C) Dhsp104 yeast transformed with plasmids encoding galactose-inducible TDP-43 and 
the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from Saccharomyces 
cerevisiae, the potentiated variant A503S, or homologs from Galdieria sulphuraria (Gs), 
Monosiga brevicollis (Mb), Chlamydomonas reinhardtii (Cr), Populus euphratica (Pe), 
and Salpingoeca rosetta (Sr)) were serially diluted 5-fold and spotted onto glucose 
(expression off) or galactose (expression on). 
(D) Western blots confirm consistent expression of FLAG-tagged Hsp104 variants and 
proteotoxic protein substrates in yeast, and that neither Hsp104 expression nor TDP-43 
expression induces upregulation of the endogenous heat shock protein Hsp26. The first 
lane are isogenic yeast that have not been grown in galactose to induce Hsp104 and 
TDP-43 expression but instead have been pretreated at 37 °C for 30 min to upregulate 
endogenous heat shock proteins. 3-phosphoglycerate kinase (PGK) is used as a loading 
control. Molecular weight markers are indicated (right). 
(E) Representative images of yeast co-expressing TDP-43-GFPS11 (and separately 
GFPS1-10 to promote GFP reassembly) and the indicated Hsp104 homologs. Cells 
were stained with DAPI to visualize nuclei (blue). Scale bar, 2.5 µm. 
(F) Quantification of cells where TDP-43 displays nuclear localization. Values represent 
means ± SEM (n=3 trials with >200 cells counted per trial). One-way ANOVA with 
Dunnett’s multiple comparisons test was used to compare Dhsp104 to all other 
conditions. ****, p<0.0001.  
(G) Quantification of cells with no, single, or multiple TDP-43 foci. Values represent 
means ± SEM (n=3). Two-way ANOVA with Tukey’s multiple comparisons test was used 
to compare the proportion of cells with either no or multiple TDP-43 foci between strains 
expressing different Hsp104 homologs and a control strain expressing ScHsp104. *, 







Figure 3–2 Alignment of all Hsp104 homologs investigated in this study.  
Amino acid sequences of Hsp104 homologs were aligned using Clustal Omega, and the 
multiple sequence alignment was visualized with JalView. Positions in the alignment are 
colored by Clustal X convention: conserved hydrophobic positions (A,I,L,M,F,W,V,C) are 
blue; conserved basic residues (K,R) are red; acidic residues (E,D) are magenta; polar 
residues (N,Q,S,T) are green; aromatic residues (H,Y) are cyan; conserved cysteines 
are pink; glycines are orange, prolines are yellow. Structural elements of Hsp104 are 
indicated. C. thermophila and ClpG are in green, TDP-43-specific homologs are colored 
in shades of blue, aSyn-specific homologs are colored in red, and non-rescuing 
homologs are colored in shades of gray. 
 
 
Figure 3–3 Hsp104 homologs do not typically induce temperature-dependent 
toxicity. 
Spotting assay showing that yeast strains expressing the indicated Hsp104 homolog do 
not show a temperature-dependent growth defect. None of the Hsp104 homologs were 
toxic at 30°C or 37°C with the exception of PfHsp104, which was toxic at both 
temperatures. PfHsp104 was even more toxic than the potentiated Hsp104 variant, 





3.2.2 Distinct Hsp104 homologs selectively suppress aSyn toxicity and 
inclusion formation in yeast 
In addition to the five Hsp104 homologs that suppress TDP-43 toxicity, we 
discovered two new Hsp104 homologs (from Thielavia terrestris (Tt) and 
Thermomyces lanuginosus (Tl)) that suppress aSyn toxicity (Figure 3-4B; see 
Figure 3-7 for an alignment comparing aSyn-rescuing homologs to ScHsp104 
and Figure 3-8 for an alignment comparing TDP-43-rescuing homologs to aSyn-
rescuing homologs). Similar to the Hsp104 homologs that suppress TDP-43 
toxicity, these new Hsp104 homologs were selective and suppressed aSyn 
toxicity but not TDP-43 or FUS toxicity (Figure 3-5B). Eight of the fifteen Hsp104 
homologs tested do not suppress TDP-43, aSyn, or FUS toxicity (Figure 3-5C). 
TtHsp104 and TlHsp104 suppressed aSyn toxicity without affecting aSyn 
expression and without inducing an HSR as indicated by Hsp26 levels (Figure 3-
4C). 
We also examined how Hsp104 homologs that suppress aSyn toxicity 
affect aSyn localization in yeast. aSyn is a lipid-binding protein that mislocalizes 
to cytoplasmic Lewy bodies in Parkinson’s disease [29]. Overexpression of aSyn 
in yeast recapitulates some aspects of this phenotype [51]. Indeed, aSyn forms 
toxic cytoplasmic foci that are detergent-insoluble and react with the amyloid-
diagnostic dye, Thioflavin-S, and cluster cytoplasmic vesicles akin to Lewy 
pathology observed in PD patients [51, 54, 121, 188-190]. We observed that all 
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Hsp104 homologs that suppress aSyn toxicity also restore aSyn localization to 
the plasma membrane in ~75% of cells (Figure 3-4D,E). Cells with membrane-
localized aSyn showed no cytoplasmic foci (Figure 3-4D,E). Taken together, our 
results demonstrate that Hsp104 homologs that suppress TDP-43 or aSyn 





Figure 3–4 Hsp104 homologs from thermophilic fungi suppress alpha-synuclein 
toxicity in yeast. 
(A) Dhsp104 yeast transformed with plasmids encoding galactose-inducible aSyn and 
the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from Saccharomyces 
cerevisiae, the potentiated variant A503S, or the Hsp104 homolog from Calcarisporiella 
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thermophila (Ct)) were serially diluted 5-fold and spotted onto glucose (expression off) or 
galactose (expression on). 
(B) Dhsp104 yeast transformed with plasmids encoding galactose-inducible aSyn and 
the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from Saccharomyces 
cerevisiae, the potentiated variant A503S, or homologs from Calcarisporiella thermophila 
(Ct), Thielavia terrestris (Tt), and Thermomyces lanuginosus (Tl)) were serially diluted 5-
fold and spotted onto glucose (expression off) or galactose (expression on). 
(C) Western blots confirm consistent expression of FLAG-tagged Hsp104 variants and 
proteotoxic protein substrates in yeast, and that neither Hsp104 expression nor αSyn 
expression induces upregulation of the endogenous heat shock protein Hsp26. The first 
lane are isogenic yeast that have not been grown in galactose to induce Hsp104 and 
αSyn expression but instead have been pretreated at 37 °C for 30 min to upregulate 
heat shock proteins. 3-phosphoglycerate kinase (PGK) is used as a loading control. 
Molecular weight markers are indicated (right). 
(D-E) Fluorescence microscopy of cells coexpressing GFP-tagged αSyn and vector, 
ScHsp104WT, ScHsp104A503S, CtHsp104, TtHsp104, or TlHsp104. Scale bar, 2.5 µm. 
αSyn localization was quantified as the number of cells with fluorescence at the 
membrane or cytoplasmic aggregates. Values are means ± SEM (n=3 trials with >200 
cells counted per trial). One-way ANOVA with Dunnett’s multiple comparisons test was 




Figure 3–5 Suppression of TDP-43 or alpha-synuclein toxicity by select Hsp104 
homologs is a substrate-specific effect. 
(A) Spotting assay showing that MbHsp104, SrHsp104, CrHsp104, PeHsp104, and 
GsHsp104, which all suppress TDP-43 toxicity, do not suppress aSyn nor FUS toxicity. 
ScHsp104A503S is included as a positive control and empty vector and ScHsp104WT are 
included as negative controls 
(B) Spotting assay showing that TtHsp104 and TlHsp104 do not suppress TDP-43 nor 
FUS toxicity 
(C) Spotting assay showing that other Hsp104 homologs investigated in this study do not 




Figure 3–6 Alignment comparing ScHsp104 to Hsp104 homologs that rescue TDP-
43 toxicity. 
Amino acid sequences of the indicated Hsp104 homologs were aligned using Clustal 
Omega, and the multiple sequence alignment was visualized with JalView. Positions in 






Figure 3–7 Alignment comparing ScHsp104 to Hsp104 homologs that rescue 
alpha-synuclein toxicity. 
Amino acid sequences of the indicated Hsp104 homologs were aligned using Clustal 
Omega, and the multiple sequence alignment was visualized with JalView. Amino acids 








Figure 3–8 Alignment comparing Hsp104 homologs that rescue TDP-43 toxicity to 
those that rescue alpha-synuclein toxicity. 
(A) Amino acid sequences of the indicated Hsp104 homologs were aligned using Clustal 
Omega, and the multiple sequence alignment was visualized with JalView. Amino acids 
are colored according to Clustal X convention, and structural elements of Hsp104 are 
indicated. TDP-43-specific Hsp104 homologs are boxed in blue and aSyn-specific 
homologs are boxed in red. 
(B) Bar chart comparing average pairwise sequence identities between Hsp104 




3.2.3 Sequence characteristics of Hsp104 homologs 
 We next sought to examine sequence relatedness among Hsp104 
homologs in an effort to understand what sets Hsp104 homologs with particular 
toxicity-suppression characteristics apart. Hsp104 homologs with particular 
suppression characteristics clustered together phylogenetically (Figure 3-1A) 
although there are exceptions. Thus, while A. thaliana and P. euphratica are 
closely related species, AtHsp104 does not suppress TDP-43 while PeHsp104 
does. We wondered whether Hsp104 homologs had particular sequence 
signatures that would predict their toxicity-suppression capacities. Multiple 
sequence alignments did not reveal any clear patterns to differentiate, for 
instance, TDP-43-suppressing Hsp104 homologs from ScHsp104 (Figure 3-6) or 
from aSyn-suppressing ones (Figure 3-8A). We next calculated pairwise 
sequence identities between each possible pair of Hsp104 homologs, and 
compared the average percent identity of pairs with similar and dissimilar toxicity 
suppression profiles (Figure 3-8B). The mean pairwise identity between 
TtHsp104 and TlHsp104, which both suppress aSyn toxicity, was 76%, which 
was unsurprising given that these homologs are from two closely related species. 
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The ten pairwise identities comparing Hsp104 homologs that both rescue TDP-
43 had a mean of 56% (with range of 51-71%), while the ten pairwise identities 
comparing one Hsp104 homolog that suppresses TDP-43 to another that 
suppresses aSyn had a mean of 44% (with range of 25-49%). Thus, homologs 
that suppress TDP-43 or aSyn seem to be more similar to one another than 
between groups. 
 
3.2.4 ClpGGI from Pseudomonas aeruginosa reduces aSyn toxicity 
 In addition to the eukaryotic Hsp104 homologs discussed above, we also 
studied two prokaryotic Hsp104 homologs: ClpB from Escherichia coli and ClpGGI 
from the pathogenic bacteria Pseudomonas aeruginosa. Wild-type ClpB does not 
suppress TDP-43, FUS, or aSyn toxicity (Figure 3-9A). We wondered whether 
ClpB activity could be enhanced via missense mutations in the middle domain, in 
analogy with Hsp104, so we also selected two previously-described hyperactive 
ClpB variants, ClpBK476D and ClpBY503D [89, 191, 192], to test for suppression of 
TDP-43, FUS, and aSyn toxicity. Neither ClpBK476D nor ClpBY503D suppressed 
TDP-43, FUS, or aSyn toxicity (Figure 3-9A). Thus, despite being able to exert 
forces of more than 50 pN and translocate polypeptides at speeds of more than 
500 residues per second [193], neither ClpB nor hyperactive ClpB variants are 
capable of suppressing TDP-43, FUS or aSyn proteotoxicity. 
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Next, we tested ClpGGI, which bears significant homology to Hsp104 but is 
distinguished from other ClpB/Hsp104 proteins by an extended N-terminal 
domain and a shorter middle domain roughly corresponding to loss of middle 
domain Motif 2 [194] (Figure 3-2). ClpGGI has been reported to be a more 
effective disaggregase than ClpB from E. coli [195]. Furthermore, we previously 
established that deleting Motif 2 from ScHsp104 yields a potentiated 
disaggregase [118]. Thus, we wondered whether ClpGGI may suppress TDP-43, 
FUS, or aSyn toxicity. Indeed, we found ClpGGI potently suppresses aSyn toxicity 
and slightly suppresses TDP-43 and FUS toxicity (Figure 3-9B). ClpB, ClpB 
variants, and ClpGGI all express robustly in yeast and do not affect TDP-43, FUS, 
or aSyn levels (Figure 3-9C). ClpB and ClpGGI are also not toxic to yeast when 
expressed at 37 °C (Figure 3-9D). Thus, ClpGGI is a prokaryotic disaggregase 
with therapeutic properties and may represent a natural example of Hsp104 





Figure 3–9 ClpB does not suppress TDP-43, FUS, or alpha-synuclein toxicity 
whereas ClpG robustly suppresses alpha-synuclein toxicity and confers 
thermotolerance to yeast. 
(A) Spotting assay demonstrating that neither ClpB nor hyperactive ClpB variants 
suppress TDP-43, FUS, or aSyn toxicity. Dashed line indicates splicing of FUS plate.  
(B) Spotting assay demonstrating slight suppression of TDP-43 and FUS toxicity, and 
robust suppression of aSyn toxicity by ClpGGI. 
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(C) Western blots show consistent expression of FLAG-tagged ClpB, ClpB variants, and 
ClpG in yeast. These Hsp104s also do not affect TDP-43, FUS, or aSyn levels in yeast. 
(D) Neither ClpB nor ClpGGI cause temperature-dependent toxicity when expressed in 
yeast. 
(E) Δhsp104 yeast carrying a plasmid encoding empty vector or the indicated Hsp104 
homolog were pre-treated at 37 °C for 30 min, treated at 50 °C for 0-60 min, and plated. 
Surviving colonies were quantified after 2d recovery. Values represent means ±SEM 
(n=3 independent transformations). 
 
 
3.2.5 Hsp104 homologs prevent TDP-43 aggregation in human cells 
We next examined whether Hsp104 homologs that suppress TDP-43 toxicity in 
yeast would have a beneficial effect in higher model systems. Thus, we 
transfected human HEK293T cells with an inducible plasmid encoding 
fluorescently-tagged TDP-43 lacking a functional nuclear-localization sequence 
(mClover3-TDP43DNLS) to enhance cytoplasmic accumulation and aggregation 
[196]. We co-transfected these cells with an empty vector or inducible plasmids 
encoding ScHsp104WT, the potentiated variant ScHsp104A503S, PeHsp104, 
SrHsp104, or a catalytically-inactive variant ScHsp104DPLA:DWB deficient in both 
peptide translocation (due to Y257A and Y662A mutations in NBD1 and NBD2 
substrate-binding pore loops) and ATP hydrolysis (due to E285Q and E687Q 
mutations in NBD1 and NBD2 Walker B motifs) [88]. PeHsp104 and SrHsp104 
display the most potent and selective suppression of TDP-43 toxicity in yeast 
(Figure 3-1B). We monitored TDP-43 expression and aggregation by pulse-
shape analysis of flow cytometry data (see methods) [197] over time and 
quantified the percentage of cells bearing aggregates upon coexpression of each 
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Hsp104 (Figure 3-10A). Expression of Hsp104 variants in HEK293T cells was 
confirmed by Western blotting (Figure 3-10B). We also monitored mClover3-
TDP-43 NLS levels by Western blot, and did not observe a strong Hsp104-
dependent effect on TDP-43 expression (Figure 3-10B), suggesting that Hsp104 
variants are not merely affecting accumulation of TDP-43 foci by reducing TDP-
43 levels. At 24 h post-transfection, all catalytically active Hsp104 variants 
significantly decreased the proportion of cells with TDP-43 aggregates compared 
to cells expressing no Hsp104 or cells expressing the catalytically-inactive 
ScHsp104DPLA:DWB [88] (Figure 3-10C, left panel, Day 1). We were surprised that 
ScHsp104WT reduced the proportion of cells with TDP-43 aggregates at this time 
point, given that it does not reduce TDP-43 aggregation in yeast (Figure 3-
1B,C). However, at 48 h post-transfection, we observed that cells expressing the 
catalytically-inactive variant ScHsp104DPLA:DWB or ScHsp104WT both had a 
significantly increased proportion of cells with TDP-43 aggregates compared to 
cells expressing no Hsp104, while cells expressing the potentiated variant 
ScHsp104A503S or the TDP-43 specific variant PeHsp104 continued to show a 
significantly lower number of cells with TDP-43 aggregates (Figure 3-10C, right 
panel, Day 2). The TDP-43-specific variant SrHsp104, meanwhile, reduced TDP-
43 aggregate burden at day 1 but not day 2, suggesting an intermediate effect 
(Figure 3-10C). Thus, while ScHsp104 and SrHsp104 show a short-lived 
suppression of TDP-43 foci formation, we show two Hsp104 variants, one 
engineered (A503S) and one natural (PeHsp104) that show an enduring 




Figure 3–10 Hsp104 homologs reduce TDP-43 aggregation in HEK293T cells. 
(A) HEK293T cells were cotransfected with doxycycline-inducible constructs encoding 
mClover3-TDP-43DNLS. Protein expression was induced with 1 µg/ml doxycycline 6h 
post-transfection. At varying times, cells were sorted by FACS into populations lacking 
TDP-43 foci (P7) or cells with TDP-43 foci (P4). Representative fluorescent microscopy 
of sorted cells is shown at right. Scale bar, 500 µm. 
(B) At 24h post-transfection, cells were processed for Western blot to confirm Hsp104 
expression and mClover3-TDP-43DNLS expression. 
(C) At 24h post-transfection, cells were analyzed by flow cytometry to quantify cells 
bearing TDP-43 aggregates (C, left). Cells were also analyzed by flow cytometry 48h 
post-transfection (C, right) Values are means ± SEM (n=3 independent transfections 
with 10,000 cells counted per trial). One-way ANOVA with Tukey’s multiple comparisons 
test was used to compare no Hsp104 (top set of asterisks) and DPLA:DWB (bottom set 
of asterisks) to all other conditions, and to each other. ***, p<0.001; ****, p<0.0001. 




3.2.6 αSyn-selective Hsp104 homologs prevent dopaminergic 
neurodegeneration in C. elegans 
To test whether CtHsp104, TtHsp104, and TlHsp104, which suppress 
αSyn toxicity in yeast, would likewise suppress αSyn toxicity in animals, we 
turned to a C. elegans model of Parkinson’s disease in which the dopamine 
transporter (dat-1) promoter is used to direct expression of αSyn to dopaminergic 
(DA) neurons [198]. We generated transgenic worms expressing αSyn either 
alone or in combination with different Hsp104 variants in DA neurons, and 
confirmed αSyn and Hsp104 expression by qRT-PCR (Figure -311A). Only 
~20% of worms expressing αSyn alone have a full complement of DA neurons at 
day 7 post-hatching (Figure 3-11B,C). Wild-type Hsp104 from S. cerevisiae does 
not protect C. elegans DA neurons in this context [108]. Surprisingly, CtHsp104 
also does not affect C. elegans DA neuron survival (Figure 3-11B,C), despite 
robust suppression of αSyn-mediated toxicity and inclusion formation in yeast 
(Figure 3-4) [95]. This lack of neuroprotection by CtHsp104 may be due to the 
fact that it is promiscuous. Indeed, coexpression of TtHsp104 or TlHsp104, which 
both selectively mitigate αSyn toxicity in yeast, both result in significant protection 
of DA neurons in C. elegans (~40% worms with normal DA neurons in each 
case) after 7 days post-hatching (Figure 3-11B,C). This level of DA neuron 
protection is comparable to that conferred by the potentiated Hsp104 variants, 
Hsp104A503S and Hsp104DPLF:A503V [108]. Thus, our results demonstrate that 
natural, substrate-specific Hsp104 homologs can function in a wide variety of 




Figure 3–11 Hsp104 homologs protect against alpha-synuclein toxicity and 
dopaminergic neurodegeneration in C. elegans. 
(A) qRT-PCR for the expression of αSyn and various Hsp104 homologs in transgenic C. 
elegans. αSyn expression was normalized to transgenic worms overexpressing αSyn 
alone. Hsp104 expression was normalized to transgenic worms overexpressing both 
αSyn and CtHsp104. Values represent means ± SEM (N=100 worms per transgenic line, 
3 independent transgenic lines examined for each genotype). The expression of either 
αSyn or Hsp104 homologs among all genotypes was not significantly different (one-way 
ANOVA, p>0.05). 
(B) αSyn and the indicated Hsp104 homolog were coexpressed in the dopaminergic 
(DA) neurons of C. elegans. Hermaphrodite nematodes have six anterior DA neurons, 
which were scored at day 7 posthatching. Worms are considered WT if they have all six 
anterior DA neurons intact (see methods for more details). TtHsp104 and TlHsp104 
significantly protect over αSyn alone, while CtHsp104 had no protective effect. Values 
represent means ± SEM (n=30 worms per genotype per replicate, 3 independent 
replicates). One-way ANOVA with Dunnett’s multiple comparisons test was used to 
compare aSyn alone to all other conditions. *, p<0.05.  
(C) Photomicrographs of the anterior region of C. elegans coexpressing GFP with αSyn. 
Worms expressing αSyn alone (top left) exhibit an age-dependent loss of DA neurons. 
Worms expressing αSyn plus either Ct (bottom left) Tt (top right) or Tl (bottom right) 
exhibit greater neuronal integrity. Arrows indicate degenerating or missing neurons. 
Arrowheads indicate normal neurons. Scale bar, 10 µm. 




3.2.7 Differential suppression of proteotoxicity by Hsp104 homologs is not 
due to changes in disaggregase activity 
Next, we sought to understand why some Hsp104 homologs suppress 
TDP-43 or aSyn toxicity while others do not. One possible explanation is that 
Hsp104 homologs differ in disaggregase activity, as has been the case with 
potentiated Hsp104 variants [108, 118-121, 145]. Potentiated disaggregases 
typically display elevated ATPase and disaggregase activities. This elevated 
activity can sometimes manifest as a temperature-dependent toxicity phenotype 
[108, 118]. However, the Hsp104 homologs we assess here (except for 
PfHsp104) are non-toxic under conditions where some potentiated Hsp104 
variants, such as Hsp104A503V, are toxic (Figure 3-3). This finding hints that 
these natural homologs are not potentiated in the same way as engineered 
variants. To explore this issue further, we directly assessed whether the toxicity-
suppression behavior of Hsp104 homologs could be rationalized by differences in 
disaggregase activity. 
First, we tested how well our Hsp104 homologs conferred thermotolerance 
to yeast. Hsp104 is an essential factor for induced thermotolerance in yeast [63], 
and Hsp104 homologs in bacteria and plants have similar functions in their 
respective hosts [199, 200]. The ability of Hsp104 to confer thermotolerance 
depends on its disaggregase activity, which solubilizes proteins trapped in heat-
induced protein assemblies [62, 64, 65, 84, 92]. Thus, thermotolerance is a 
convenient in vivo proxy for disaggregase activity among different Hsp104 
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homologs. Indeed, ~75% of wild-type yeast survive a 20-min heat shock at 50°C 
whereas ~1% of Δhsp104 mutants survive the same shock (Figure 3-12A,B). 
Expressing FLAG-tagged ScHsp104 from a plasmid effectively complements the 
thermotolerance defect of Δhsp104 yeast (Figure 3-12A,B). We generated 
transgenic yeast strains in which Hsp104 homologs are expressed under the 
control of the native S. cerevisiae HSP104 promoter, and assessed the 
thermotolerance phenotypes of these strains. We observed a range of 
phenotypes. Specifically, 15 of 17 Hsp104 homologs tested conferred some 
degree of thermotolerance above Δhsp104 alone (Figure 3-12A,B). The two 
exceptions were ClpB from Escherichia coli and Hsp104 from Populus euphratica 
(Figure 3-12A,B). Some homologs, such as those from Thielavia terrestris, 
Galdieria sulphuraria, and Dictyostelium discoideum strongly complement 
thermotolerance while others were quite weak (Figure 3-12A,B). These 
differences are not due to differences in expression, as all homologs were 
consistently expressed, as confirmed by Western blot (Figure 3-12C). 
Thermotolerance phenotypes are not explained by the evolutionary divergence 
time of a particular species from S. cerevisiae (Figure 3-12D). Likewise, 
thermotolerance was not noticeably different between Hsp104 homologs that 
reduced TDP-43 or aSyn toxicity compared to those that did not (Figure 3-12E). 
Interestingly, ClpGGI confers a strong thermotolerance phenotype to Δhsp104 
yeast (Figure 3-9E) while ClpB does not, although both are from prokaryotes. 
This difference may be due to the fact that ClpGGI is a stand-alone disaggregase 
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and does not depend on Hsp70 and Hsp40 for disaggregation [194, 195] while 
ClpB is incompatible with yeast Hsp70 and Hsp40 [201]. Nevertheless, our 
results cumulatively demonstrate that evolutionarily diverse Hsp104 homologs 
confer thermotolerance to Dhsp104 yeast, but differences in thermotolerance 
activity do not explain differences in suppression of TDP-43 or aSyn toxicity.  
We next expressed and purified several Hsp104 homologs (MbHsp104, 
CrHsp104, TtHsp104, TlHsp104, ScHsp104, and CtHsp104) to define their 
biochemical properties. All Hsp104 homologs are active ATPases, and display 
increased ATPase activity with increasing temperature (Figure 3-12F). These 
findings are consistent with the fact that Hsp104 is a disaggregase induced by 
thermal stress. We also investigated the disaggregase activity of Hsp104 
homologs by assessing their ability to disaggregate disordered luciferase 
aggregates in vitro [64, 88]. Each Hsp104 homolog was able to disassemble and 
reactivate aggregated luciferase (Figure 3-12G,H). Luciferase disaggregation 
required the presence of Hsp70 and Hsp40 chaperones, which could be from 
yeast (Ssa1, Sis1, and Ydj1 Figure 3-12H) or human (Hsc70, Hdj1, and Hdj2 
Figure 3-12G). We did not observe differences between luciferase 
disaggregation activity of Hsp104 homologs that suppress TDP-43 toxicity versus 
those that suppress aSyn (Figure 3-12G,H).  
Next, we tested the activity of several Hsp104 homologs (ScHsp104, 
CtHsp104, TtHsp104, AtHsp104, and MtHsp104) against an ordered amyloid 
substrate, semen-derived enhancer of viral infection (SEVI) [202]. As previously 
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reported [89, 95], all Hsp104 homologs tested rapidly remodeled SEVI fibrils 
(Figure 3-13A). Electron microscopy revealed that Hsp104 homologs remodeled 
SEVI fibrils into small, amorphous structures (Figure 3-13B). Thus, eukaryotic 
Hsp104 homologs are generally able to remodel amyloid fibrils. However, there 
was not an obvious difference in amyloid-remodeling activity between homologs 
that also suppress aSyn toxicity (CtHsp104 and TtHsp104) and those that do not 
(ScHsp104, AtHsp104, and MtHsp104). Taken together, these findings suggest 
that differences in proteotoxicity suppression by Hsp104 homologs is not simply 
due to differences in general disaggregase activity of Hsp104 homologs. 
 
3.2.8 Hsp104 homologs inhibit protein aggregation in an ATP-independent 
manner 
 Since differences in general disaggregase activity do not explain 
differences in proteotoxicity suppression among Hsp104 homologs, we wondered 
whether Hsp104 homologs may act instead to inhibit protein aggregation. To test 
this possibility, we reconstituted TDP-43 aggregation in vitro to test how Hsp104 
homologs affect TDP-43 aggregation. We performed reactions in the presence 
(Figure 3-12I) or absence (Figure 3-12J) of ATP. Hsp104 from Monosiga 
brevicollis and Chlamydomonas reinhardtii, which selectively suppress TDP-43 
toxicity and foci formation in yeast, inhibit TDP-43 aggregation in vitro, whereas 
Hsp104 from Saccharomyces cerevisiae has no effect (Figure 3-12I,J). Hsp104-
mediated inhibition of TDP-43 aggregation occurred in the presence or absence 
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of ATP (Figure 3-12I,J). Hsp104 homologs did not inhibit TDP-43 aggregation 
merely by inhibiting cleavage of the MBP tag by TEV protease (Figure 3-14). 
Thus, unexpectedly, specific Hsp104 homologs appear to suppress TDP-43 






Figure 3–12 Hsp104 homologs function in induced thermotolerance and are 
ATPase-driven disaggregases, but differences in disaggregase activity do not 
explain suppression of TDP-43 or alpha-synuclein toxicity. 
(A) WT or Δhsp104 yeast carrying a plasmid encoding the indicated Hsp104 homolog 
under the control of the native HSP104 promoter were pre-treated at 37 °C for 30 min, 
treated at 50 °C for 0-60 min, and plated. Surviving colonies were quantified after 2d 
recovery. Values represent means ±SEM (n=3 independent transformations). 
(B) Hsp104 homologs ranked by thermotolerance performance after a 20 min heat 
shock at 50°C. 
(C) Expression of Hsp104 homologs from the HSP104 promoter was confirmed by 
Western blotting. Molecular weight markers are indicated (right). 
(D) Survival after 20 min heat shock does not track with the evolutionary separation 
between a given species and S. cerevisiae.  
(E) Thermotolerance activity of Hsp104 homologs that suppress TDP-43 or αSyn does 
not noticeably differ from Hsp104 homologs that do not suppress TDP-43 or αSyn 
toxicity. 
(F) ATPase activity of the indicated Hsp104 homologs. Values represent means ± SEM 
(n=3).  
(G) Luciferase aggregates (50 nM) were incubated with the indicated Hsp104 (0.167 µM 
hexamer) with or without 0.167 µM Ssa1, 0.073 µM Ydj1, and 0.073 µM Sis1 for 90 min 
at 25°C. Values represent means ± SEM (n=3). 
(H) Luciferase aggregates were treated as in (B) but Ssa1, Ydj1, and Sis1 were replaced 
with Hsc70, Hdj1, and Hdj2. Values represent means ± SEM (n=3). 
(I) TDP-43 (3 µM) was incubated in the presence of the indicated Hsp104 (6 µM) and 5 
mM ATP, and turbidity was measured at 3h relative to TDP-43 aggregation reactions 
containing no Hsp104. Values represent means +/- SEM (n=3). 





Figure 3–13 Hsp104 homologs remodel SEVI fibers. 
(A) SEVI fibrils (20 µM monomer) were incubated with buffer (untreated) or the indicated 
Hsp104 homolog (3 µM) for 0-24 h. Fibril integrity was assessed by ThT fluorescence. 
Values represent means ± SEM (n=3). 
(B) Representative EM images of SEVI fibrils incubated with buffer (untreated) or the 
indicated Hsp104 homolog (3 µM) for 3 h. Scale bar is indicated (bottom right of gallery). 




Figure 3–14 Hsp104 homologs do not affect MBP-TEV-TDP43 cleavage by TEV 
protease. 
Western blot of MBP-TEV-TDP43 incubated either alone, or in combination with TEV 
protease, Hsp104 homologs, and ATP, as indicated above lanes. Molecular weight 
markers are indicated (right). 
 
 
3.2.9 ATPase-independent passive chaperone activity underlies 
suppression of TDP-43 and aSyn toxicity by Hsp104 homologs  
Since we determined that Hsp104 homologs engage in passive chaperone 
activity to inhibit TDP-43 aggregation in vitro, we next tested whether or not this 
reflected the predominant mechanism by which Hsp104 homologs suppress 
TDP-43 or aSyn toxicity in yeast. Thus, we generated a series of mutants for 
each Hsp104 homolog intended to disrupt their disaggregase activity. Hsp104 
disaggregase activity is driven by: (1) ATP binding and hydrolysis, which are 
mediated by Walker A and Walker B motifs, respectively, and which drive 
conformational changes within the hexamer to support substrate translocation 
[84, 88, 97], and (2) substrate translocation through the central pore of the 
hexamer, which is mediated by tyrosine-bearing pore loops [85, 88, 203, 204]. 
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These motifs are highly conserved among all Hsp104 homologs (Figures 3-15A 
and 3-2). We mutated: (1) conserved lysine residues in the Walker A motifs to 
either alanine or threonine (Hsp104DWA(KA) and Hsp104DWA(KT)) in NBD1 and 
NBD2 to impair ATP binding, (2) conserved glutamate residues in the Walker B 
motifs to either alanine or glutamine (e.g. Hsp104DWB(EA) or Hsp104DWB(EQ)) in 
NBD1 and NBD2 to impair ATP hydrolysis, and (3) conserved tyrosines in the 
pore loops to alanine (e.g. Hsp104DPLA) in NBD1 and NBD2 to impair substrate 
threading through the central hexamer pore [88]. We also generated mutants 
lacking the NTD, which also plays a role in substrate binding and processing [98, 
99]. We monitored expression of Hsp104 mutant proteins by Western blotting, 
and found all mutants were expressed similarly to wild-type protein, from either 
the galactose or native HSP104 promoter (Figure 3-16A,H). Strains expressing 
Walker A, Walker B, or pore-loop mutant proteins are all severely impaired in 
thermotolerance compared to wild-type controls, while DN mutants are only 
mildly impaired in thermotolerance compared to wild-type proteins (Figure 3-16I). 
The only exception is PeHsp104, where the wild-type protein confers no 
thermotolerance benefit over Dhsp104 cells, which precludes any conclusions 
being drawn about the impact of mutations on this protein (Figure 3-12B, 3-16I). 
These findings are similar to thermotolerance phenotypes of ScHsp104 mutants 
that have been previously reported [84, 88, 98]. Thus, we confirm that these 
mutations have a conserved effect on Hsp104 disaggregase activity. 
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Next, we examined how these mutations affect the ability of different 
Hsp104 homologs to reduce TDP-43 or aSyn toxicity in yeast. TDP-43 or aSyn 
expression levels were unaffected by Hsp104 mutants, as assessed by Western 
blot (Figure 3-16A,H). All of the aforementioned mutations strongly impair the 
ability of a potentiated Hsp104 variant, ScHsp104A503S, to suppress TDP-43 and 
aSyn toxicity [98, 145] (Figure 3-15B). Thus, ScHsp104A503S suppresses TDP-43 
toxicity by a disaggregase-mediated mechanism that necessitates ATP binding 
and hydrolysis and substrate-engagement by conserved pore-loop tyrosines 
[145]. Remarkably, however, Hsp104 homolog-mediated suppression of TDP-43 
or aSyn toxicity was largely unaffected by these mutations (Figure 3-
15C,D,E,F,G,H,I,J). For example, mutation of conserved pore-loop tyrosines to 
alanine had no effect on suppression of TDP-43 or aSyn toxicity (Figure 3-
15C,D,E,F,G,H,I,J). Thus, canonical substrate translocation is not required to 
mitigate TDP-43 or aSyn toxicity. Likewise, in most cases, mutation of Walker A 
or Walker B motifs did not affect suppression of TDP-43 or aSyn toxicity (Figure 
3-15C,D,E,F,G,H,I,J). There were, however, some exceptions: CrHsp104 which 
was inhibited by mutations in the Walker B motifs (Figure 3-15E), and 
PeHsp104, which was modestly inhibited by K to A but not K to T substitutions in 
the Walker A motif and E to A but not E to Q substitutions in the Walker B motifs 
(Figure 3-15F). Thus, CrHsp104 and PeHsp104 likely require ATPase activity for 
optimal suppression of toxicity, but this requirement was not coupled to substrate 
translocation by conserved pore-loop tyrosines. Nevertheless, the remaining 
Hsp104 homologs tested here (GsHp104, MbHsp104. SrHsp104, CtHsp104, 
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TtHsp104, and TlHsp104) suppressed TDP-43 or aSyn toxicity by a mechanism 
that does not require ATPase activity or conserved pore-loop tyrosines that 
engage substrate in the Hsp104 channel. Mechanistically, these findings suggest 
that toxicity suppression by the Hsp104 homologs is primarily due to ATPase-
independent chaperoning of specific substrates, such as TDP-43 or aSyn, and 







Figure 3–15 Genetic variation within Hsp104 homologs enables their 
disaggregase-independent suppression of TDP-43 or alpha-synuclein toxicity. 
(A) WebLogo sequence logos demonstrating high conservation of Walker A, tyrosine-
bearing pore loops, and Walker B motifs in both NBD1 and NBD2 across all Hsp104 
homologs.  
(B) Spotting assay demonstrating that suppression of TDP-43 (left) and aSyn (right) 
toxicity by ScHsp104A503S (A503S) is inhibited by mutations in Walker A (DWA), pore 
loop (DPLA), and Walker B (DWB) motifs. 
(C-G) Spotting assays demonstrate that suppression of TDP-43 toxicity by GsHsp104 
(C), MbHsp104, (D), CrHsp104 (E), PeHsp104 (F), and SrHsp104 (G) is resistant to 
multiple mutations that impair ATP-driven disaggregase activity. 
(H-J) Spotting assays demonstrate that suppression of aSyn toxicity by CtHsp104 (H), 






Figure 3–16 Hsp104 mutants are consistently expressed and are defective in 
thermotolerance. 
(A-H) Western blots show consistent expression of all homologs and mutants, both from 
pGAL and pHSP104. Molecular weight markers are indicated (right). 
(I) Survival of yeast expressing GsHsp104, MbHsp104, CrHsp104, PeHsp104, 
SrHsp104, CtHsp104, TtHsp104, TlHsp104, or the indicated chimera was assessed 
following 20 min heat shock at 50 °C. Values represent means ±SEM (n=3 independent 
transformations). Top dashed line indicates average survival of strains expressing wild-
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3.2.10 Suppression of TDP-43 toxicity by MbHsp104 and CrHsp104, and 
suppression of aSyn toxicity by TtHsp104 is mediated by the NTD 
 Next, we sought to identify the requisite architecture of Hsp104 homologs 
that enables TDP-43 or aSyn proteotoxicity suppression. The engineered 
ScHsp104 variant, Hsp104A503S, requires the NTD to mitigate TDP-43 and aSyn 
toxicity (Figure 3-15B) [98]. TDP-43 or aSyn proteotoxicity suppression by 
several Hsp104 homologs (GsHsp104, PeHsp104, SrHsp104, CtHsp104, and 
TlHsp104) is unaffected by NTD deletion (Figure 3-15C, F, G, H, J). 
Interestingly, MbHsp104ΔN and CrHsp104ΔN are unable to suppress TDP-43 
toxicity (Figure 3-15D,E), and TtHsp104ΔN is unable to suppress aSyn toxicity 
(Figure 3-15I). Thus, proteotoxicity suppression by these Hsp104 homologs 
appears to be mediated by their NTDs. 
We wondered whether the NTDs might drive the toxicity suppression 
phenotypes for MbHsp104, CrHsp104, and TtHsp104. To test this possibility, we 
made a series of chimeras in which we systematically replaced domains of 
ScHsp104 with the homologous domains from other Hsp104 homologs (see 
Figure 3-17A for illustration of domain boundaries and chimeras). First, we found 
that replacing the NTD of ScHsp104 with the NTD of either MbHsp104 or 
CrHsp104 did not enable suppression of TDP-43 toxicity by the resulting 
chimeras (Figures 3-17B,C). Similarly, replacing the ScHsp104 NTD with the 
NTD from TtHsp104 did not enable suppression of aSyn toxicity by the resulting 
chimera (Figure 3-17D). Thus, proteotoxicity suppression by MbHsp104, 
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CrHsp104, and TtHsp104 is not simply transmitted through or encoded by the 
NTD. Rather, the NTD must work together with neighboring domains of the same 
Hsp104 homolog to enable toxicity suppression. 
 
3.2.11 Suppression of TDP-43 toxicity is enabled by NBD1 and MD residues 
in Hsp104 homologs 
Based on our observation that suppression of TDP-43 and aSyn toxicity by 
MbHsp104, CrHsp104, and TtHsp104 is not conferred solely by the NTD (Figure 
3-17B,C,D), and the observation that DN mutants of other homologs (GsHsp104, 
PeHsp104, SrHsp104, CtHsp104, and TlHsp104) retained their ability to reduce 
either TDP-43 or aSyn toxicity (Figure 3-15C, F, G, H, J), we reasoned that 
residues in other domains must also contribute to substrate selectivity. Within the 
ScHsp104 hexamer, the NTD interacts with NBD1 and the MD [99]. Thus, we 
made a series of additional chimeras by progressively replacing the NTD, NBD1 
or MD of ScHsp104 for the homologous domain from another Hsp104 homolog 
(see Figure 3-17A for illustration). Generally, the chimeras expressed well in 
yeast (Figure 3-18). We observed that chimeras consisting of the NTD, NBD1, 
and MD from a TDP-43-selective homolog appended to the NBD2 and CTD from 
ScHsp104 phenocopied the TDP-43 suppression phenotype associated with the 
homolog itself (Figure 3-17B, C, E, F, G). These same chimeras do not reduce 
aSyn toxicity (Figure 3-19A,B,C,D,E). Thus, these chimeras encompass the 
sequence determinants that are crucial for passive chaperoning of TDP-43. 
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Chimeras where cognate NTD:NBD1:MD networks were disrupted do not reduce 
TDP-43 toxicity (Figure 3-17B, C, E, F, G). We conclude that genetic variation in 







Figure 3–17 Interactions between the NTD, NBD1, and MD support proteotoxicity 
suppression by Hsp104 homologs. 
(A) Color codes and domain boundaries and labels of Hsp104 homologs. 
(B) Spotting assay of Dhsp104 yeast coexpressing TDP-43 and the indicated chimeric 
Hsp104s between ScHsp104 and MbHsp104 illustrates that chimeras possessing the 
NTD, NBD1, and MD from MbHsp104 copy the TDP-43 toxicity suppression phenotype 
of MbHsp104. 
(C) Spotting assay of Dhsp104 yeast coexpressing TDP-43 and the indicated chimeric 
Hsp104 between ScHsp104 and CrHsp104 illustrates that chimeras possessing the 
NTD, NBD1, and MD from CrHsp104 copy the TDP-43 toxicity suppression phenotype of 
CrHsp104. 
(D) Spotting assay of Dhsp104 strains coexpressing aSyn and the indicated chimeric 
Hsp104 between ScHsp104 and TtHsp104 illustrates that no chimeras between 
ScHsp104 and TtHsp104 replicate the aSyn toxicity-suppressing phenotype of 
TtHsp104. 
(E) Spotting assay of Dhsp104 yeast coexpressing TDP-43 and the indicated chimeric 
Hsp104 between ScHsp104 and GsHsp104 illustrates that chimeras possessing the 
NTD, NBD1, and MD from GsHsp104 copy the TDP-43 toxicity suppression phenotype 
of GsHsp104. 
(F) Spotting assay of Dhsp104 yeast coexpressing TDP-43 and the indicated chimeric 
Hsp104 between ScHsp104 and PeHsp104 illustrates that chimeras possessing the 
NTD, NBD1, and MD from PeHsp104 copy the TDP-43 toxicity suppression phenotype 
of PeHsp104. 
(G) Spotting assay of Dhsp104 yeast coexpressing TDP-43 and the indicated chimeric 
Hsp104 between ScHsp104 and SrHsp104 illustrates that chimeras possessing the 
NTD, NBD1, and MD from SrHsp104 copy the TDP-43 toxicity suppression phenotype of 
SrHsp104. 
(H) Spotting assay of Dhsp104 strains coexpressing the indicated chimeric Hsp104 and 
aSyn illustrates that chimeras possessing the NTD and NBD1 from CtHsp104 copies the 
aSyn toxicity-suppressing phenotype of CtHsp104WT. 
(I) Spotting assay of Dhsp104 strains coexpressing aSyn and the indicated chimeric 
Hsp104 between ScHsp104 and TlHsp104 illustrates that no chimeras between 
ScHsp104 and TlHsp104 replicate the aSyn toxicity-suppressing phenotype of 
TlHsp104. 
(J-K) Spotting assays of Dhsp104 strains coexpressing the indicated chimeric Hsp104 
and aSyn illustrates that NBD2 from TtHsp104 (J) or TlHsp104 (K) is not sufficient to 
copy the aSyn toxicity-suppression phenotype of TtHsp104 or TlHsp104. 
(L) Spotting assay of Dhsp104 strains coexpressing TDP-43 and either full-length 
PeHsp104 or SrHsp104, or monomeric fragments derived from these homologs 






Figure 3–18 Chimeric Hsp104 variants and proteotoxic substrates are consistently 
expressed in yeast. 
(A) Color code of Hsp104 homologs, and schematic of Hsp104 domain organization.  
(B-K) Western blots show that chimeras between ScHsp104 and GsHsp104 (B), 
MbHsp104 (C), CrHsp104 (D), PeHsp104 (E), SrHsp104 (F), CtHsp104 (G), TtHsp104 
(H,J) and TlHsp104 (I,K) are expressed consistently and at a level comparable to wild-
type protein. TDP-43 (B-F) and aSyn (G-I) are expressed consistently in all strains. 
Molecular weight markers are indicated at right of each panel. 
(L) Western blot showing expression of PeHsp104, SrHsp104, or fragments derived 
from these homologs in TDP-43-expressing yeast strains. Molecular weight markers are 




Figure 3–19 Characterization of Hsp104 chimera specificity. 
(A) Spotting assay of Dhsp104 strains coexpressing aSyn and the indicated chimeras 
between ScHsp104 and GsHsp104 shows that none of these chimeras suppress aSyn 
toxicity. 
(B) Spotting assay of Dhsp104 strains coexpressing aSyn and the indicated chimeras 




(C) Spotting assay of Dhsp104 strains coexpressing aSyn and the indicated chimeras 
between ScHsp104 and CrHsp104 shows that none of these chimeras suppress aSyn 
toxicity. 
(D) Spotting assay of Dhsp104 strains coexpressing aSyn and the indicated chimeras 
between ScHsp104 and PeHsp104 shows that a chimera possessing the NTD and 
NBD1 from PeHsp104 suppresses aSyn toxicity. 
(E) Spotting assay of Dhsp104 strains coexpressing aSyn and the indicated chimeras 
between ScHsp104 and SrHsp104 shows that none of these chimeras suppress aSyn 
toxicity. 
(F) Spotting assay of Dhsp104 strains coexpressing TDP-43 and the indicated chimeras 
between ScHsp104 and CtHsp104 shows that none of these chimeras suppress TDP-43 
toxicity. 
(G) Spotting assay of Dhsp104 strains coexpressing TDP-43 and the indicated chimeras 
between ScHsp104 and TtHsp104 shows that none of these chimeras suppress TDP-43 
toxicity. 
(H) Spotting assay of Dhsp104 strains coexpressing TDP-43 and the indicated chimeras 





3.2.12 Non-cognate NTD:NBD1 units can yield toxic chimeras at 37°C 
We next assessed the fitness effects intrinsic to the chimeras. We 
expressed all chimeras in Dhsp104 yeast at 37 ºC in the absence of any toxic 
substrate protein to observe any intrinsic toxicity associated with the chimeras 
themselves. We observed that NTD replacement alone does not cause toxicity 
(Figure 3-20A,B,C,D,E,F,G,H, third row in all panels). By contrast, replacing both 
the NTD and NBD1 resulted in toxicity in several cases (e.g. for GsHsp104, 
CrHsp104, PeHsp104, SrHsp104, and CtHsp104; Figure 3-20A,C,D,E,F, 
boxed), although TtHsp104 and TlHsp104 aSyn-specific variants) were 
exceptions Figure 3-20G, H). Interestingly, no toxicity was observed in chimeras 
where the NTD, NBD1, and MD were replaced together (Figure 3-
20A,B,C,D,E,F,G,H, fifth row), nor in chimeras where the MD was replaced alone 
(Figure 3-20A,B,C,D,E,F,G,H, sixth row) or in combination with the NTD (Figure 
3-20A,B,C,D,E,F,G,H, seventh row). These findings suggest that altered non-
cognate interactions between the NTD:NBD1 unit and the MD can elicit off-target 





Figure 3–20 Characterization of chimera intrinsic toxicity. 
Strains expressing chimeras between ScHsp104 and GsHsp104 (A), MbHsp104 (B), 
CrHsp104 (C), PeHsp104 (D), SrHsp104 (E), CtHsp104 (F), TtHsp104 (G), and 
TlHsp104 (H) were spotted onto glucose and galactose media, and incubated at 37 ºC 
for 2-3 days to observe growth. In several cases (panels A, C, D, E, and F) chimeras 




3.2.13 Hsp104 chimeras display reduced thermotolerance 
We then characterized the thermotolerance activity of all chimeras (Figure 
3-21) to understand how perturbing cognate interdomain interactions affects the 
disaggregase activity of each chimera. We found that, while swapping the NTD 
alone generally has a minimal effect on thermotolerance activity (the exception 
was SrNTDScNBD1:MD:NBD2:CTD which displayed minimal thermotolerance) swaps of 
subsequent domains, either alone or in combination, severely impair 
thermotolerance function (Figure 3-21). Some of the weak thermotolerance 
phenotypes may be attributable to low expression levels of certain chimeras from 
pHSP104; for instance, several chimeras between MbHsp104 and ScHsp104 are 
poorly expressed from pHSP104 (Figure 3-18C). But, expression levels of 
chimeras alone are insufficient to explain their thermotolerance phenotypes: even 
specific chimeras that reduce TDP-43 toxicity and express well from pHSP104 
(e.g. CrNTD:NBD2:MDScNBD2:CTD) fail to confer thermotolerance. We conclude that 
this observation provides further evidence that the mechanism that enables 





Figure 3–21 Thermotolerance activity of Hsp104 chimeras. 
Survival of yeast expressing GsHsp104, MbHsp104, CrHsp104, PeHsp104, SrHsp104, 
CtHsp104, TtHsp104, TlHsp104, or a chimera between one of these (as indicated by 
color in bar chart) and ScHsp104 was assessed following 20 min heat shock at 50 °C. 
Values are relative to wild-type ScHsp104 (single black bar at left) and represent means 
±SEM (n=3 independent transformations). Illustrations on x-axis indicate chimera 
composition. Gray indicates portions of the chimera from ScHsp104 and white indicates 
variable regions from other homologs 
 
3.2.14 Select chimeras mimic potentiated ScHsp104 variants to suppress 
aSyn toxicity 
Interestingly, two chimeras consisting of cognate NTD:NBD1 pairs fused 
to MD:NBD2:CTD from ScHsp104 unexpectedly suppressed aSyn toxicity. First, 
a chimera consisting of the CtHsp104 NTD and NBD1 fused to the ScHsp104 
MD, NBD2, and CTD suppressed aSyn toxicity even more strongly than 
CtHsp104WT (Figure 3-17H). Similarly, a chimera consisting of the PeHsp104 
NTD and NBD1 fused to the ScHsp104 MD, NBD2, and CTD reduced aSyn 
toxicity (Figure 3-19D). This finding was particularly unexpected because full-
132 
 
length PeHsp104 is specific to TDP-43, and this same chimera is inactive against 
TDP-43 (Figure 3-17F). Both of these chimeras were toxic to yeast when 
expressed alone at 37°C (Figure 3-20D, F, boxed). Thus, in these cases, 
disruption of interaction between the NTD:NBD1 unit and the MD appears to 
mimic potentiated ScHsp104 variants and enables suppression of aSyn toxicity. 
 
3.2.15 The NBD2:CTD unit of TtHsp104 and TlHsp104 contribute to 
suppression of aSyn toxicity 
For the aSyn-specific Hsp104 homologs, TtHsp104 and TlHsp104, 
chimeras consisting of NTD:NBD1:MD from TtHsp104 or TlHsp104 fused to 
NBD2:CTD from ScHsp104 were unable to reduce aSyn toxicity (Figure 3-17D, 
I). To test whether suppression of aSyn toxicity is encoded by residues within 
NBD2:CTD, we tested chimeras in which NTD:NBD1:MD were from ScHsp104 
and NBD2:CTD was from either TtHsp104 or TlHsp104. However, these 
chimeras were also incapable of suppressing aSyn toxicity (Figure 3-17J, K; see 
Figure 3-18J, K for accompanying Western blots). Thus, these results suggest 
that additional residues or contacts in the NBD2:CTD unit are necessary but not 




3.2.16 Homolog-mediated suppression of TDP-43 toxicity requires the 
NBD2:CTD unit 
Finally, we tested whether NBD2 was required for suppression of TDP-43 
toxicity by Hsp104 homologs, or whether expressing Hsp104 fragments 
encompassing the NTD, NBD1, and MD (which contain sequence determinants 
that reduce TDP-43 toxicity) would recapitulate the suppression of toxicity seen 
with the full-length homolog. We therefore co-expressed PeHsp1041-541and 
SrHsp1041-551 with TDP-43 in yeast. Neither of these fragments reduce TDP-43 
toxicity (Figure 3-17L; see Figure 3-18L for accompanying Western blot). Two 
additional fragments, PeHsp104767-914 and SrHsp104781-892, which correspond to 
the small domain of NBD2 and the CTD also did not reduce TDP-43 toxicity 
(Figure 3-17L). Since these Hsp104 fragments are likely monomeric [205, 206], 
we thus conclude that proteotoxicity suppression is an emergent property of 
hexameric Hsp104 homologs or chimeras. 
 
3.3 Discussion 
Here, we used yeast toxicity models to identify naturally occurring Hsp104 
homologs, from diverse eukaryotic hosts, capable of buffering proteotoxicity of 
several proteins implicated in human neurodegenerative diseases, including 
TDP-43 and αSyn (Figures 3-1 and 3-4). Excitingly, Hsp104 homologs that 
suppress TDP-43 toxicity in yeast also suppress TDP-43 aggregation in human 
cells (Figure 3-10), and Hsp104 homologs that suppress aSyn toxicity in yeast 
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also suppress aSyn toxicity-induced neurodegeneration in C. elegans (Figure 3-
11). Thus, we suggest that, like previously-defined potentiated Hsp104 variants, 
these naturally-occurring Hsp104 variants may be able to mitigate proteotoxicity 
in a wide variety of circumstances, including in metazoan systems.  
Several features of the Hsp104 homologs presented here contrast with 
potentiated Hsp104 variants. Hsp104 homologs are substrate-specific and 
typically only suppress either TDP-43 or aSyn toxicity (the exception is 
CtHsp104). Indeed, we did not isolate any Hsp104 homologs capable of 
suppressing FUS toxicity. In contrast, potentiated Hsp104 variants typically are 
able to suppress toxicity of multiple toxic substrates (Figures 3-1, 3-4, and 3-5) 
[108, 118-121]. Natural Hsp104 homologs also displayed no intrinsic toxicity, 
even when expressed at elevated temperatures (Figure 3-3). Thus, extant 
Hsp104 homologs have likely been filtered through natural selection to avoid 
deleterious and destabilizing sequences. In contrast, potentiated Hsp104 variants 
have predominantly been engineered by destabilizing the NBD1:MD interface 
[99, 108, 118-120]. This difference is further reflected in fundamental mechanistic 
differences between how the Hsp104 homologs described here and potentiated 
Hsp104 variants operate to antagonize proteotoxic misfolding. Engineered 
Hsp104 variants are generally enhanced disaggregases [108, 118, 119, 121]. We 
hypothesize that these enhanced disaggregase and unfoldase activities may 
come at the cost of substrate specificity (e.g. by mistargeting natively-folded 
complexes for disassembly), analogous to trade-offs between speed and fidelity 
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observed in other NTPase molecular machines, such as RNA polymerases [207]. 
However, the Hsp104 homologs presented here are not similarly enhanced 
disaggregases, and in fact do not require disaggregase activity to antagonize 
proteotoxic misfolding of TDP-43 or aSyn. Rather, they appear to act as ATP-
independent chaperones to suppress toxicity of specific substrates (Figures 3-12 
and 3-15). 
 The dual role of Hsp104 as a molecular chaperone capable of preventing 
substrate misfolding in addition to a disaggregase capable of reversing protein 
aggregation has been long-appreciated [77, 78]. Both of these activities require 
ATPase activity for maximum effect, although disaggregase activity is much more 
sensitive to reduced ATPase activity than chaperone activity [77, 78]. Here, we 
find that diverse Hsp104 homologs are able to suppress toxicity of select 
substrates in a manner that requires neither active ATPase domains nor 
substrate engagement by the canonical pore loops (Figure 3-15). Rather, we 
have uncovered genetic variation outside of these core AAA+ features that 
enables molecular recognition of specific substrates. Thus, in future work it will 
be important to tune this genetic variation to create designer disaggregases with 
highly specific molecular recognition. Indeed, we envision making modular 
disaggregases by combining potentiating mutations with molecular recognition 




 What sequence determinants of Hsp104 homologs enable their toxicity 
suppression phenotypes? Hsp104 homologs that suppress TDP-43 or suppress 
aSyn are more similar to each other than between groups (average sequence 
identities of 56%, 76%, and 44%, respectively; Figure 3-8B). To further address 
this question, we first tested the effect of deleting the NTD on the toxicity 
suppression phenotypes associated with Hsp104 homologs (Figure 3-15). We 
observed that suppression of TDP-43 toxicity by MbHsp104 and CrHsp104, and 
suppression of aSyn toxicity by TtHsp104, depends on the presence of the NTD 
of these homologs (Figure 3-15). The ScHsp104 NTD enables many aspects of 
ScHsp104 function, including hexamer cooperativity, substrate binding, amyloid 
dissolution, and proteotoxicity suppression by potentiated Hsp104 variants [98, 
99]. We suggest that the NTD-dependent rescue phenotypes we observed may 
reflect a role of NTD-substrate binding in suppressing proteotoxicity.  
While the NTD is necessary for proteotoxicity suppression under some 
circumstances, it is not universally required. Three out of five TDP-43-specific 
homologs did not require the NTD to suppress TDP-43 toxicity, and TlHsp104 did 
not require the NTD to mitigate aSyn toxicity (Figure 3-15). Furthermore, simply 
replacing the ScHsp104 NTD with the NTD from MbHsp104 or CrHsp104 does 
not enable suppression of TDP-43 toxicity, nor does replacing the ScHsp104 
NTD with the NTD from TtHsp104 impart suppression of aSyn toxicity (Figure 3-
17). Thus, we reasoned that additional domains must be required. Indeed, for 
TDP-43, we found that replacing the NTD:NBD1:MD unit of the ScHsp104 
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hexamer with the homologous domains from any TDP-43-rescuing homolog 
enables suppression of TDP-43 toxicity by the resulting chimera (Figure 3-17). 
The NBD2 and CTD domains were required to facilitate suppression of toxicity, 
as fragments of PeHsp104 and SrHsp104 encompassing NTD:NBD1:MD but 
lacking NBD2 and the CTD failed to suppress toxicity. However, NBD2:CTD 
could be from ScHsp104. In contrast, NBD2:CTD could not be from ScHsp104 
for suppression of aSyn toxicity by TtHsp104 and TlHsp104 (Figure 3-17). We 
propose two explanations for these divergent observations. The first is that, 
particularly for the homologs where NTD deletion does not diminish suppression 
of toxicity (e.g. GsHsp104, PeHsp104, and SrHsp104 for TDP-43 and TlHsp104 
for aSyn), there are important sequence determinants throughout the protein that 
enable each homolog to produce a protective phenotype. The second possible 
explanation is that these other domains contribute to suppression of toxicity 
indirectly by stabilizing overall protein architecture of the chimeras. There are no 
obvious trends in the primary sequence of the homologs, however, that would 
clarify these two competing possibilities. Indeed, further work is needed to gain a 
complete understanding of how homologous Hsp104 sequences confer variable 
substrate-specific proteotoxicity suppression. 
 That nearly half of the Hsp104 homologs we tested (8/17) were able to 
antagonize toxicity of either TDP-43 or aSyn (or both, in the case of CtHsp104) 
was unanticipated. There are no clear TDP-43 or aSyn homologs in the host 
species from which we selected Hsp104 homologs to test. Our observation that, 
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for a given Hsp104, there was not a predictable relationship between TDP-43 or 
aSyn toxicity suppression and thermotolerance function, which may more closely 
reflect the primary in vivo function of these Hsp104 homologs, suggests one 
interpretation involving cryptic genetic variation [208]. Variation that is neutral or 
nearly neutral with respect to thermotolerance function, but which enables 
suppression of TDP-43 or aSyn, may have accumulated in these lineages in the 
absence of selective pressure and was only revealed by our synthetic 
experimental paradigm. Alternatively, it is possible that the Hsp104 homologs we 
tested are adapted to host proteomes that have higher-than-average content of 
TDP-43-like or aSyn-like motifs, which is reflected in their ability to selectively 
antagonize misfolding of similar motifs in TDP-43 or aSyn. Nevertheless, the fact 
that Hsp104 homologs that are active against at least one of TDP-43 or aSyn 
were so widespread amongst diverse eukaryotic lineages, and the fact that we 
have now identified ~100 potentiating mutations in Hsp104 that enable similar 
toxicity suppression phenotypes (albeit by different mechanisms) suggests that 
Hsp104, and possibly other AAA+ proteins, are uniquely poised to buffer 






3.4 Materials and Methods 
3.4.1 Bioinformatic analyses 
Multiple sequence alignments of Hsp104 homologs were generated with 
Clustal Omega [209]. Multiple sequence alignments were visualized in JalView 
[210]. The phylogenetic tree in Figure 3-1 was generated using EMBL-EBI 
Simple Phylogeny tool [211]. Pairwise sequence identities in Figure 3-8B were 
calculated using UniProt Align tool. Divergence times shown in Figure 3-12 were 
from TimeTree [212].  
 
3.4.2 Yeast strains and media 
All yeast were WT W303a (MATa, can1-100, his3-11,15, leu2-3,112, trp1-
1, ura3-1, ade2-1) or the isogenic strain W303aΔhsp104 [213]. Yeast were grown 
in rich medium (YPD) or in the appropriate synthetic selection media. Media was 
supplemented with 2% glucose, raffinose, or galactose. 
 
3.4.3 Plasmids 
Yeast expression vectors encoding TDP-43 (pAG303GAL-TDP-43), FUS 
(pAG303GAL-FUS), and αSyn-GFP (pAG303GAL-αSyn-GFP and pAG304GAL-
αSyn-GFP) were from Aaron Gitler [52-54]. pRS313HSE-ScHsp104WT-FLAG, 
pAG416GAL-ScHsp104WT-FLAG, pAG416GAL-ScHsp104A503S-FLAG, and 
pAG416GAL-CtHsp104-FLAG have been described previously [95]. cDNAs 
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encoding some Hsp104 homologs were kind gifts from Adrian Tsang (Concordia 
University; TtHsp104, TlHsp104, ChtHsp104, LtHsp104, MtHsp104, StHsp104, 
and TaHsp104), Susan Lindquist (Whitehead Institute; AtHsp104), and Simon 
Alberti (MPI-CBG; DdHsp104), while yeast codon-optimized cDNAs encoding 
other Hsp104 homologs were synthesized by Invitrogen (MbHsp104 and 
PfHsp104) or Genscript (GsHsp104, CrHsp104, SrHsp104, and PeHsp104). 
Hsp104 cDNAs codon-optimized for expression in mammalian cells were used 
for experiments shown in Figure 3-10. Gateway BP reactions were used to 
shuttle Hsp104 genes into a Gateway entry vector, pDONR221-ccdB. The entry 
clones were then used to shuttle Hsp104 ORFs into suitable yeast (pAG416GAL-
ccdB or pAG413GAL-ccdB or pRS313HSE-ccdB), C. elegans (pDAT-ccdB), or 
mammalian (pInducer20-ccdB) expression vectors via LR reactions. MbHsp104 
and CrHsp104 were cloned into pNOTAG for bacterial expression through NdeI 
and SacI sites. Hsp104 mutants were obtained by Quikchange mutagenesis. 
Hsp104 chimeras were cloned by overlap-extension PCR. 
Doxycycline-inducible TDP-43DNLS mammalian expression vector [196] 
was modified as follows. Human wild-type TDP-43 was amplified in two separate 
PCR reactions excluding the NLS and reassembled using Gibson cloning (NEB) 
into a Doxycycline-inducible expression vector containing an N-terminal 










3.4.4 Yeast transformation and spotting assays 
Yeast were transformed according to standard protocols using 
polyethylene glycol and lithium acetate [170]. For spotting assays, yeast were 
grown to saturation overnight in synthetic raffinose dropout media at 30 °C. 
Cultures were normalized and serially diluted 5-fold and spotted in duplicate onto 
synthetic dropout media containing glucose or galactose. Plates were analyzed 
after growth for 2-3 days at 30 °C. 
 
3.4.5 Assessing toxicity of Hsp104 homologs and chimeras 
W303aΔhsp104 yeast were transformed with the indicated Hsp104 
plasmid. Transformants were grown to saturation overnight in synthetic raffinose 
media. Cultures were normalized, spotted onto synthetic dropout media 
containing glucose or galactose, and incubated at 30 °C or 37 °C for 2-3 d before 
growth was documented. 
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3.4.6 Western blotting 
Yeast were grown in galactose-containing media to induce protein 
expression for 5h (for strains expressing Hsp104 variants alone or with TDP-43) 
or 8h (for strains expressing αSyn). Cultures were normalized to OD600=0.6, and 
6 mL of cells were harvested. For heat shock controls, samples were incubated 
at 37 °C for 30 minutes prior to processing. Yeast lysates were extracted by 
incubation with 0.1M NaOH at room temperature for 5 min. Lysates were mixed 
with SDS sample buffer, boiled for 5 min, and subjected to Tris-HCl SDS-PAGE 
(4-20% gradient, Bio-Rad) followed by transfer to a PVDF membrane (Millipore). 
Membranes were blocked in Odyssey blocking buffer (LI-COR) for 1h at room 
temperature or overnight at 4 °C. Primary antibody incubations were performed 
at 4 °C overnight or at room temperature for 2h. After washing with PBST, 
membranes were incubated with fluorescently labeled secondary antibodies at 
room temperature for 1h, followed by washing with PBST. Proteins were 
detected using an Odyssey Fc Dual-Mode Imaging system. Primary antibodies 
used: mouse monoclonal anti-FLAG M2 (Sigma-Aldrich), rabbit polyclonal anti-
TDP-43 (Proteintech), rabbit polyclonal anti-GFP (Sigma-Aldrich), mouse 
monoclonal 3-phosphoglycerate kinase (Novex), rabbit polyclonal anti-Hsp26 
(Johannes Buchner, TU-Munich), fluorescently labeled anti-mouse and anti-




3.4.7 Fluorescence microscopy 
To visualize changes in TDP-43 and aSyn localization in response to 
coexpression of various Hsp104 variants, yeast strains expressing fluorescently-
tagged TDP-43 and aSyn were previously generated and described [108]. For 
microscopy, these strains were grown for 5 h (TDP-43) or 8 h aSyn) in galactose-
containing media at 30 °C. For TDP-43 microscopy, cells were harvested and 
fixed with ice-cold 70% ethanol, washed 3 times with ice-cold PBS, and stained 
with 4’,6-diamidino-2-phenylindole (DAPI) in Vectashield mounting medium 
(Vector Laboratories) to visualize nuclei. For aSyn, imaging was performed with 
live cells. Images were collected at 100x magnification using a Leica-DMIRBE 
microscope and processed using ImageJ software (NIH). 
 
3.4.8 HEK-293T cell culture and transfections 
HEK-293T cells were maintained in Dulbecco’s modified Eagle’s medium, 
high glucose (Gibco) containing 10% fetal bovine serum (Life Sciences), 1% non-
essential amino acids (Gibco), and 1% anti-anti (Gibco). Cells were plated in 
gelatin-coated 6-well plates at a density of 3x10^6 cells/plate 24hr before 
transfection. Cells were transfected with 2 µg total DNA and 7.35 µl 
polyethylenimine HCl MAX transfection reagent (Polysciences, Inc). Wells co-
transfected with mClover3-TDP NLS and HSP104 variants received 1 µg of 
each plasmid. Media was changed 6hrs post-transfection to media containing 1 
µg/ml of doxycycline hyclate (Sigma-Aldrich) in order to induce transgene 
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expression. Transfected cells were lifted every 24 h over 2 days, at which point 
cells were analyzed by FACS (FACSAria Fusion BD). Cells were gated to have a 
narrow range of FCS and SSC values and to be fluorescence positive. TDP-43 
aggregation was quantified by comparing the height (FITC-H) to the width (FIRC-
W) of the fluorescence channel using 488nm laser and FITC filters.  
 
3.4.9 Generation of transgenic C. elegans and neurodegeneration analysis 
Nematodes were maintained through well-established methods [214]. 
Constructs were injected into animals to create transgenic line using previously 
described methods [215]. Strains UA381 (baln11 [Pdat-1 :: aSyn, Pdat-1 ::GFP]; 
baEx210 [Pdat-1::CtHsp104, rol-6], UA382 (baln11 [Pdat-1 :: aSyn, Pdat-1 ::GFP]; 
baEx211 [Pdat-1::TtHsp104, rol-6], UA383 (baln11 [Pdat-1 :: aSyn, Pdat-1 ::GFP]; 
baEx212 [Pdat-1::TIHsp104, rol-6] were generated by injecting 50 ng/μl of 
corresponding plasmid construct into UA44 (baln11 [Pdat-1 :: aSyn, Pdat-1 ::GFP]) 
with phenotypic marker (rol-6, 50 ng/μl, for roller expression). Three independent 
stable lines were created for each group. For dopaminergic neurodegeneration 
analyses, the transgenic animals were scored as described previously [216]. 
Briefly, on the day of analysis, the six anterior dopaminergic neurons [four CEP 
(cephalic) and two ADE (anterior deirid)] were examined in 30 animals randomly 
selected for each trial worms that express the roller marker in the body wall 
muscle cells. Neurons were analyzed for any degenerative phenotypes, such as 
a missing dendritic process, cell body loss, or a blebbing neuronal process. Each 
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animal was scored as having normal or wild-type neurons when none of the 
degenerative phenotypes were present in any anterior dopaminergic neurons. 
Three independent transgenic worm lines were analyzed per genetic background 
and an average of total percentage of worms with normal neurons was reported 
in the study. One-way ANOVA, followed by a Dunnett’s multiple comparisons 
post hoc test, was performed for statistical analysis using GraphPad Prism 
Software. 
 
3.4.10 Quantitative real-time PCR 
RNA isolation and RT-qPCR was performed on worms using previously 
published methods [217]. Briefly, total RNA was isolated from 100 young adult 
(day 4 post hatching) nematodes from corresponding transgenic lines using TRI 
reagent (Molecular Research Center). The genomic DNA contamination was 
removed with 1 µl of DNaseI (Promega) treatment for 60 minutes at 37oC, then 
with DNase Stop solution for 10 minutes at 65oC. 1µg of RNA was used for cDNA 
synthesis using the iScript Reverse Transcription Supermix for RT-qPCR (Bio-
Rad) following the manufacturer’s protocol. RT-qPCR was performed using IQ-
SYBR Green Supermix (Bio-Rad) with the Bio-Rad CFX96 Real-Time System. 
Each reaction contained 7.5 μl of the IQ SYBR Green Supermix, 200 nM of 
forward and reverse primers and 5 ng of cDNA, to a final volume of 15 μl. The 
cycling conditions were as follows: polymerase activation and DNA denaturation 
at 95°C for 3 min, followed by 35 cycles of 10 s at 95°C, 30 s at 60°C. After the 
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final cycle, a melting curve analysis was performed using the default setting of 
CFX96 Real-Time System. A single melt peak for each targeted gene was 
observed and no non-specific amplification was detected in each reaction mixture 
by agarose gel electrophoresis. PCR efficiency was calculated from standard 
curves that were generated using serial dilution (Eα-syn=98.8%, ETtHsp104=101.0%, 
ETlHsp104=97.4%, Etba-1=98.8%, Ecdc-42=98.4%, Esnb-1=95.3%). The expression 
levels of aSyn and Hsp104 variants were normalized to three reference genes 
(snb-1, cdc-42, and tba-1). No amplification was detected in NTC and NRT 
controls. The reference target stability was analyzed by GeNorm and passed for 
all reference genes listed above. All target genes were measured in triplicates for 
three independent transgenic lines for each sample in this study. The data 
analysis was performed by the Gene Expression Module of CFX Manager 
software. 
The following primers were used for the assays;  
CtHsp104 Forward: GACGAAGCGTGTGCCAATAC   
CtHsp104 Reverse: CACTTCCTGGAGCCGCTG 
TtHsp104 Forward: CAACTACTTCCTGCCCGAG   
TtHsp104 Reverse: ATCTGGACGTTGCGGTCGT  
TlHsp104 Forward: AACCGTCTCACCAAGCGTG    
TlHsp104 Reverse: GCCTCTCCGAGATAGTCCT 
aSyn Forward: ATGTAGGCTCCAAAACCAAGG 
aSyn Reverse: ACTGCTCCTCCAACATTTGTC 
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snb-1 Forward:  CCGGATAAGACCATCTTGACG 
snb-1 Reverse:  GACGACTTCATCAACCTGAGC 
cdc-42 Forward: CCGAGAAAAATGGGTGCCTG 
cdc-42 Reverse: TTCTCGAGCATTCCTGGATCAT 
tba-1 Forward: ATCTCTGCTGACAAGGCTTAC 
tba-1 Reverse: GTACAAGAGGCAAACAGCCAT 
 
3.4.11 Thermotolerance 
W303aΔhsp104 yeast were transformed with plasmids bearing either 
Hsp104 from S. cerevisiae, the indicated Hsp104 homolog, or Hsp104 mutant 
under the native HSP104 promoter (except for TtHsp104 and derivative mutants, 
which were expressed from pGAL), or an empty vector control. Transformants 
were selected, grown to saturation in yeast minimal media (SD-His), and then 
diluted to OD600=0.2 in fresh SD-His. Yeast were allowed to double at 30 °C, 
after which cultures were normalized. Cells were then heat shocked at 50 °C for 
the indicated time and cooled for 2 min on ice. Cultures were then diluted 1000-
fold, plated on SD-His, and plates were incubated at 30 °C for 2-3 days to 




3.4.12 Protein expression and purification 
Untagged ScHsp104 was expressed from the pNOTAG-ScHsp104 vector 
[205] and purified as previously described [102, 145]. Briefly, pNOTAG-
ScHsp104 was used to transform BL21(DE3)RIL E. coli. Transformed cells were 
grown in 2xYT broth supplemented with 25 µg/ml chloramphenicol and 100 µg/ml 
ampicillin at 37 °C until an OD600 of 0.4-0.6 was reached, at which point cells 
were cooled to 15 °C. Expression was induced by addition of 1 mM isopropyl 1-
thio-β-D-galactopyranoside for 15-18 h. Cells were harvested by centrifugation 
(4,000×g, 4°C, 25 min), resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 10 
mM MgCl2, 2.5% glycerol, 2 mM β-mercaptoethanol, 5 µM pepstatin, c0mplete 
EDTA-free protease inhibitors (Roche). Cells were treated on ice with 20 mg 
lysozyme per 1L culture and lysed by sonication. Cell debris was removed by 
centrifugation at 16,000×g at 4°C for 20 min, and the supernatant was applied to 
Affi-Gel Blue resin (Bio-Rad). Resin was incubated with the lysates for 4 h at 4 °C 
with slow rotation. Resin was then washed 4 times with wash buffer (50 mM Tris-
HCl, pH 8.0, 10 mM MgCl2, 100 mM KCl, 2.5% glycerol, 2 mM β-
mercaptoethanol). ScHsp104 was eluted with wash buffer supplemented with 1 
M KCl. The protein was then exchanged into running buffer Q (20 mM Tris-HCl 
pH 8.0, 0.5 mM EDTA, 5 mM MgCl2, 50 mM NaCl), further purified by ResourceQ 
anion exchange chromatography, and eluted with a linear salt gradient (50 mM-1 
M NaCl). Eluted protein was then exchanged into storage buffer (40 mM HEPES-
KOH pH 7.4, 150 mM KCl, 20 mM MgCl2, 10% glycerol, 1 mM DTT), snap-
frozen, and stored at -80 °C until use. 
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MbHsp104 and CrHsp104 were expressed as untagged proteins by 
subcloning the MbHsp104 and CrHsp104 ORFs into pNOTAG through NdeI and 
SacI sites. Protein expression and lysis were carried out as for ScHsp104. 
However, MbHsp104 and CrHsp104 bound poorly to Affi-Blue resin, even after 
extended incubation times (data not shown). Instead, MbHsp104 and CrHsp104 
were precipitated from clarified bacterial lysates by addition of solid ammonium 
sulfate to 40% of saturation. Precipitates were collected by centrifugation 
(16,000×g at 4 °C, 20 min) and resuspended in buffer containing 50 mM Tris-
HCl, pH 8.0, 10 mM MgCl2, 100 mM KCl, 2.5% glycerol, 2 mM β-
mercaptoethanol. To resolubilize precipitates, ammonium sulfate was removed 
by dialysis against this buffer, with 3 buffer changes. The dialyzate was filtered 
and applied to a 5 mL HiTrapQ column and purified with running buffer Q (20 mM 
Tris pH 8.0, 0.5 mM EDTA, 5 mM MgCl2, 50 mM NaCl) and eluted with a linear 
gradient of buffer Q+ (20 mM Tris pH 8.0, 0.5 mM EDTA, 5mM MgCl2, 1 M NaCl) 
over 40 column volumes. Peak fractions were collected, pooled, and exchanged 
into size exclusion buffer (40 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM 
MgCl2 1 mM DTT) and further purified by size exclusion chromatography on a 
pre-equilibrated Superdex 200 column (GE healthcare). Protein in size exclusion 
buffer was concentrated to ~10 mg/mL, supplemented with 10% glycerol, snap-
frozen and stored at -80 °C until use. 
CtHsp104, TtHsp104, and TlHsp104 were expressed from pMCSG68 
vector as TEV protease-cleavable His6-tagged fusion proteins. Protein 
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expression and lysis were carried out as for other Hsp104 homologs, except in 
this case lysis buffer consisted of 40 mM HEPES-KOH pH 7.4, 500 mM KCl, 20 
mM MgCl2, 2.5% glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol 
supplemented with 5 µM pepstatin A and complete protease inhibitor tablets. 
Clarified lysate was loaded onto Ni-NTA resin. The resin was washed with 10 
volumes of wash buffer (same formulation as lysis buffer except without protease 
inhibitors) and eluted in wash buffer supplemented with 350 mM imidazole. TEV 
protease was added to the eluted protein, and the sample was dialyzed against 
wash buffer containing no imidazole for 4 h at room temperature followed by 
~16h at 4 °C. After dialysis and cleavage, the protein was loaded onto a second 
Ni-NTA column to remove the His6 tag and uncleaved protein. Eluted protein was 
pooled, concentrated, and exchanged into high salt storage buffer (40 mM 
HEPES-KOH pH 7.4, 500 mM KCl, 20 mM MgCl2, 10% glycerol, and 1 mM DTT), 
snap-frozen in liquid nitrogen, and stored at -80 °C until further use. 
 Ssa1, Hsc70, Sis1, Ydj1, Hdj1, and Hdj2 (in pESUMO (Life Sensors)) 
were expressed as N-terminally His6-SUMO-tagged proteins in BL21(DE3)RIL 
cells. Transformed cells were grown at 37 °C in Luria broth supplemented with 25 
µg/ml chloramphenicol and 100 µg/ml ampicillin to an OD600 ~0.5. Cultures were 
cooled to 15 °C, and expression was induced with 1 mM IPTG for 16 h. Cells 
were harvested, resuspended in lysis buffer (50 mM HEPES pH 7.5, 750 mM 
KCl, 5 mM MgCl2, 10% glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol, 5 
µM pepstatin A, and c0mplete protease inhibitor (Roche)), and lysed by 
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treatment with lysozyme and sonication. Lysates were clarified by centrifugation 
(16,000×g, 20 min, 4°C), and incubated with Ni-NTA resin for 90 min at 4°C. 
Resin was washed with 10 column volumes of wash buffer (50 mM HEPES pH 
7.5, 750 mM KCl, 10 mM MgCl2, 10% glycerol, 20 mM imidazole, 1 mM ATP, 2 
mM β-mercaptoethanol) and eluted with 2 column volumes of elution buffer 
(wash buffer+300 mM imidazole). To cleave the His6-SUMO tag, Ulp1 was added 
at a 1:100 molar ratio, and imidazole was removed by dialysis against wash 
buffer. After dialysis, protein was loaded onto a 5 mL HisTrap column (GE 
Healthcare) and eluted with a linear imidazole gradient (20-350 mM) over 40 
column volumes. Fractions containing cleaved protein were pooled, 
concentrated, and purified further by Resource Q (Ssa1, Hsc70, Ydj1, and Hdj2) 
or Resource S (Sis1 and Hdj1) ion exchange chromatography. 
 TDP-43 was expressed with an N-terminal, TEV-cleavable maltose 
binding protein (MBP) tag in BL21(DE3)RIL cells. Transformed cells were grown 
at 37 °C in Luria broth supplemented with 25 µg/ml chloramphenicol and 100 
µg/ml ampicillin to an OD600 ~0.8. Cultures were cooled to 15 °C, and expression 
was induced with 1 mM IPTG for 16 h. Cells were harvested, resuspended in 
lysis buffer (50 mM HEPES-KOH pH 7.5, 500 mM NaCl, 10% glycerol, 2 mM 
EDTA, 2 mM DTT, and c0mplete protease inhibitor (Roche)), and lysed by 
treatment with lysozyme and sonication. Lysates were clarified by centrifugation 
(16,000×g, 20 min, 4 °C). Cleared lysate was added to a 50% slurry of amylose 
resin (New England Biolabs) in lysis buffer and incubated at 4 °C for 30 min to 
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bind MBP-TDP-43. The resin was washed with lysis buffer, and eluted MBP-TEV 
with elution buffer (50 mM HEPES-KOH pH 7.5, 500 mM NaCl, 10% glycerol, 2 
mM EDTA, 2 mM DTT, 10 mM maltose). Purified fractions were pooled, snap-
frozen, and stored at -80 °C until use. 
 
3.4.13 ATPase activity 
Hsp104 (0.25 µM monomer) was incubated with ATP (1 mM) for 5 min at 
the indicated temperatures in buffer (25 mM HEPES-KOH pH 7.4, 150 mM 
potassium acetate, 10 mM magnesium acetate, 10 mM DTT). ATPase activity 
was determined by inorganic phosphate release using a malachite green 
phosphate detection kit (Innova). Background hydrolysis was determined at time 
zero and subtracted. 
 
3.4.14 Luciferase reactivation 
Aggregated luciferase (50 nM) was incubated with Hsp104 (0.167 µM 
hexamer) with ATP (5 mM) and an ATP regeneration system (ARS; 1 mM 
creatine phosphate, 0.25 µM creatine kinase) plus or minus 0.167 µM Hsp70 
(Ssa1 or Hsc70) and 0.167 µM Hsp40 (Sis1, Ydj1, Hdj1, or Hdj2, as indicated). 





3.4.15 Semen-Derived Enhancer of Virus Infection (SEVI) remodeling 
SEVI remodeling was performed as previously described [89]. SEVI fibrils 
(20 µM monomer) were incubated with Hsp104 homologs (3 µM hexamer) in 
LRB buffer in the presence of ATP (5 mM) and an ATP regeneration system (0.1 
mM ATP, 0.02 mg/mL creatine kinase, 10 mM creatine phosphate). Samples 
were incubated at 37 °C for the duration of the experiments. At various time 
points, aliquots were removed, added to a 96-well plate containing a solution of 
25 µM ThT in LRB buffer. ThT fluorescence characteristics were measured on a 
Tecan Safire2 microplate reader with excitation and emission filters set to 440 nm 
and 482 nm, respectively. To assess fibril morphology by negative stain EM, 
reaction aliquots were spotted on Formvar carbon-coated grids (EM Sciences) 
and stained with 2% uranyl acetate. Samples were visualized using a JEOL-1010 
electron microscope. 
 
3.4.16 TDP-43 aggregation experiments 
TDP-43 aggregation was initiated by incubating 3 µM MBP-TEV-TDP-43 
with TEV protease in assembly buffer (40 mM HEPES-KOH pH 7.5, 150 mM 
NaCl, 10 mM MgCl2, 1 mM DTT) without agitation. Aggregation was monitored by 
turbidity (A395 nm) in a TECAN Infinite M1000 plate reader. In some reactions, 
either ScHsp104, MbHsp104, or CrHsp104 were added (6 µM) with or without 
ATP (5 µM) and regeneration system (1 mM creatine phosphate and 0.25 µM 
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creatine kinase). We verified that Hsp104 homologs nor ATP affected cleavage 




CHAPTER 4 Discussion 
 
 The AAA+ protein disaggregase Hsp104 couples energy derived from 
ATP hydrolysis to perform mechanical work to remodel protein aggregates [87]. 
Potentiated Hsp104 variants harness this activity and adapt it to antagonize a 
range of proteotoxic misfolding events associated with neurodegenerative 
disease [108]. However, potentiated Hsp104 variants are promiscuous 
disaggregases, a feature that manifests in intrinsic toxicity due to off-target 
effects [108, 121]. In this thesis, we aimed to discover therapeutic Hsp104 
variants with diminished propensity for off-target effects. We hypothesized that by 
exploring natural Hsp104 sequence diversity, we might capture therapeutic 
sequence variation that accumulated over evolutionary time while simultaneously 
avoiding overly deleterious sequences that likely were filtered out by natural 
selection. Here, I conclude this thesis by highlighting the major findings from our 
work and outlining future avenues of inquiry. 
 
4.1 Conclusions 
In Chapter 2, we reported two structures of an Hsp104 homolog from the 
thermophilic fungus Calcarisporiella thermophila (CtHsp104): an X-ray crystal 
structure at 2.70 Å (Figure 2-1) [95] and a cryo-EM single particle reconstruction 
(Figure 2-6) [95]. Both structures revealed left-handed, helical assemblies with 
all domains clearly resolved [95]. These structures add to a growing body of 
156 
 
literature on AAA+ protein structures, which has revealed highly conserved 
structural features among many AAA+ protein translocases [192, 218, 219]. In 
our structures we are able to clearly resolve electron density for the NTD, MD, 
and CTD in all protomers of the hexamer, which is lacking in some other cryo-EM 
models of Hsp104 [85, 96]. We also established that CtHsp104 antagonizes 
several toxic protein-misfolding events in vivo where Hsp104 from S. cerevisiae 
(ScHsp104) is ineffective, including rescue of TDP-43, polyglutamine, and aSyn 
toxicity (Figure 2-14) [95]. 
In Chapter 3, we asked how pervasive therapeutic Hsp104 homologs are 
[220]. We screened a cross-kingdom collection of an additional 15 eukaryotic 
Hsp104 homologs spanning ~2 billion years of evolution encompassing fungi, 
plants, protozoa, and chromista for their ability to suppress TDP-43, FUS, and 
αSyn toxicity in yeast (Figure 3-1A) [220]. Surprisingly, we discovered that 8/15 
of the eukaryotic Hsp104 homologs were capable of suppressing TDP-43 or 
αSyn toxicity (Figure 3-1; Figure 3-4) [220]. Moreover, they suppressed toxicity 
in an apparently substrate-specific fashion (Figure 3-5) [220]. Thus, Hsp104s 
from Galdieria sulphuraria, Monosiga brevicollis, Chlamydomonas reinhardtii, 
Populus euphratica, and Salpingoeca rosetta suppress TDP-43 toxicity but not 
αSyn nor FUS toxicity (Figure 3-1; Figure 3-5) [220]. Similarly, Hsp104s from 
Thielavia terrestris and Thermomyces lanuginosus suppress αSyn toxicity but not 
TDP-43 nor FUS toxicity (Figure 3-4; Figure 3-5). We also screened one distant 
Hsp104 homolog (ClpGGI) from the bacteria Pseudomonas aeruginosa, which 
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differs from Hsp104 in that it has an expanded NTD and lacks Motif 2 of the 
middle domain [220]. We found that ClpGGI suppresses αSyn toxicity and 
moderately suppresses TDP-43 and FUS toxicity (Figure 3-9) [220]. 
Next, we determined that Hsp104 homologs that suppress TDP-43 toxicity 
in yeast suppress TDP-43 aggregation in human cells (Figure 3-10) [220]. 
Likewise, Hsp104 homologs that suppress αSyn toxicity in yeast protect C. 
elegans from αSyn-mediated dopaminergic neurodegeneration, respectively 
(Figure 3-11) [220]. These results demonstrate that these Hsp104 homologs are 
functional in metazoa, which may motivate efforts to translate these homologs to 
more sophisticated neurodegenerative disease models [220]. 
Finally, we discovered that the homologs achieve substrate specificity 
through divergent, enhanced passive chaperone activity that enables 
neutralization of select substrates (e.g. TDP-43 or αSyn) (Figure 3-15) [220]. 
Chimeragenesis experiments revealed that genetic variation within specific 
regions of Hsp104 contribute to proteotoxicity suppression (Figure 3-17) [220]. 
These experiments showed that for TDP-43-suppressing homologs, variation 
within the top ring (e.g. NTD, NBD1, and MD) of the hexamer are responsible for 
facilitating toxicity suppression (Figure 3-17) [220]. By contrast, for αSyn-
suppressing homologs variation throughout the entire homolog contributes to 




4.2 Future Directions 
 
4.2.1 Identifying additional therapeutic Hsp104 homologs 
 Can we use the information gained from our survey of Hsp104 homologs 
to predict new therapeutic Hsp104 homologs? Although our survey suggests that 
therapeutic Hsp104 homologs are quite pervasive, the fact that Hsp104 
homologs from Salpingoeca rosetta and Monosiga brevicollis, which were the 
only two annotated choanoflagellate homologs available at the outset of this 
work, both suppress TDP-43 toxicity [220], does suggest that choanoflagellate 
clade may harbor additional therapeutic Hsp104 homologs. Recently, an 
additional 19 choanoflagellate genomes have been sequenced and annotated 
[221]. It will be interesting to screen these newly-annotated Hsp104 homologs for 
proteotoxicity suppression. Given that these homologs are from a single clade, 
they could even yield insight into functionally-important residues that we are 
missing in our work due to the degree of dissimilarity of our homologs from one 
another. 
4.2.2 Hsp104 as a drug target for antiparasitic agents 
 Hsp104 from the parasitic protozoan Plasmodium falciparum (PfHsp104) 
is toxic when expressed in yeast cultured at 37 °C. This toxicity may reflect 
functional repurposing of Hsp104 in P. falciparum, where it forms part of a 
translocon that unfolds parasitic proteins and translocates them into the host 
erythrocyte [184]. Thus, PfHsp104 may be predisposed to toxic promiscuous 
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unfolding of soluble cytoplasmic proteins. Nevertheless, this observation provides 
an intriguing opportunity to develop a screening platform, taking advantage of 
this growth phenotype in yeast, to identify PfHsp104 inhibitors. Indeed, as a 
proof-of-principle, we have already shown that the toxic growth defect associated 
with PfHsp104 expression can be rescued by mutations that impair PfHsp104 
ATPase activity (Figure 4-1). Inhibiting PfHsp104 is likely to be therapeutically 
useful because PfHsp104 is essential for Plasmodium survival [222, 223] and 
because it is a target that is novel to the parasite, thus limiting toxic off-target 
effects. Excitingly, this strategy may be applicable not just to Plasmodium but to 
many related pathogenic parasites including Toxoplasma, Cryptosporidium, 
Babesia, and Theileria. Although PfHsp104 is unique in its translocon function 
[224], inhibiting Hsp104 could render these species vulnerable to the host 
environment and thereby be therapeutic.  
 
Figure 4–1 A yeast screening platform for PfHsp104 inhibitors. 
(Left) Expression of untagged or FLAG-tagged PfHsp104 from P. falciparum in yeast is 
toxic at 37 °C, whereas the ATP-binding deficient mutant PfHsp104DWA is less toxic. The 
Dpdr1,3 strain was chosen because it is amenable to small molecule screens (Right) 
Expression of FLAG-tagged PfHsp104 was monitored by Western blot. 
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4.2.3 Testing Hsp104 homologs in animal models and delivery challenges 
 That the Hsp104 homologs studied here are expressed, well-tolerated, 
and therapeutic in human cells and in C. elegans should motivate further 
investigation of the therapeutic potential of these and other Hsp104 proteins in 
more sophisticated animal models of neurodegenerative disease, such as 
rodents. However, several technical hurdles must be overcome for Hsp104-
based technologies to be viable therapeutic options to counter proteopathies. 
The first challenge is how to deliver Hsp104. Viral delivery of Hsp104 has been 
effective in mitigating proteopathy in rodent models in the past [109], suggesting 
gene therapy may be a promising strategy. Indeed, the prospects for gene 
therapy in neurodegenerative disease seem brighter today than ever before. 
AAV-based replacement of defective genes to treat two neurodegenerative 
diseases, hereditary blindness and spinal muscular atrophy, have gained 
approval from the Food and Drug Administration (FDA) in recent years [225]. 
 
4.2.4 Towards ‘designer’ disaggregases: understanding the basis of 
passive chaperone activity 
 The overarching goal of our work is to understand and develop substrate-
specific disaggregases that can be deployed to mitigate proteotoxic stress in 
neurodegenerative disease. A major finding from the work presented here is that 
Hsp104 homologs employ divergent passive chaperone activity to suppress 
toxicity of substrates (Figure 3-15) [220]. Thus, manipulating Hsp104 passive 
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chaperone activity may be a strategy for engineering selective Hsp104-based 
therapeutic disaggregases [220].  
Our data demonstrates that passive chaperoning of TDP-43 and aSyn by 
Hsp104 homologs mitigates TDP-43 and aSyn toxicity in yeast (Figure 3-1 and 
Figure 3-4) [220] and C. elegans (Figure 3-11) [220]. These findings suggests 
that Hsp104 homologs maintain TDP-43 and aSyn in conformations that are non-
toxic. Microscopy data shows that aSyn is localized to the plasma membrane in 
yeast coexpressing aSyn and Hsp104 homologs that suppress aSyn toxicity 
(Figure 3-4) [220]. These data suggest that Hsp104 homologs that suppress 
aSyn toxicity may be able to maintain aSyn in a functional state that is able to 
bind the lipid membrane. Thus, in this context, Hsp104-mediated passive 
chaperoning of aSyn appears to phenocopy active protein remodeling seen with 
potentiated Hsp104 variants [108].  
TDP-43 is maintained in a diffuse, cytoplasmic state by Hsp104 homologs 
that suppress TDP-43 toxicity (Figure 3-1) [220]. This observation contrasts 
TDP-43-suppressing Hsp104 homologs with potentiated Hsp104 variants [108, 
220], which do facilitate TDP-43 nuclear reentry [108, 220]. One potential 
explanation for this difference is that Hsp104 homologs may occlude the nuclear 
localization sequence (NLS) on TDP-43 from recognition by yeast nuclear-import 
machinery. It seems unlikely that Hsp104 homologs bind the NLS directly, as 
Hsp104 homologs PeHsp104 and SrHsp104 suppress aggregation in HEK293T 
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cells of TDP-43 lacking an NLS, which argues against this possibility (Figure 3-
10) [220]. However, Hsp104 homologs could bind TDP-43 near the NLS and 
sterically occlude the NLS from recognition by nuclear import receptors. The 
Hsp104 binding site on TDP-43 could be elucidated using peptide arrays [226]. 
This explanation implicitly assumes that monomeric TDP-43 is the substrate for 
Hsp104 homologs. This assumption is supported by our in vitro experiments, 
which show that Hsp104 homologs MbHsp104 and CrHsp104 seem likely to 
interact with soluble TDP-43 to inhibit its aggregation (Figure 3-12) [220]. 
However, in cells Hsp104 homologs may also engage oligomeric TDP-43 or 
perhaps even small aggregated forms of TDP-43. Indeed, if TDP-43 remains in 
an aggregated state, this may impede its nuclear reentry. Whether or not Hsp104 
homologs engage and suppress these species could be assessed by testing 
whether TDP-43 oligomers or aggregates pre-incubated with Hsp104 are 
deficient in seeding fresh TDP-43 aggregation reactions. Overall, the fact that 
Hsp104 homologs do not facilitate TDP-43 nuclear reentry may pose a challenge 
to their therapeutic utility. Indeed, TDP-43 pathogenicity in ALS likely results from 
a gain of toxic function associated with TDP-43 aggregates (which can be 
mitigated by Hsp104 homologs) and a loss of function associated with loss of 
nuclear TDP-43 (which apparently cannot be mitigated by Hsp104 homologs; 
Figure 3-1) [220, 227]. 
A particularly attractive hypothesis is that it may be possible to generate 
highly potent and selective ‘designer’ disaggregases by combining potentiated 
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variants, which impart robust protein-disaggregase activity, with variants that 
impart enhanced passive chaperone activity, which acts as a selectivity filter to 
impart substrate specificity. To this end, we investigated whether we could boost 
activity of Hsp104 homologs by introducing MD mutations that potentiate 
ScHsp104 (Figure 4-2A). However, none of the MD mutations that potentiate 
ScHsp104 enhance MbHsp104 suppression of TDP-43 toxicity (Figure 4-2A). 
Similarly, we also tested several NBD1 mutations that potentiate ScHsp104, 
reasoning that, since the Hsp104 NBD1 is more conserved across homologs 
than the MD, these variants might be more efficacious (Figure 4-2B). However, 
none of the NBD1 mutations enhance MbHsp104 suppression of TDP-43 toxicity 
either (Figure 4-2B). Potentiating mutations therefore appear to be lineage-
specific, although it remains possible that the potentiating NBD2 mutation (N566I 
in ScHsp104) could potentiate many Hsp104 homologs. Therefore, development 
of designer disaggregases requires a finer understanding of how passive 
chaperone activity manifests in Hsp104:substrate interactions at a molecular 
level, so that we may be able to engineer it into potentiated ScHsp104 variants. 
Although this remains unclear, our mutational analysis suggests a role for the 
NTD (e.g. MbHsp104 suppresses TDP-43 toxicity whereas MbHsp104DN does 
not; Figure 3-15) [220]. Our chimeragenesis experiments suggest a role for the 
top ring (i.e. NTD, NBD1, and MD) of Hsp104 in mediating substrate interaction. 
However, these are imperfect experiments because swapping or deleting entire 
Hsp104 domains disrupts both Hsp104:substrate interfaces as well as 
164 
 
interdomain or interprotomer interfaces within Hsp104. As a result, loss-of-
function due to the latter disruption may mask any gain-of-function of the former. 
Indeed, chimeras comprised of the NTD, NBD1, and MD from MbHsp104 and 
NBD2 from ScHsp104 rescue TDP-43, yet many of these chimeras are defective 
in thermotolerance activity, indicating loss-of-function arising from non-cognate 
NBD1:NBD2 and MD:NBD2 interactions (Figure 3-21). Clearly, more work must 
be done to more finely delineate residues within Hsp104 domains that contribute 
to substrate interactions versus those that are necessary to maintain interdomain 
compatibility. 
 
Figure 4–2 MD or NBD1 mutations that potentiate ScHsp104 do not potentiate 
MbHsp104. 
Mutations in the MD (A) or NBD1 (B) of MbHsp104 do not enhance MbHsp104-
mediated suppression of TDP-43 toxicity. Mutations were chosen based on positional 
homology with MD mutations that potentiate ScHsp104. 
 
High-throughput genetics experiments such as deep mutational scanning 
could be used to disambiguate residues involved in substrate engagement from 
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those involved in functionally-important interdomain or interprotomer interfaces. 
In deep mutational scanning studies, a library of mutants derived from a protein 
of interest is subjected to biological selection [228, 229]. Deep sequencing pre- 
and post-selection is used to identify how the abundance of individual variants 
within the library changes during selection [228, 229]. The degree of enrichment 
or depletion of individual variants upon selection provides a quantitative measure 
of the fitness effect of that variant [228, 229]. Applied to Hsp104, a library of 
variants derived from an Hsp104 homolog would be subjected to two parallel 
biological screens. In the first screen, variants would be selected for their ability 
to suppress proteotoxicity of a given substrate. In the second, variants would be 
selected for their ability to confer thermotolerance in yeast. By comparing the 
results from these two screens, it will be possible to identify residues that 
contribute to substrate toxicity suppression but do not impact basic protein-
disaggregase function. 
Structural biology is a complementary tool to deepen our understanding of 
Hsp104:substrate interactions. It will thus be interesting in future work to solve 
structures of additional Hsp104 homologs in different nucleotide states. Hsp104 
undergoes dramatic conformational rearrangements upon substrate and 
nucleotide binding [85], which can be distinct for different Hsp104 homologs. 
Thus, while Hsp104 is proposed to alternate between a closed and extended 
state [85], ClpB does not access an extended conformation [192]. Thus, it would 
be interesting to know how other Hsp104 homologs differ in their conformational 
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cycling in response to ATP and substrate binding. It will also be interesting to 
understand the role of the NTD from a structural perspective. Our mutational 
experiments suggest that some Hsp104 homologs mediate substrate interaction 
via their NTDs. Our CtHsp104 structure is distinguished from many other Hsp104 
structures by the presence of clearly-resolved NTDs for all protomers. If the NTD 
remains well-resolved in different nucleotide and substrate states, we may be 
able to learn how the Hsp104 NTD mediates initial substrate engagement and 
coordinates with the rest of the Hsp104 hexamer when substrate is present. In a 
recently-published cryo-EM structure of casein-bound ClpB, for instance, a trimer 
of NTDs forms an apparent entrance channel for substrate to enter ClpB, and 
substrate can be seen interacting with a hydrophobic groove, which is previously-
identified substrate interaction domain [192]. In addition to cryo-EM, other 
biophysical tools such as HX-MS or synchrotron X-ray footprinting may be useful 
to identify specific sequences within Hsp104 homologs that engage substrate 
[97, 99, 122]. Such sequences could be identified by comparing hydrogen-
deuterium exchange rates or hydroxyl radical footprints between Hsp104 
incubated with and without substrate.  
Cryo-EM structures of substrate-bound Hsp104 have revealed that 
Hsp104-substrate interactions are mediated almost entirely by the pore loops, 
making them an intriguing target for further engineering to achieve substrate 
specificity. Indeed, our group recently discovered that mutating Hsp104 pore 
loops on top of a potentiated background (e.g. Hsp104Y257T:K358D) yields an 
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apparently aSyn-specific Hsp104 variant [230]. However, the mechanism by 
which these variants impart substrate specificity is unclear. Although this strategy 
only resulted in isolation of aSyn-specific variants, it is possible that deep 
mutational scanning of all possible combinations of the NBD1 (residues 256-259) 
and NBD2 (residues 661-664) pore loop motifs may result in isolating variants 
that therapeutically suppress other toxic substrate (e.g. TDP-43 or FUS). 
 
4.2.5 Loss of middle domain Motif 2 may be a conserved mode of Hsp104 
potentiation 
 An alternative approach to the experiments outlined in 4.2.4, we may be 
able to meet the same objective by potentiating Hsp104 homologs which already 
display substrate-specific behavior. It is interesting to note, however, that many 
of the potentiating mutations that have been isolated in the context of ScHsp104 
do not potentiate other Hsp104 homologs when introduced at homologous 
positions (Figure 4-2A). Here, we identified ClpGGI from Pseudomonas 
aeruginosa as a suppressor of TDP-43, FUS, and aSyn toxicity (Figure 3-9) 
[220]. ClpGGI is homologous to Hsp104 except that it has an expanded NTD and 
the architecture of the ClpG middle domain is altered such that it resembles Motif 
2 deletion. In other work, our lab found that deleting Motif 2 from the middle 
domain of ScHsp104 potentiates it [118]. Thus, it is interesting to consider the 
possibility that ClpGGI may be naturally potentiated in this manner. Another 
bacterial Hsp100, ClpC from Bacillus subtilis, also lacks middle domain Motif 2, 
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raising the possibility that it may be naturally potentiated like ClpGGI [231]. ClpC 
naturally collaborates with an adaptor protein, MecA, which mediates its 
hexamerization, and the protease ClpP [231]. It may be possible to decouple 
ClpC disaggregase activity from ClpP-mediated proteolysis by mutating IGL 
loops on ClpC that mediate ClpP interaction [92]. It may be that, in contrast to 
single missense mutations which may have varying effects across lineages, 
potentiation via Motif 2 deletion is a conserved mechanism to potentiate Hsp104 
homologs. 
 It is also interesting to note that ClpGGI is non-toxic to yeast and indeed 
complements thermotolerance in Dhsp104 cells (Figure 3-9) [220]. It is 
interesting to consider that the NTD of ClpGGI, which is roughly twice the size of 
other Hsp104 NTDs, may limit promiscuous ClpG-mediated unfolding. If true, it 
may be interesting to replace the ScHsp104 NTD with the ClpG NTD, or 
otherwise enhance the ScHsp104 NTD, to mitigate toxicity of potentiated Hsp104 
variants. 
 
4.2.6 AAA+ proteins as drug targets for neurodegenerative disease 
Finally, and perhaps most intriguingly, it may be possible to unlock 
protein-disaggregase activity of native human AAA+ proteins via pharmacologic 
modulation, thus obviating the complex challenges associated with genetic 
engineering. For instance, pharmacologic upregulation of the cyclic adenosine 
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monophosphate/protein kinase A pathway leads to proteasome phosphorylation 
that stimulates proteasome activity [232]. Remarkably, the same treatment 
administered to transgenic mice expressing pathogenic tau led to decreased tau 
deposition and improved cognitive performance [233]. A recent study 
demonstrated that proteasomes directly fragment tau and aSyn fibrils, although 
these fragments are more cytotoxic than untreated fibrils, somewhat confounding 
a beneficial role for the proteasome in eliminating misfolded protein conformers 
[234]. However, proteasome stimulation through phosphorylation may enable the 
complete eradication of toxic protein conformers. Similarly, although Hsp104 
lacks a direct human homolog, emerging human genetics data implicates several 
human AAA+ proteins in neurodegenerative diseases, including p97/valosin-
containing protein [235, 236], torsin A [237-239], and Skd3 [240-242], and 
suggests that these proteins may have some level of protein-disaggregase 
activity that may become overwhelmed in neurodegeneration. Likewise, another 
AAA+ protein, RuvBL, might disassemble protein aggregates [243]. It will be 
exciting to delineate how these proteins interface with the human proteostasis 
network and to explore the potentiation of these endogenous human AAA+ 
proteins via small-molecule modulation to enhance human proteostasis [174, 
244]. Clearly, a wide range of literature now points to a critical utility of AAA+ 
proteins to counteract protein misfolding in neurodegenerative disease, and it will 
be interesting to explore the biochemical basis of protein unfolding by 
endogenous human AAA+ proteins in the future. 
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4.3 Materials and Methods 
4.3.1 Yeast strains and media 
All yeast were WT W303a (MATa, can1-100, his3-11,15, leu2-3,112, trp1-
1, ura3-1, ade2-1) or the isogenic strains W303aΔpdr1,3, or W303aΔhsp104 
[213]. Yeast were grown in rich medium (YPD) or in the appropriate synthetic 




PfHsp104 cDNA was synthesized by Invitrogen. Gateway BP reactions 
were used to shuttle PfHsp104 gene into a Gateway entry vector, pDONR221-
ccdB. The entry clone was then used to shuttle PfHsp104 into a yeast expression 
yector (pAG416GAL-ccdB) via LR reaction. A C-terminal 1xFLAG tag was 
encoded in some variants to facilitate protein detection by Western blot (see 
below). pAG416GAL-MbHsp104-FLAG has been described previously (Chapter 
3) [220]. Hsp104 mutants were obtained by Quikchange mutagenesis. 
 
4.3.3 Yeast transformation and spotting assays 
Yeast were transformed according to standard protocols using 
polyethylene glycol and lithium acetate [170]. For spotting assays, yeast were 
grown to saturation overnight in synthetic raffinose dropout media at 30 °C. 
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Cultures were normalized and serially diluted 5-fold and spotted in duplicate onto 
synthetic dropout media containing glucose or galactose. Plates were analyzed 
after growth for 2-3 days at 30 °C or 37 °C, as indicated. 
 
4.3.4 Western blotting 
Yeast were grown in galactose-containing media to induce protein 
expression for 5h. Cultures were normalized to OD600=0.6, and 6 mL of cells 
were harvested. Yeast lysates were extracted by incubation with 0.1M NaOH at 
room temperature for 5 min. Lysates were mixed with SDS sample buffer, boiled 
for 5 min, and subjected to Tris-HCl SDS-PAGE (4-20% gradient, Bio-Rad) 
followed by transfer to a PVDF membrane (Millipore). Membranes were blocked 
in Odyssey blocking buffer (LI-COR) for 1h at room temperature or overnight at 4 
°C. Primary antibody incubations were performed at 4 °C overnight. After 
washing with PBST, membranes were incubated with fluorescently labeled 
secondary antibodies at room temperature for 1h, followed by washing with 
PBST. Proteins were detected using an Odyssey Fc Dual-Mode Imaging system. 
Primary antibodies used: mouse monoclonal anti-FLAG M2 (Sigma-Aldrich), 
mouse monoclonal 3-phosphoglycerate kinase (Novex), fluorescently labeled 
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